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The increasing occurrence of multi drug resistant bacterial infections has 
underlined the urgent need for the development of new and more potent 
antibiotics. Bacterial RNA polymerase (RNAP) is a validated target that allows 
efficacy and selective toxicity. Unfortunately the efficacy of clinically used RNAP 
inhibitors (rifamycins) is threatened by the emergence of bacterial resistance. 
The recent identification of the binding region of myxopyronin (Myx), a natural 
product antibiotic, coupled with the availability of crystal structural data, offers 
the possibility of using a ligand- and structure-based design approach for the 
identification of new drug-like RNA polymerase inhibitors.  
Validation studies of different docking algorithms were performed on the 
available X-ray co-crystal structures of Thermus thermophilus RNAP and 
several ligand- and structure-based virtual screening protocols on the Myx 
binding region were applied to identify hits for SAR-based exploration. 
A combined ligand- and structure-based protocol identified two 
compounds which showed selective inhibitory activity towards E. coli RNAP in 
the micromolar range of concentration. A SAR expansion programme based 
upon one of these active molecules was conducted via the synthesis of a 
chemical library of acylhydrazones in order to identify the factors determining 
potency and to validate the putative binding mode. Similarity-based virtual 
screening and docking studies were also applied to explore the close chemical 
space of the initial hit and to prioritize the synthesis of analogs. Some of the 
designed compounds showed better inhibitory activity than the initial hit and 
moreover, one derivative possessed moderate activity towards S. aureus 
SH1000.  
A structure-based virtual screening protocol was then conducted on an 
in-house chemical database, applying a preliminary library filtering approach  
based on physico-chemical descriptors. The identification of a hit active in the 
micromolar range of concentration underlined the predictive power of this 
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Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 





1.1  Antibiotics 
 Antibiotics (literally ‘against life’) are substances produced by 
microorganisms and can be classified on the basis of their target and 
additionally on their capability of inducing cell death (bactericidal drugs) or 
inhibiting cell growth (bacteriostatic drugs).1 Cell death caused by bactericidal 
drugs results from the interaction of the drug molecule with a specific target in 
the microorganism leading to alterations in the biochemistry of the bacterium 
both at the molecular and ultrastructural level.1 
Common mechanisms of cell death induced by antibiotics include DNA 
damage via breaking double stranded DNA with inhibitors of topoisomerase II 
(DNA gyrase),2 arrest of DNA-dependent RNA synthesis (rifamycins),3  damage 
of the cell wall and alteration of its structural integrity (inhibitors of cell wall 
synthesis),
4
 or impairment of cellular energetics, ribosome binding and protein 
translation using inhibitors of protein synthesis.1, 5 Recently it has been 
discovered that the mode of action of all classes of bactericidal antibiotics 
features drug-induced stress including the production of free radicals which are 
responsible for oxidative damage and alteration of  bacterial metabolism.1, 6, 7, 8 
Since the discovery of penicillin other more effective antibiotics have been 
discovered and designed using chemical modification and often via an 
understanding of the interactions of the drugs with their target.1 The successful 
clinical use of these new molecules lead to widespread optimism and 
confidence in the fight of modern medicine against infectious diseases during 
the ‘era of antibiotics’ between 1940 and 1970. However since that period, the 
increasing prevalence of drug-resistant bacteria9 has underlined the importance 
of exploring and finding new antibacterials.1,10  
1.2 Bacterial multi drug resistance 
1.2.1  Current situation 
 Bacterial multi drug resistance is a global healthcare problem and despite 
the successful use of antibiotics for decades, bacterial infectious diseases are 
2 
 
the main cause of death worldwide, killing 13-17 million people per year and 
causing 25% of deaths according to the World Health Organization.11, 12, 13, 14 
The mortality and the socio-economical impact of infectious disease is 
enormous and the fight against multidrug resistant microorganisms is one of the 
most challenging global health problems.11, 12, 13, 14 Paul Ehrlich said ‘Drug 
resistance follows the drug like a faithful shadow’.15 Resistance has developed 
within 1-4 years after the clinical introduction of the major classes of antibiotics 
and thanks to the consistent increase in international trade and travel, 
multidrug-resistant pathogens are representing a global problem.15 In addition, 
about 50% of antibiotics are used for prophylaxis, chemotherapy and growth 
promotion in animals and this is worsening the problem.10 Antibiotic resistance 
in Gram-positive and Gram-negative pathogens is growing rapidly and only six 
new antibiotics have been approved since 2003.13 This reflects the challenge of 
identifying new drug classes and the low level of interest from pharmaceutical 
and biotechnology companies in antibacterial drug discovery for economic 
reasons.
11, 12, 13, 14
 Among Gram-positive pathogens, Staphylococcus aureus, 
Streptococcus pneumoniae, Mycobacterium tubercolosis and Enterococci 
constitute a significant public health concern while in Gram-negative pathogens,  
the opportunistic healthcare infections caused by Pseudomonas aeruginosa, 
Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia 
cepacia are of particular concern.11, 12, 13, 14 There is an urgent need to discover 
new therapeutic agents and the main strategies are the search for antibiotics 
with novel mechanisms of action, the identification of new molecular target 
sites, and the chemical modification of known effective molecules to override 
the mechanisms of resistance.11, 12, 13, 14 
1.2.2  Molecular mechanisms of resistance 
Antibacterial resistance can be classified as intrinsic, where bacteria are 
naturally resistant to the antibiotic without any previous exposure, or acquired 
from environmental organisms by horizontal gene transmission (HGT).16 
An example of intrinsic resistance is that utilised by Pseudomonas 
aeruginosa, whose low membrane permeability is the main reason for its innate 
resistance to many antibiotics. Acquired resistance is caused by acquisition of a 
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genetic element like a plasmid and/or transposon or by a chromosome 
mutation.10 Mutations of DNA occurs randomly during its replication at a 
frequency of 10-9-10-10 per base pair and copying errors may lead to the partial 
or complete deletion of individual genes.17 Classical experiments have shown 
that production of pre-existing variants and not the emergence of new mutants 
occurs under the administration of antibiotics but the presence of bacterial 
strains which are hypermutable, as a consequence of the inactivation of the 
proofreading and DNA mismatch-repair system, make the mutation rate 200-
fold higher than normal cells.17 Specific resistance mechanisms include: I) 
chemical inactivation of the drug molecules by enzymes, II) decreased drug 
accumulation within the pathogen by decreasing uptake or increasing efflux, III) 
alteration of binding sites which reduces the affinity for antibiotics, IV) 
development of alternative metabolic pathways.15 
1.2.3  Antibiotics: timeline, challenges and discovery strategy 
Most of the antibiotics used today were discovered before 1970 during the 
‘golden age’ of discovery which started in 1945 and declined in 1965 where 
antibiotics were isolated from natural sources like soil Streptomycetes and 
fungi.18 Since 1970 only three new classes of antibiotics reached the market: 
oxazolidinones (discovered in 1978 and introduced in 2003), lipopeptides 
(discovered in 1986 and introduced in 2003) and carbapenems (discovered in 
1975 and introduced in 1985) although this latter class has close chemical 
similarity with β-lactams and its novelty is debateable.18 Most of the advances in 
antibacterial drug discovery since 1970 came via improvements of already 
known antibiotic classes with chemical analogues bearing increased potency 
and greater ability to overcome existing resistance, but during the last two 
decades this strategy has not delivered a sufficient number of antibiotics in 
particular against Gram-negative bacteria related infections.18 The reasons for 
this discovery void are the partial withdrawal of ‘Big Pharma’ from this area of 
research which is mainly linked with regulatory and commercial challenges, the 
concomitant unsuccessful discovery strategy, and the simultaneous rise of 
multi-drug resistant bacteria.18 
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From an economic point of view, the development of new antibiotics is also 
facing some considerable challenges. These include difficulties in licensing and 
relatively low economical income following the launch of molecules used for 
short-course treatments which attack multiple target species developing 
resistance in short time scales.16, 18 In addition, an antibiotic requires the ability 
to reach multiple body compartments and not to show toxicity for daily dosages 
which are usually higher than for other pharmaceuticals.16, 18 
With regard to the discovery strategy, during the ‘Golden Age’ of discovery 
of antibiotics, the approach consisted of empirical screening of synthetic 
chemicals, natural compounds from fermentation broths, and extracts of 
microorganisms with no regard to mechanism of action, and selectivity was only 
tested later in assays or on animals.16 Empirical screening from synthetic 
chemicals delivered important antibacterials like salvarsan, sulphonamides, 
nitrofurans, chloramphenicol, and quinolones, while many important antibiotic 
classes were discovered from natural products isolated from fermentation 
broths and extracts of microorganisms such as β-lactams, aminoglycosides, 
ansamycines and tetracyclines.16 To avoid redundancy in the chemical diversity 
of the discovered scaffolds, in the early 1960s, a ‘de-replication’ strategy was 
attempted which focussed on targets or pathways (cell wall or protein synthesis 
inhibition) but the output of novel antibiotic classes started decreasing in 1977 
and gradually moved into the ‘genomic era’ in the 1990s which mostly failed to 
deliver results.16 This change was necessary because mining natural sources 
became less productive and did not offer good chemical diversity within the 
discovered scaffolds.16 
During the ‘genomic era’, the ability to clone genes and to produce purified 
proteins to be used for in vitro screening and assays allowed genomic-based 
and target-directed screening.16 The systematic sequencing of pathogen 
genomes identified many targets not present in mammalian counterparts and an 
intense high-throughput screening of in-house synthetic chemical libraries was 
performed leaving apart natural compounds.16 The compound libraries yielded 
very few hits when compared to other therapeutic areas and even fewer leads.16 
No antibiotic was developed using this approach during a 20 year time.16 
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One reason for this failure of discovery could be ascribed to the chemical 
composition of compound libraries. These libraries are generally biased towards 
molecules compliant with Lipinski’s ‘rule of five’ with consequently good oral 
absorption but many existing antibiotics do not conform to this rule especially 
the ones which are administered via the parenteral route.16, 18 According to 
some authors,19 antibacterial agents reside within a unique physicochemical 
property space when compared to other therapeutics. Another problem is that a 
compound binding to a target does not necessarily show antibiotic activity 
because it may not be able to penetrate the bacterial membranes or to 
overcome removal from the cell by efflux processes mediated by membrane 
transporters.18 
1.2.4 Antibiotics in the pipeline and the future of antibacterial 
discovery 
Over the past 20 years (from 1983 to 2002) FDA approvals of new 
antibacterial agents decreased. Comparing the period from 1998 to 2008 with 
the period from 1983 to 1987, the approvals of antibacterial agents decreased 
by 56%.20 During this period, forty compounds were under evaluation in clinical 
trials at various phases with an equal distribution between natural products and 
synthetically derived molecules.21 Some new strategies were adopted by the 
companies for the compounds in the pipeline which included: (i) the search for 
new classes of molecules that bind well-established targets such as the non-
quinolone topoisomerase inhibitors GSK299423 1.1 (Figure 1.1), non β-lactam 
inhibitors of β-lactamases such as NXL104 1.2, MK7655 1.3 and ME1071 1.4 
(Figure 1.1); (ii) inhibitors for multidrug efflux mediated mechanisms which could 
restore the activity of known antibiotics like quinolones towards bacterial 
species relying on this resistance mechanism such as P. aeruginosa; (iii) 
screening of unconventional chemical classes to overcome the limitations of 
classical compound libraries like the boron-based Leu-tRNA synthetase inhibitor 
GSK2251052 1.5 (Figure 1.1).18 A rediscovered interest in natural products has 
recently occurred which involves two main strategies: screening of various 
organism groups different from soil Streptomycetes such as plants, deep sea 
bacteria and antifungal Actinomycetes which colonize the nests of ants or 
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manipulating the non-expressed regulatory gene clusters in Streptomycetes 
since many existing antibiotics are only growth-phase dependent regulatory 
products.18 Combinatorial synthesis through Diversity-Oriented Synthesis 
(DOS), and Biology-Oriented Synthesis (BIOS) will enhance the diversity of 
HTS libraries, while Fragment-Based Drug Discovery (FBDD), thanks to the 
growing number of solved crystallographic and nuclear magnetic resonance 
structures of bacterial targets with bound ligands, will deliver small molecules 
which are more likely to bind to selected targets when compared to larger 
molecules and will constitute a valuable starting point for optimization.16 
 
Figure 1.1 Structures of new classes of antibiotics18 
1.2.5  Requirements for an optimal antibacterial target and the 
problem of bacterial cell penetration 
An antibacterial target should be considered amenable if it is (i) essential 
for the organism function to allow inhibition of bacterial growth or death; (ii) 
conserved among different bacterial species to provide a good spectrum of 
activity; (iii) lacking structural homology with the mammalian host in order to 
avoid toxicity, (iv) ‘druggable’ since it should possess a site or a structure where 
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small drug-like molecules can bind.16 Additional desirable criteria are: (v) good 
solubility and stability of the enzyme in terms of delivering good quality and 
highly resolved X-ray crystallography data, (vi) an intrinsic low frequency of 
mutations to allow inhibitors to be effective for a reasonable time when used as 
monotherapeutic agents.16 Unfortunately, in the field of antibacterials, the 
generally observed rapid development of resistance by single target enzymes 
constitutes a big challenge.16 Developing inhibitors for multiple enzymes like 
fluoroquinolones (inhibition of DNA gyrase and topoisomerase IV) or targets 
encoded by multiple genes (such as rRNA inhibitors) could be advantageous 
with respect to single target-based antibacterial agents.16  
The spectrum of activity of antibacterials is crucially dependent on cell 
permeability and the target distribution16 within the bacterium. Targets can be 
external to the cell or in the cytoplasm and most antibiotics inhibit one among 
the several cellular targets.16 Bacteria are prokaryotic cells with high intracellular 
pressure and are protected from osmolysis by a rigid peptidoglycan layer, 
constituted by strands of glycan and peptide covalently cross-linked, which 
contributes to cell wall rigidity.16, 22, 23 Bacterial cells can be classified according 
to their ability to retain the violet Gram-staining and Gram-positive bacteria have 
a thicker peptidoglycan layer (30-100 nm thick) when compared to Gram-
negative strains (20-30 nm thick).10, 16, 23 An additional lipopolysaccaride outer 
membrane (OM) is present in Gram-negative bacteria and this represents an 









Figure 1.2  Structure of Gram-positive and Gram-negative bacteria. 
      
cytoplasm 











 Uncharged and lipophilic molecules can readily diffuse through the CM 
while charged hydrophilic molecules can rely on active transport via solute-
specific carriers and permeases.16 The OM is globally impermeable but 
molecules can transit through porins, water-filled channels which are selective 
for hydrophilic and charged solutes with a size exclusion for high molecular 
weight molecules (in E. coli the upper limit is 600 Daltons).16 Porins can be 
bypassed thanks to solute-specific facilitated diffusion channels and some 
natural antibiotics exploit these solute-specific routes.16 The presence of 
specific efflux pumps in Gram-negative organisms contributes to the difficulties 
in the discovery of specific drugs for this class of bacteria.16 Another important 
aspect of antibacterial agents is target-specific selectivity. When an inhibitor is 
discovered via empirical (phenotypic) screening for growth inhibition, it should 
not possess non specific antibacterial activity via cytotoxicity such as detergent 
action, alkylation or ‘energy poisoning’.16 This is equally important also for 
compounds identified via in vitro enzyme inhibition but a linkage between 
enzyme-based inhibitory potency and minimum inhibitory concentration (MIC) is 
not obvious for many compound classes because of the inability to cross the 
bacterial membranes or to concentrate inside the cell avoiding removal by efflux 
pumps.16 
Possible approaches to overcome the problem of bacterial cell penetration 
include the alteration of the physicochemical properties of inhibitors to enhance 
uptake and limit efflux, but these modifications may reduce binding affinity to the 
molecular target.24 The use of docking methodologies could help to predict 
whether the modifications are tolerated within the binding site.24 Another 
approach is to exploit bacterial iron uptake through siderophores as a ‘Trojan 
horse’ strategy for drug delivery. Bacterial cells require iron as an essential 
element in a variety of metabolic pathways and high-affinity iron uptake is 
mediated by siderophore-dependent processes.25 Some siderophore 
conjugates have already been made with existing drug classes, such as β-
lactam antibiotics25 and in some cases antibacterial activity was better when 
compared to the non-conjugated drugs. However, not all inhibitors will be 
chemically amenable to coupling with siderophores and drug release is then 
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necessary within the bacterial cytoplasm. Moreover good pharmacokinetic 
properties are required for systemic administration.24 
To conclude, the choice of a suitable target can be considered a rate-
limiting step of any antibacterial drug discovery program.16 
 
1.3 Bacterial DNA-dependent RNA polymerase 
1.3.1 Structure 
RNAP is a nucleotidyl transferase enzyme with a molecular mass of about 
400kDa and is responsible for the transfer of genetic information from DNA to 
RNA in a process called transcription which is the first step of the expression of 





Figure 1.3 Expression of genetic information 
 
The DNA-dependent RNA polymerase (RNAP) in prokaryotic cells is 
responsible for the biosynthesis of all types of RNAs (r-RNA, mRNA, t-RNA) 
while in eukaryotic cells this enzyme is present in three different forms (RNAP-I, 
RNAP-II, RNAP-III) where each of these is respectively involved in the 
biosynthesis of r-RNAs, m-RNAs and t-RNAs.27 Eukaryotic RNAPs contain 14 
subunits in RNAP-I, 12 subunits in RNAP-II and 17 subunits in RNAP-III and all 
of these three enzymes are similar from a structural and functional point of view 
while prokaryotic core RNAPs consists of five subunits (α2 β β′ ω) in association 
with the σ factor to form an holoenzyme which can bind a promoter27 (Figure 
1.4). In the eukaryotic cell the specific binding of a promoter is performed by 
transcription factors in association with the RNAPs.27  





RNAP (Figure 1.4) is a ‘crab claw’-shaped molecule and the large β and β′ 
subunits form the ‘pincers’ with a large channel between them which locates the 
3′ hydroxyl of the RNA within the active site, the 8-9 base pair long RNA-DNA 
hybrid at the growing end of the transcript, a DNA duplex downstream of the 
hybrid and a 6-nucleotide long single-stranded RNA upstream of the hybrid.28 
The active site is directly connected to the surface of the enzyme by a 
secondary channel which is a passageway for the incoming nucleotide 
triphosphate substrates. This channel is required as the presence of the nucleic 
acids blocks access from the main channel.28 The two ‘pincers’ of the ‘crab 
claw’ are bridged by a bridge helix (Figure 1.5), a long α helix that spans the 




Figure 1.4 Various subunits of the T. aquaticus RNA polymerase (PDB 1I6V) 
(see colour code) and the positions of the Cleft, Pore and RNA exit channel.  
 











Figure 1.5 Structural elements of RNAP in the region of the DNA-RNA hybrid 
(PDB 1I6V). 
 
The active site of the RNAP is located on the floor of the cleft formed by 
the β and β′ subunits.26 The RNA-channel and the secondary channel for 
nucleotide triphosphate (NTP) substrates are the two access channels that 
connect the inner part of the enzyme with the external surface.26 Three 
aspartate residues in the active centre coordinate a catalytic Mg2+ ion while 
another Mg2+ ion is bound to the incoming NTP.26 The bridge helix (also called 
the F helix) and the trigger loop (also called G/G loop) (Figure 1.5), together 
with various other loops are important for the loading of NTPs and for catalysis 
and translocation and all these flexible structures are in the downstream face of 
the active centre.26 
 
1.3.2  Catalytic reaction mechanism 
The process of transcription consists of three main stages (Figure 1.6): 











Figure 1.6 Intermediates in the transcription cycle. RNAP in grey, DNA in blue, 
nascent RNA in red, multidomain σ factor in purple. Adapted from Mooney et 
al.29 
 
The process begins when the σ initiation factor binds to the core enzyme 
and starts the recognition and melting of promoter sequences on DNA making 
possible the synthesis of the RNA transcript.26 The initiation of transcription can 
be divided into several sub-steps and the first is the binding of a promoter 
which, after structural rearrangement, melts the double helix at the promoter 
site and forms the secondary complex.26 Once the first nucleotide is associated 
with the nascent RNA chain, the first ternary complex is formed which evolves 
to an early ternary complex after the incorporation of the second nucleotide of 
the RNA chain with the subsequent formation of the first phosphodiester bond.26 
This complex can undergo abortive initiation via the release of its dinucleotide 
component or it can undergo elongation of the dinucleotide.26 The abortive 
initiation stops after the incorporation of 9-11 nucleotides into the emerging 
RNA chain and at this stage the ternary complex is stabilised, the initiation has 
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ended and the elongation process can begin via the formation of a stable 
transcription elongation complex following a significant conformational 
change.26 This complex is very stable and upon its formation the initiation factor 
σ is released allowing the enzyme to decouple from the promoter.26 The highly 
efficient transcription cycle ends when a stop signal is recognized with the 
subsequent dissociation of the transcribing complex and release of the RNA 
polymerase which is readily available for a new round of transcription.26 
 As indicated earlier, two magnesium ions are involved in the mechanism of 
phosphodiester bond formation catalysed by RNA polymerase.27 As indicated 
previously, the first Mg2+ ion is coordinated by three conserved aspartates 
included in the NADFDGD motif of the β′ subunit and this ion catalyses the 
nucleophilic attack of the 3′-oxygen of the growing RNA chain on the 5′ α-
phosphate of the incoming nucleotide (Scheme 1.1), whilst the second Mg2+ ion 
is chelated to the incoming NTP and is also coordinated by three aspartates 
(two from the β′ and one from the β subunit located in a conserved ED motif).27 
After phosphodiester bond formation, the enzyme is translocated along the 
nucleic acid template for the addition of the next nucleotide.27 The enzyme's 
active site is one of the regions which is highly conserved between prokaryotes 
and eukaryotes.27 The nucleic acids are accommodated into the positively 
charged cleft formed by the β and β′ subunits.27 The ‘wall’ domain contained 
within the β subunit closes the upstream extremity of this cleft and the ‘flap’ 
element contained within this domain is a binding site for transcription factors 







Scheme 1.1 Mechanism of ribonucleotide addition to the RNA chain. 
 
1.4 RNAP inhibitors and their mechanism of action 
1.4.1 Rifamycins  
1.4.1.1 Chemistry and biological activity 
The ansamycin antibiotics are characterized by a basket-like molecular 
shape which comprises an aromatic moiety bridged by an aliphatic chain (ansa) 
in two nonadjacent positions.3 The aromatic portion can be a naphthalene or a 
naphthoquinone (naphthalenic ansamycins) or a benzene or benzoquinone ring 
(benzenic ansamycins). The rifamycins are members of the ansamycins family 
and were isolated from Amicolatopsis mediterranei as a complex mixture of 
cognate compounds in 1959 by Sensi and co-workers at Lepetit SA in Italy.30 
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The rifamycins have a broad spectrum of antibiotic activity against Gram-
positive and, to a lesser extent, against Gram-negative bacteria.31 The lower 
activity with Gram-negative strains is due to the diminished penetration of the 
antibiotic through the outer cell membrane.31 Interestingly, ansamycins are also 
active against the transcription machinery of the eukaryotic parasite 
Plasmodium falciparum.32, 33, 34 Rifamycin SV 1.9 was the first rifamycin in 
clinical use and is a biosynthetic precursor of rifamycin B 1.6 which, in 
comparison has relatively modest activity.35, 36, 37, 38, 39 However rifamycin B 1.6 
can be easily converted to rifamycin SV 1.9 in various ways (chemically, 
microbiologically and by biotransformations).35, 36, 37 With regards to the 
chemical transformation route (Scheme 1.2) rifamycin B 1.6 is converted 
spontaneously and reversibly to rifamycin O 1.7 in an aqueous oxygenated 
solution and the latter is hydrolysed with concomitant loss of glycolic acid to 
rifamycin S 1.8. Rifamycin SV 1.9 is obtained using a mild reduction of rifamycin 
S3 1.8. 
 


















Starting from the easily accessible intermediate 3-formylrifamycin SV 1.10 
(Figure 1.7), many derivatives functionalised at the C-3 position have been 
prepared using semisynthesis and among these, rifampicin 1.11 (Figure 1.8) 
has a particularly pronounced activity towards Gram-positive bacteria (such as 
multidrug resistant Staphylococcus aureus) and in particular against 
mycobacteria. Moreover it has a weaker activity against Gram-negative 
bacteria.40, 41, 42, 43 Rifampicin 1.11 exhibits good oral bioavailability and is one of 
the most important drugs for the treatment of tuberculosis, leprosy and 
mycobacterial infections associated with AIDS.3, 44 Rifabutin 1.12 (Figure 1.8) 
and rifapentine 1.13 (Figure 1.9) are other semisynthetic derivatives introduced 
later to clinical use and rifabutin 1.12 has showed activity against a number of 
rifampicin-resistant clinical pathogens.34 Nowadays the ansamycins currently in 
therapeutic use are rifampicin 1.11, rifabutin 1.12, 34 rifapentine 1.13, rifalazil 








Rifampicin 1.11 exhibits its antibacterial activity by strongly binding the 
prokaryotic DNA-dependent RNA polymerase and inhibiting RNA synthesis.3, 46, 
47 This inhibition mechanism is shared by all the antibacterially active rifamycins 
despite the many structural modifications made in these molecules to alter the 
pharmacokinetics and the selectivity for the prokaryotic enzyme. The eukaryotic 
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DNA-dependent RNA polymerase has a weaker affinity to rifampicin 1.11 
compared to prokaryotic RNAP allowing in this way selective toxicity towards 
bacteria.3 
 
1.4.1.2 Mechanism of action 
 Following genetic analysis of rifamycin resistant strains and the X-ray 
crystallographic based structure elucidation of the core enzyme in complex with 
various inhibitors, much information has been obtained concerning the mode of 
action of the rifamycins. In particular, it has been determined that rifampicin 
1.11 binds to a site in the β subunit 12 Å away from the active site in the path of 
the nascent RNA. Twelve residues from the β subunit are involved in hydrogen 
bonds or van der Waals interactions with rifampicin 1.11. 26, 48 Interestingly, the 
substituent in the C3 position of rifampicin 1.11 does not interact with the 
protein and this suggests that the rifampicin 1.11 is sterically blocking the 
synthesis of an RNA product longer than three nucleotides. Indeed, mutation of 
some residues confers resistance to rifampicin by altering the binding pocket 
geometry.48 According to the crystal structure of rifampicin 1.11 in complex with 
the Thermus aquaticus core DNA dependent RNAP,48 rifampicin 1.11 binding 
(Figure 1.11) involves hydrogen bonding interactions between the hydroxyl 
groups at C-1, C-8, C-21 and C-23 and the carbonyl oxygen of the C-25 
acetoxy group with the amino acid residues Arg409, Ser411, Gln393, His406, 
Asp396 and Phe394. The binding of the antibiotic is reinforced by additional 
hydrophobic interactions with Glu445, Ile452, Gly414, Leu413, Leu391 and 
Gln390. The orientation of the bound antibiotic interferes sterically with the 
nascent oligonucleotide chain after the first or second chain elongation step and 
it is evident that there is no effect on the initiation or translocation step.49 
Unfortunately this steric model is not able to account for several amino acid 
substitutions that confer resistance to rifampicin 1.11 but not to rifabutin 1.12 
and also in close analogues which have a fused ring in C3 and C4. Following 
analysis of crystal structures of rifabutin 1.12 and rifapentine 1.13 co-crystal 
structures (T. Thermophilus RNAP holoenzyme which includes the σ-subunit in 
addition to the α2ββ′ω assembly), an allosteric mechanism of action for 
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rifampicin 1.11, rifabutin 1.12 and rifapentine 1.13 was recently proposed.50, 51 
While in rifapentine 1.13 there is no contact between the C3 substituent and the 




Figure 1.11 Schematic diagram of RNAP β subunit interactions with rifampicin 
indicated in green (PDB 1I6V) 1.11. 
 
Regarding rifampicin 1.11, according to a recent study,50, 51 the binding of 
this molecule to RNAP results in the propagation of an allosteric signal for 19 Å 
up to the active site inducing a decrease in affinity of the major catalytic Mg2+ 
ion with a consequent decrease in speed of the catalytic reaction and 
dissociation of the short DNA/RNA duplex. This mechanism of action has been 
called the β-pathway (Figure 1.12) and stops the transcription process in vitro at 
the second phosphodiester bond when the process starts from a dinucleotide. 
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This mechanism is activated by the interactions of the ansamycin core 
(aromatic ring and ansa) with the residues in the β-subunit and this mechanism 
is shared by all the rifamycins.50, 51 The C-3/C-4 substituted rifamycins like 
rifabutin 1.12 can affect the formation of the first phosphodiester bond via the σ-
pathway (Figure 1.12) thanks to the contacts between the aromatic substituent 
and the σ-subunit, with the same effect on the major catalytic Mg2+ and 
consequent decrease in speed of the catalytic reaction and dissociation of the 
short DNA/RNA duplex.50, 51 This last mechanism is a unique characteristic of 
C3/C4 substituted rifamycins which are also able to act within the β-pathway at 
the same time. A recent study52 has shown that this allosteric modulation for the 
binding affinity of the major catalytic Mg2+ is not possible and these researchers 
have cast doubt on the allosteric modulation mechanism.  
 
 
Figure 1.12 Two-pathway mechanism of rifamycins action. (A) The β pathway, 
induced fit mechanism shown with the cyan lightning, RNA in yellow, DNA 
template in red and blue. (B) The σ pathway, induced fit mechanism shown with 
the purple lightning, RNA in yellow, DNA template in red and blue.51 
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1.4.1.3 Structure activity relationships 
Several rifamycin analogues have been prepared with the purpose of 
improving bioavailability and antimicrobial activity. 
Rifamycin SV 1.9 (Scheme 1.2) was modified at various positions and 
these reveal that changes in the ansa chain generally negatively affect the 
activity and in particular, substitution and elimination of the two hydroxyl groups 
at C-21 and C-23 results in a large decrease of activity.26, 53, 54, 55 All the 
modifications which leave hydroxyl groups unmodified but which alter the 
conformation of the ansa chain are also unfavourable.26, 53, 54, 55 Alterations in 
the ansa rings are unfavourable with the exception of deacetylation at C-25 and 
the inversion of configuration at this stereocenter which have no negative 
influence upon activity. The hydroxyl group at C-8 is essential for antimicrobial 
activity while keto groups in the chromophoric moiety can be modified to 
hydroxyl groups in position C-1 and C-4 with no loss of activity.26 
 Many rifamycin derivatives with substitutions at position C-3 and/or 
position C4 have been prepared.56, 57, 58, 59, 60 Among the C3/C4 position 
derivatives the most important are rifaximin 1.15 61, 62 and rifabutin 1.12. 62 
 Rifapentine 1.13 is more active than rifampicin 1.11 against 
Mycobacterium tuberculosis and has a longer half-life which allows once weekly 
administration. It is approved for the treatment of tuberculosis but unfortunately 
some bacterial strains which are resistant to rifampicin 1.11 usually are also 
cross-resistant to rifapentine 1.13. 63 
 Rifaximin26 1.15 is active against bacterial enteropathogens and it is 
approved for this use while rifabutin 1.12 is active against certain rifampicin-
resistant clinical pathogens and it is also in clinical use since 1994. 
 Rifalazil26 1.14, a benzoxazino derivative, shows better pharmacokinetic 
properties and less side effects like interaction with liver microsomial enzymes 
compared to rifampicin 1.11 even if some rifampicin-resistant strains show 
cross-resistance with rifalazil 1.14. 
Some 25-hydroxyl analogues were synthesised and showed better efficacy 
than the 25-O-acetyl derivatives on some bacterial strains.26 
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Finally new rifabutin 1.12 analogues (Figure 1.13) such as 
spiropiperidylrifamycins64 1.16, spirorifamycins65 1.17, C-11 oxime66 derivatives 
and C-25 carbamates, were also prepared and generally showed activity on 
certain wild type strains of S. aureus and improved activity on some mutant 
strains. In particular, the C-25 carbamates diminish susceptibility to rifamycin-
specific ADP-ribosyl transferases which are responsible for resistance by 
inactivation on some opportunistic pathogens including Mycobacterium 




Figure 1.13 Spiro-piperidyl-rifamicin 1.16 and spirorifamycin analogues45 1.17. 
 
1.4.1.4 Resistance to rifamycins 
Bacteria and fungi exist in communities and they both need to 
communicate with each other and to compete as well. These organisms 
synthesize low molecular weight compounds to favour symbiosis or to inhibit the 
growth of competitors and bacteria have developed various strategies to survive 
in the presence of such antibiotics.34 
Rifampicin 1.11 blocks transcription initiation by binding to conserved 
amino acids near the active centre of RNAP and one of the main causes of 
bacterial resistance are the mutations of these amino acids.34,48 The rate of 
resistance of pathogens to rifampicin 1.11 is 10-8 to 10-9 per bacterium per cell 
division. Many bacterial strains resistant to rifampicin 1.11 such as Escherichia 
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coli, Staphylococcus aureus, Bacillus subtilis, Mycobacterium tuberculosis etc. 
have mutations in the RNAP active centre located in the β-subunit which is 
encoded by the rpoB gene.34,48,3 This binding site is highly conserved among 
bacteria.48 Generally the binding of molecules to RNAP involves twelve residues 
and in most cases mutagenesis of each of these generates a spontaneous 
resistant phenotype. Single point mutations of amino acids are more common 
than insertions and deletions and 95% of these are located in four regions in the 
N-terminal half of the β-subunit.68 In E. coli the mutations which confer 
resistance are located in the central region and in the N-terminus of the β-
subunit while in M. tuberculosis, these are located in a ‘hot-spot’ within the 
central region where the mutation of Ser411, His406, Asp396 (according to the 
Thermus aquaticus numbering) account respectively for 41%, 36% and 9% of 
the clinically isolated resistant phenotypes.68,69,70 High levels of resistance to 
rifampicin 1.11 have been reported in more than 1% of rifampicin resistant 
strains with the (V176F) mutation (M. tuberculosis numbering).71 Following 
studies on the rpoB gene in Thermus aquaticus, it has been reported that 
twelve amino acids are involved in hydrogen bonding or van der Waals 
interactions with the bound rifampicin and all of them are susceptible to 
mutation with the mutation of Glu445 being lethal for the microorganism.3,34 
Interestingly, twelve of the twenty-three sites that can confer rifampicin 1.11 
resistance when mutated do not make direct interactions with the bound 
antibiotic but are able to alter the overall conformation of the rifampicin binding 
site.3,34 Other mutations which occur at high rate have been reported but most 
of them do not lead to clinical isolates due to reduced fitness of the 
microorganisms.34 Duplication of the rpoB gene in Nocardia sp. seems to be a 
novel resistance mechanism confirmed using knockout studies.34 In addition to 
the mutation of the target strategy other resistance mechanisms have been 
reported such as the expression of RNAP binding proteins induced by exposure 
to low concentration of rifampicin in Streptomyces coelicolor, Corynebacterium 
diphtheriae, M. tuberculosis and M. leprae confers resistance.3, 34, 67, 72 Covalent 
modifications that neutralise rifampicin are also possible in a variety of ways 
such as glycosylation, ribosylation, phosphorylation. Finally and equally 
important, an additional strategy of resistance is the modification of membrane 
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permeability that prevents the entry of the antibiotic inside the cell or the over-
expression of membrane-associated energy-driven efflux pumps.34 Some 
examples of reduced efficacy resulting from the presence of efflux pumps have 
been reported in some species of Mycobacteria which are generally intrinsically 
resistant to many antibiotics thanks to the lipid-rich character of their cell wall 
but are susceptible to rifampicin 1.11. 34,73 
 
1.4.2  Lipiarmycin 
 
Lipiarmycin 1.18 (Figure 1.14) is a natural compound mixture of four 
factors (B3, B4, A3, A4) from Actinoplanes decanensis74, 75 and is active only 
against Gram-positive bacteria.34 This antibiotic mixture interferes with the 
initiation step of RNA biosynthesis. As for rifampicin 1.11, at much higher 
concentrations, lipiarmycin affects chain elongation during DNA synthesis.34 
Lipiarmycin is more effective in inhibiting the transcription of the core enzyme 
rather than the holoenzyme.34 An important mutation within the RNAP, located 
in the DNA channel opposite to the rifampicin binding site and proximal to the σ-
subunit, confers high lipiarmycin resistance.34 Tiacumicin B, also known as 
fidaxomicin (OPT-80),76 the major component of the tiacumicin complex from 
Dactylosporangium auranticum, is identical to lipiarmycin A3 1.18 and is active 
against Gram-positive bacteria including Clostridium difficile.77, 78 It has a low 
propensity to select for resistant mutants and showed no cross resistance with 
rifampicin 1.11 and other antibiotics.77, 78 Fidaxomicin resistance-mutants have 
been mapped within the switch-2 region into the β′ subunit and the σ70 subunit 
region 3.2.77 fidaxomicin acts by blocking the initiation process only if added 
before the formation of the open promoter complex in which DNA strands are 
separated but RNA synthesis has not yet started.77 These observations led to 
the conclusion that fidaxomicin operates with a mechanism distinct from the 
other known transcription initiation or elongation inhibitors.77, 78 Fidaxomicin was 









Figure 1.14 Lipiarmycin A3 1.18 structure.34 
 
1.4.3  GE23077 
 
GE2307779, 80, 81 (Figure 1.15), a cyclic heptapeptide containing four 
unnatural amino acids, is a potent and selective inhibitor of bacterial RNAP both 
from Gram-positive and Gram-negative derived enzymes. It is a mixture of four 
major components (A1 1.19, A2, B1 1.20 and B2) and has a similar mechanism 
of action to rifampicin 1.11 but acts at a different binding site to that of rifampicin 
since it does not show any cross-resistance with the latter. Recent studies,82 
using a combination of genetic, biochemical, and structural approaches, 
showed that GE23077 binds directly to the RNAP active centre nucleotide 
binding site preventing transcription initiation. Notably, GE23077 resistance was 
unusually small, reflecting the fact that its binding site on RNAP includes 
residues of the RNAP active centre which are essential for RNAP activity.82 
Unfortunately, GE23077 shows only modest antimicrobial activity against some 
strains of Moraxella catharralis, Neisseria gonorrhoeae and Mycobacterium 
smegmatis  in spite of its potent in vitro activity.81 This is probably due to its 











1.4.4  Streptolydigin 
 
Streptolydigin 1.21 83, 84 (Figure 1.16), isolated from Streptomyces lydigus, 
is a tetramic acid antibiotic which binds to a site adjacent (20 Å away) to, but not 
overlapping, the RNAP active site. Binding of streptolydigin stabilises the 
straight-bridge-helix conformational state as revealed via X-ray structure 
analysis of its complex with RNAP of T. thermophylus.85 Biochemical, 
mutagenesis and modelling studies have revealed that the RNAP active site 
can exist in two alternative conformational states: straight-bridge-helix and bent-
bridge-helix. This unique inhibition mechanism results in a lack of cross-
resistance with the other RNAP inhibitors.86 Streptolydigin 1.21 is not as 
medically important as rifampicin 1.11 because it is not able to cross bacterial 
membranes and its Ki is 10
4-105 times higher when compared with that for 
rifampicin 1.11. Streptolydigin 1.21 is a non-competitive allosteric inhibitor 
because it interacts directly with the bridging helix and nearby structures, 
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Figure 1.16 Structure of streptolydigin 1.21. 
 
1.4.5  Sorangicin 
 
Sorangicin 1.22 (Figure 1.17) is a selective bacterial RNAP inhibitor that 
acts mainly on Gram-positive bacteria. It is a macrolide polyether and was 
isolated from a Sorangium cellulosum strain.87 Following the determination of 
the crystal structure of sorangicin 1.22 in complex with the T. aquaticus core 
RNAP enzyme88 it was established that the antibiotic binds to a site located in 
the same RNAP β-subunit pocket as that for rifampicin 1.11, partially 
overlapping its binding site and for this reason, sorangicin 1.22 shows partial 
cross-resistance with rifampicin 1.11. Sorangicin 1.22 inhibits transcription by 
blocking the transcript at the length of 2-3 nucleotides and has an increased 
conformational flexibility when compared to rifampicin 1.11, this can allow to 








Figure 1.17 Structure of sorangicin 1.22. 
 
1.4.6  Microcin J25 
 
Microcin J25 1.23 (Figure 1.18) is a cyclic peptide composed of twenty-one 
amino acid residues89, 90 and is derived from the microcins, a miscellaneous 
group of antibiotics produced mostly by strains of E. coli. Microcin J25 binds 
inside the RNAP secondary channel blocking access to NTPs and halting 
transcription. It has a good range of bactericidal activity against Gram-negative 
bacteria although resistant strains with amino acidic substitutions both in the β 







Figure 1.18 Structure and sequence of microcin J25 1.23  (PDB 1PP5). 
 
1.4.7  Capistruin  
 
Capistruin91 1.24 (Figure 1.19) is a cyclic peptide (threaded lasso 
peptide) consisting of nineteen amino acid residues, is ribosomally synthesized 
and post-translationally modified by Burkholderia thailandensis E264.91 Its 
structure is similar to that of Microcin J25 and it inhibits wild type E. coli RNAP 
but not mutant Microcin J25 resistant E. coli RNAP bearing a substitution in the 
RNAP secondary channel.91 Despite the low sequence similarity between 
Capistruin and Microcin J25, in view of their similar three-dimensional structures 
and their inhibition of bacterial RNAP through possibly identical or overlapping 
binding sites within the RNAP secondary channel, it is possible to conclude that 






                                                                                                         1.23                              1.24   
 
Figure 1.19 Capistruin 1.24 structure and its comparison with Microcin J25 
1.23. Aminoacids reported in blue and red are highly mutable, in particular, the 
red ones are detrimental for the antibiotic activity. Adapted from Kuznedelov et 
al. 91  
 
1.4.8  ‘Switch region’ inhibitors 
The recent discovery of myxopyronin B (MyxB) 1.26 (Figure 1.20), an α-
pyrone natural product antibiotic that inhibits bacterial RNAP and the 
determination of its X-ray co-crystal structure with Thermus thermophylus 
RNAP92, 93 allowed the identification of the ‘switch region’, a new ligand binding 
site within the RNAP enzyme.94 This highly mobile structural element, 
composed of five segments denominated ‘switch 1’ through ‘switch 5’, mediates 
the conformational changes and the interactions required for loading DNA into 
the RNAP during transcription initiation.92, 94 The ‘switch region’ is located at the 
base of the RNAP β′ subunit, known as the clamp, and operates as a ‘hinge’ 
mediating the opening and the closure of the clamp required respectively for 
loading the double-stranded DNA into the active centre cleft and to retain it 
during transcription.92, 94 The ‘switch region’ residues are conserved in Gram-
positive and Gram-negative RNAP allowing a broad spectrum antibacterial 
activity moreover they are not conserved in eukaryotic RNAPs.92, 94 It has also 
been found that the structurally related natural antibiotic Corallopyronin A and 
the macrocyclic-lactone antibiotic Ripostatin are binding the ‘switch region’ and 
together with MyxB they do not exhibit cross-resistance with rifamycins since 
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this region is distinct and remote from the rifamycin binding site.92, 94 All these 
three natural antibiotics will be discussed in detail below. 
1.4.8.1 Myxopyronins 
The myxopyronins 1.25-1.27 
95
 (Figure 1.20), produced by the 
Myxobacterium Myxococcus fulvus, are polyketide-derived α-pyrone antibiotics 
which inhibit transcription initiation by interacting with the RNAP ‘switch region’ 





Figure 1.20 Structures of Myxopyronins.95 
 
These inhibitors are active against many Gram-positive and some Gram-
negative bacteria26 with MICs lower than 12.5 µg/mL and inhibited the 
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transcription and growth of S. aureus with an IC50 of 14 µM (7-
desmethylmyxopyronin B 1.27) (Figure 1.20).92,96 Previous studies97 have 
shown that these compounds lack in vivo efficacy in a mouse model as a 
consequence of the high affinity to serum albumin whilst no acute toxicity was 
exhibited at doses of up to at least 100 mg/kg. Two different mechanisms of 
action were proposed for MyxB 1.26. Mukhopadhyay92 et al. suggested that 
MyxB 1.26 prevents the interaction of RNAP with promoter DNA by locking the 
clamp in a closed conformation thus halting transcription initiation and does not 
efficiently inhibit the subsequent steps involving interaction of RNAP with 
promoter DNA. Belogurov93 et al. proposed that MyxB 1.26 stabilizes the 
refolding of ‘switch 2’ impeding the accommodation of the melted template DNA 
near the transcription start site in the RNAP-promoter open complex during 
transcription initiation. Crystal structures,92, 93 of myxopyronin A (MyxA) 1.25 
and its 7-desmethyl analogue (dMyxB) 1.27 in complex with T. thermophylus 
(Figures 1.21a and 1.21b) have been determined and these reveal that binding 
occurs predominantly within a nearly completely enclosed hydrophobic 





Figure 1.21a Crystal structure of T. thermophylus RNAP-dMyx B 1.27 complex 





Figure 1.21b Schematic diagram of T. thermophylus RNAP-dMyx B 1.27 
complex (PDB 3EQL). H-bonds in red dashed lines, van der Waals interactions 
in black. 
 
The α-pyrone ring is close to the active-centre cleft while the two lipophilic 
side chains are stretched into two different hydrophobic pockets. Whilst 
hydrophobic interactions are prevalent in binding, specific hydrogen bond 
interactions are performed by polar groups on the α-pyrone ring and ene-
carbamate group.  
Interestingly, in the co-crystal structure proposed by Mukhopadhyay92 et al. 
the ene-carbamate moiety is involved in a specific network of hydrogen bonds 
centred on an ordered water molecule while in the co-crystal structure obtained 
by Belogurov
93
 et al. the water molecule is absent because the ene-carbamate 
moiety is rotated by 180 degrees along the axis perpendicular to the carbonyl 
group establishing direct hydrogen bond interactions with the nearby amino-
acidic residues (Figure 1.22).  
Those differences between the two co-crystal structures could be a 
consequence of the slightly dissimilar structures of MyxA 1.25 and dMyxB 1.27 





Figure 1.22 Overlay of the co-crystal structure proposed by Mukhopadhyay92 et 
al. in cyan (PDB 3DXJ) with the co-crystal structure obtained by Belogurov93 et 
al. in green (PDB 3EQL). 
The first total syntheses of MyxA 1.25 and MyxB 1.26 were reported95 in 
1998 and since then several MyxB analogues have been synthesized99,100 
without any knowledge of the structure within the binding site and the majority of 
them resulted less potent on E. coli RNAP with a decreased antibacterial 
activity when compared to the biological activity of the parent compound. MyxB 
1.26 structure resulted very sensitive to structural modification and only a close 
analogue, dMyxB 1.27 possessed comparable biological activity.99 
A recent report101 has evaluated the resistance properties (frequency, 
spectrum, and fitness costs) of MyxB 1.26 in Staphylococcus aureus. The 
authors
101
 located six substitutions in the RNAP β subunit and five in the RNAP 
β′ subunit which conferred resistance to MyxB 1.26 and observed that the 
resistance rate for MyxB is comparable to the resistance rate for rifampicin 1.11. 
Notably, all substitutions conferring MyxB resistance exhibit significant fitness 
costs (4 to 15% per generation) while at least three substitutions conferring 
rifampicin resistance exhibit no fitness costs.101 These observations, together 
with the previously established inverse correlation between fitness cost and 
clinical prevalence, lead to the conclusion that MyxB resistance is likely to have 
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lower clinical prevalence than rifampicin resistance and suggest that the ‘switch 
region’ is a viable starting point for drug discovery.101 The difference in fitness 
costs of MyxB resistance and rifampicin resistance presumably relates to the 
fact that the binding site on RNAP for MyxB (the RNAP ‘switch region’) is 
responsible for critical functions in opening and closing the RNAP active-centre 
cleft and in DNA binding whereas the binding site on RNAP for rifampicin 
performs no critical functions.101 
1.4.8.2  Corallopyronins 
The corallopyronins, isolated from Corallococcus coralloides,97 are α-
pyrone antibiotics structurally related to myxopyronin B (MyxB).102 
Corallopyronin A (CorA) 1.28 (Figure 1.23), has been found to inhibit bacterial 
RNAP in vitro (IC50  0.73 μM) and is active against Gram-positive bacteria.
102 A 
recent total synthesis of CorA 1.28 has been reported.103 Resistant mutants of 
S. aureus to CorA 1.28 were easily selected and the mutations were located in 
the β and β′ subunits of RNAP.102 Cross-resistance to the related α-pyrone 
antibiotic MyxB 1.26 but not with the other known bacterial RNAP inhibitors was 
observed and therefore it is possible to conclude that CorA shares the same 
binding site of MyxB102 within RNAP. 
When compared to rifampicin 1.11, CorA 1.28 has a limited spectrum of 
antibacterial activity, low activity both as an RNAP inhibitor and as an 
antibacterial agent and, like rifampicin, a high propensity for selection of 
resistance.102 For these reasons, CorA is of limited interest for development as 
a future drug candidate.102 However, the eventual synthesis of derivatives of 
CorA with improved physicochemical features could represent a viable starting 
point for future antibiotic candidates.102 
 
Figure 1.23 Structure of CorA 1.28. 97 
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1.4.8.3  Ripostatins 
Ripostatins104,105 A 1.29 and B 1.30 (Figure 1.24) are two polyketide-
derived macrocyclic lactones from a strain of Sporangium cellulosum with a 
narrow antibiotic spectrum on S. aureus and some E. coli strains due to their 
limited ability to cross membranes. Ripostatins (Rip) are structurally different to 
MyxB 1.26 and CorA 1.28 but share similar size and hydrophobic character.92 
The high levels of cross resistance with MyxB 1.26 and CorA 1.28 and the 
location of Rip resistant mutants in the switch region suggest that they probably 
share the same binding site to that of MyxB 1.26 and CorA 1.28 although no X-
ray co-crystal structures have been reported.
92
 Ripostatin A 1.29 selectively 
inhibits the initiation step of bacterial RNA synthesis (IC50  0.8 μM), preventing 
interaction of RNAP with the promoter DNA.92 Several total synthesis 
approaches have been reported for these molecules.106,106b,107,108,109 
 
 
Figure 1.24 Ripostatin A 1.29 and B 1.30 structure.105 
1.4.8.4  Synthetic inhibitors of the ‘switch region’ 
1.4.8.4.1  Pyridyl-Benzamides 
A recent structure-based drug design approach (SBDD), and in particular a 
fragment based drug design (FBDD) strategy using the de-novo design 
SPROUT software, has been applied to the dMyxB 1.27 binding site.110 Using 
the co-crystal structure of the Thermus thermophylus RNAP Myxopyronin 
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complex (PDB: 3EQL),93 a weak E. coli in vitro inhibitor 1.31 (IC50 151 µM) 
(Figure 1.25) was identified and then chemically optimized.110 Subsequently, 
SAR studies were performed to deliver some selective inhibitors of RNAP in the 
low micro-molar range but disappointingly none of these compounds exhibited 
antibacterial activity.24, 110  
 
Figure 1.25 Structure of pyridyl-benzamide 1.31. 110 
1.4.8.4.2  Myxopyronin based synthetic hybrids 
A recent report111 described the use of a hybrid strategy involving 
incorporating the antibiotic holomycin 1.32 (Figure 1.26) into a myxopyronin-
type skeleton in order to improve antimicrobial activity, reduce lipophilicity and 
improve stability of the antibiotic myxopyronin A 1.25. Holomycin 1.32 shows a 
moderate broad spectrum antibacterial activity against Gram-positive and 
Gram-negative bacteria, inhibits RNA synthesis and in addition, has a 
favourable CLogP value (2.0).111 Two types of hybrid derivatives were designed 
based on the reported X-ray crystal structure of RNA polymerase bound with 
MyxA (PDB: 3DXJ)92 and derivative 1.33 (Figure 1.26) showed moderate 
antibacterial activity on B. subtilis (MIC 16 µg/µL) and in vitro inhibition of E. coli 
RNAP (14 µM) whilst it was ineffective in terms of antibacterial activity against 
E. coli due to its low penetration ability in Gram-negative bacteria.111 
Subsequent docking studies on RNAP complex with MyxA (PDB: 3DXJ)92 






Figure 1.26 Structures of holomycin 1.32 and its derivative 1.33. 111 
 
1.4.8.4.3  Squaramides 
Following high-throughput screening for novel inhibitors of a transcription-
coupled translation assay using E. coli S30 extracts, a series of E. coli RNAP 
inhibitors with a squaramide core 1.34 (Figure 1.27) were discovered by 
AstraZeneca.112 The observation that this series had antibacterial activity 
against efflux-negative strains of E. coli and H. influenzae was exploited to 
show that squaramides exhibit their inhibitory activity within the ‘switch region’ 
of RNAP via the location of resistance mutations and the lack of cross 
resistance with the other known classes of RNAP inhibitors like rifampicin 1.11. 
112 Docking studies on homology models of the ‘switch region’ bearing the 
experimentally observed mutations delivered a binding mode consistent with the 
MIC profile on mutants.112 Despite the low micro molar activity (IC50 = 0.3 µM) 
observed with some analogues, no antimicrobial activity was observed against 




Figure 1.27 Structure of squaramide 1.34. 112 
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1.4.9  Tagetitoxin 
The phytotoxin Tagetitoxin 1.35 113,114,115 (Figure 1.28) produced by 
Pseudomonas syringae pv. Tagetis is a non-selective RNAP inhibitor due to its 
evolutionary conserved binding site. It was co-crystallized with the T. 
thermophylus RNAP116 which revealed that tagetitoxin 1.35 binds to the base of 
the RNAP secondary channel, close to the active site and interacts with the 
incoming NTPs by altering the substrate loading or by stabilizing the enzymatic 
complex in an inactive state. Tagetitoxin 1.35 does not inhibit the growth of any 







Figure 1.28 Tagetitoxin 1.35 structure.117 
 
 
1.4.10  Other synthetic RNAP inhibitors 
1.4.10.1  CBR703 and analogues 
CBR703 1.36 118 (Figure 1.29) is the progenitor of a synthetic class of 
selective bacterial RNAP inhibitors identified by Cumbre Pharmaceuticals from 
a high-throughput screen of a library of ~300,000 compounds with the aim of 
inhibiting E. coli RNAP. The hit molecule, CBR703, showed selective inhibition 
of E. coli RNAP with an IC50 value of 10 μM but did not show any antibacterial 
activity against Gram-positive or Gram-negative species. However, the 
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observation that CBR703 possessed antibacterial activity against E. coli tolC 
mutant strains led to the conclusion that the compound is specifically effluxed 
out from the cell. Synthetic variants of CBR703, like CBR9379 1.37 and 
CBR9393 1.38 (Figure 1.29), led to improved potency against the enzymatic 
target with no significantly improved antibiotic activity. Following studies on 
mutations which confer resistance, it has been proposed that these inhibitors 
bind to a surface-exposed groove at the junction of the β′ bridge helix and the β 
subunit preventing the β′ bridge helix to adopt the correct conformation for 
nucleotide addition by allosterically altering its conformation. A systematic SAR 
exploration has been performed by Cumbre Pharmaceuticals and reported in a 
patent119 in 2002. Further development on this class was recently attempted by 
Zhu et al.120 by synthesizing thirty analogues but the compounds which showed 
antibacterial activity correlated with a significant cytotoxicity toward HEK293 
cells. Furthermore, the reported effects on biofilm formation by a previous 
study,121 which were among the main reasons for synthesizing CBR703 
analogues, were suspected to be artefacts due to compound precipitation. 
Finally, these authors120 concluded that this class of compounds is unattractive 




Figure 1.29 CBR703 1.36, CBR9379 1.37 and CBR9393 1.38 structures.118 
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1.4.10.2  Ureidothiophenes 
Ureidothiophenes122 are a class of bacterial RNAP inhibitors identified 
following high-throughput screening of a commercial library of compounds 
against S. aureus RNAP holoenzyme. The progenitor of this synthetic class is 
compound 1.39 (Figure 1.30), which displayed low micro-molar IC50 value and 
potent selective antibacterial activity against some S. aureus strains but not on 




Figure 1.30 Structure of 1.39. 122 
 
Antibacterial activity was abolished upon addition of human and mouse 
serum to the growth medium suggesting that the hydrophobic nature of these 
compounds results in poor pharmacokinetic properties.122 The SAR exploration 
led to many analogues with in vitro nanomolar potency but very stringent 
structural requirements were needed to retain antibacterial activity which were 
not compatible with the need for derivatives with improved pharmacokinetic 
properties.122 Ureidothiophenes showed good antibacterial activity against 
rifampicin-resistant strains of S. aureus, suggesting an alternate mechanism of 
action or binding site on the RNAP holoenzyme.122 Macromolecular synthesis 
assays122 concluded that the mode of action of these compounds is the 
inhibition of both RNA and protein biosynthesis. Studies conducted by our 
collaborators (unpublished data123) showed a preference for the inhibition of 
protein biosynthesis, suggesting off-target inhibition in the cell. We concluded 




1.4.11  Peptides as protein-protein interaction inhibitors 
 
A recent study,124 considered the interface between the E. coli RNAP core 
enzyme and σ70 factor as a potential binding site for inhibiting the assembling of 
the RNAP holoenzyme which is essential for transcription inhibition. The lack of 
homology between the bacterial σ70 subunit and the mammalian homologues 
permits selective inhibition of bacterial RNAP with a broad spectrum of antibiotic 
activity due to its essential role in transcription.124 A peptide approach was 
undertaken for generating new inhibitors of this crucial protein-protein 
interaction and sixteen peptides covering different regions of E. coli core 
enzyme and the σ70 interface were designed and some of them, derived from 
the σ70 2.2 region, showed strong RNAP inhibition with IC50 values in the low 
micromolar range.124 ELISA-based binding experiments and the observation 
that transcription initiation was inhibited strongly supported the σ70-core enzyme 
interface as a target site.124 These data could lead to the generation of novel 
RNAP inhibitors targeting RNAP with a new mode of action.124 
 
1.4.12  Small molecules as protein-protein interaction inhibitors125 
 
Following the flexible alignment of structurally similar selected synthetic 
molecules that were known to inhibit bacterial RNAP, a pharmacophore model 
was developed by Hinsberger et al.125 Despite the fact there were no empirical 
data confirming those molecules share the same binding region, this 
pharmacophore model was subsequently used to perform virtual screening. 
Three hit compounds bearing an anthranilic acid core, 1.40, 1.41 and 1.42 





Figure 1.31 Structures of 1.40, 1.41 and 1.42. 
 
 Hit compounds were then chemically optimised yielding novel derivatives 
with improved in vitro potency. In particular, the most potent compound, 1.43 
(Figure 1.32), showed an IC50 of 9 μM on E. coli RNAP and fair antibacterial 
activity on Gram-positive strains (S. aureus MIC = 6 μg / mL). The authors125 
demonstrated that the new inhibitors acted via a dual target effect via 
preventing the protein-protein interaction between σ70 and the RNAP core 
enzyme and inhibiting bacterial lipid biosynthesis. This dual target effect could 
account for the relatively low MIC values and the significantly lower resistance 
rate compared to the clinically used inhibitor Rifampicin 1.11. 
 
 




1.5  Thesis aims and objectives 
The work presented in this thesis describes the application of in silico 
techniques to design rationally novel inhibitors of bacterial RNAP targeting the 
myxopyronin binding region of the enzyme. An iterative process has been 
devised which comprised in silico techniques to identify putative inhibitors, 
chemical synthesis and biological evaluation. 
Within these categories, the aims and objectives of the project are: 
Objective 1: To use in silico techniques to identify putative RNAP 
inhibitors 
The aims under this objective are: 
a) To learn and understand the principles of ligand and structure-based 
virtual screening including all the computational techniques required 
such as docking. 
b) To validate the software and the computational protocols. 
c) To formulate hypotheses for rational design on the basis of 
computational predictions and refine them after biological evaluation 
results. 
 
Objective 2: To use synthetic chemistry to produce putative 
inhibitors 
The aims under this objective are: 
a) To apply modern organic synthesis techniques to prepare compound 
libraries corresponding the in silico designed molecular scaffolds. 
b) To conduct Structure Activity Relationship exploration and analysis 
using the synthesized analogues in an iterative process together with 
the in silico techniques. 
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c) To ensure a high level of purity for the synthesized compounds to 
enable biological evaluation. 
d) To ensure full chemical characterization for all synthesized 
compounds to publication standard. 
Objective 3: To subject the synthesised molecules to preliminary 
biological evaluation 
The aims under this objective are: 
a) To measure in vitro percentage inhibition against E. coli RNAP at 
100μM and then to select compounds with more than 50% inhibition 
for chemical optimization.  
b) To determine in parallel, for the most potent analogues, IC50 values, 
MICs against a panel of representative Gram-positive and negative 
bacterial strains, and the potential for promiscuous inhibition on 
unrelated enzymes such as malate dehydrogenase and 
chymotrypsin.  
c) To progress promising compounds to further biological evaluation 
including membrane integrity assessment and specificity for inhibition 
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2. Computational Methodologies 
2.1 Virtual Screening approaches 
High-throughput screening (HTS) of chemical libraries is a well-established 
method in drug discovery1 but its main drawback is represented by the cost of 
randomly screening increasingly large databases.2 Virtual screening (VS) is a 
computational technique capable of selecting the most promising compounds 
from an electronic chemical database for experimental screening.3 VS 
approaches can be both ligand-based and structure-based.4,5 Structure-based 
virtual screening (SBVS) involves the docking of molecules within the active site 
of target proteins for hit identification and is a complementary methodology to 
HTS allowing a higher hit rate and, at the same time, reducing the cost and 
duration of a screening campaign.6 A SBVS protocol can be summarized in 
three main steps: 1) database preparation (filtering, protonation states, charges, 
most stable tautomers), 2) docking, 3) post-docking analysis (clustering of 
poses, consensus scoring,7 visual inspection).  
 
2.2 Docking 
The availability of several techniques (X-ray crystallography, NMR, 
homology modeling) providing structural information about biological targets has 
opened up a vast field of drug discovery, Structure Based Drug Design (SBDD), 
which mainly relies in docking techniques.  
All docking software are composed of two basic modules: a search 
algorithm and an evaluating algorithm (scoring function). The search algorithm 
identifies all possible interactions between the ligand and the biological target 
while the scoring function estimates the free energy of binding of the ligand 
poses generated within the binding site. The main uses of docking in drug 
discovery are:8,9 1) predicting the binding mode of a ligand with known 
biological activity, 2) identification of potential new ligands via SBVS, 3) 





2.2.1 Challenges in docking  
The success of docking techniques depends on the correct sampling of a 
flexible molecule within its biological target via the search algorithm and from 
the precise energetic evaluation of generated poses via the scoring function.8 
Any possible error deriving from those two algorithms will generate ‘hard’ and 
‘soft’ errors in evaluating the energy of ligand-protein interactions when 
compared to the empirical data derived from the analysis of co-crystals 
structures of ligands with proteins.8 A ‘soft’ error is generated when the 
predicted binding energy is underestimated while a ‘hard’ error comes from the 
opposite situation.
8
 The consequence of ‘soft’ and ‘hard’ errors are the 
generation of false negatives and false positives in a virtual screening protocol 
respectively.  
Docking can be visualized as a multi-step process where any consecutive 
step introduces additional degrees of complexity.10  
 
2.2.2 Search algorithms 
Generating ligand poses is challenging even for small molecules due to the 
presence of many conformational degrees of freedom. Conformational sampling 
must be performed rapidly for a large database of molecules and at the same 
time needs to be accurate.10 Several strategies for solving this problem are 
adopted11 and docking algorithms can be differentiated as stochastic or 
deterministic and are described in detail in the following Sections for each 
software evaluated in this thesis. Stochastic algorithms include a random factor 
and their results are not always reproducible while for deterministic algorithms, 
reproducible results are always given.11 The main drawback of deterministic 
algorithms when compared with stochastic ones is the fact that they can 
generate a conformation which is trapped in a local minima of the potential 
energy surface.11 With regard to protein flexibility, it is not feasible from a 
computational point of view and several approximations are needed (partial 







2.2.3  Scoring functions 
Scoring functions are used for two purposes:11 1) to aid the generation of 
ligand poses via their optimization during conformational sampling, 2) to rank 
each solution of docked ligands included in a database.  
The aim of a scoring function is to give a fast and possibly accurate 
estimation of the free energy of binding when protein-ligand complexes are 
generated during docking.11 
The free energy of binding is expressed by the Gibbs-Helmholtz equation 
(2.1): 
 
ΔG = ΔH - TΔS  (2.1) 
 
where ΔG represents the free energy of binding, ΔH the enthalpy, T the 
temperature in Kelvin and ΔS the entropy. 
Scoring functions can be divided into three main classes:10 
Force-field based: molecular mechanics force fields are used to quantify 
the receptor-ligand interaction which is generally the sum of two energies, the 
receptor-ligand interaction energy and the internal ligand energy. In most cases 
only a single conformation of the protein is considered in order to omit the 
calculation of internal protein energy.10 Van der Waals and electrostatic energy 
terms are used to describe the interaction between ligand and receptor.10 
Empirical scoring functions: are a sum of several parameterized functions 
for reproducing experimental data such as binding energies.10 Coefficients of 
various terms are obtained from regression analysis of empirical data.10 
Knowledge-based scoring functions: are designed to reproduce 
experimental structures rather than binding energies.10 They are essentially 
based on data like defined atomic interaction pair potentials found in limited sets 
of protein-ligand complex structures.10 
 
2.2.4  Main limitations of scoring functions 
In order to give a fast evaluation of results, most of the scoring functions 
omit or simplify some of its energetic terms such as calculating enthalpic 
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contributions but neglecting entropic factors (often limited to loss of torsional 
entropy of ligands only) and solvation effects.10 Other limitations are constituted 
by their dependence on molecular data sets used to gather coefficients of the 
terms used in functions for regression analysis and fitting.10 As a consequence 
of those simplifications and limitations, a fast, robust and accurate scoring 
function for all biological targets does not exist.10 In order to overcome the 
imperfections of current scoring functions, consensus scoring7 is applied in 
docking and VS approaches. Consensus scoring consists of combining different 
and unrelated scoring functions (e.g. combining a force-field based with a 
knowledge-based scoring function) with the aim of reducing and balancing 
errors of the individual scoring functions and consequently, improving the 
chances of identifying ‘true’ ligands.10  
 
2.3 Glide (Grid based ligand docking with energetic)
14
 
Glide is a protein-ligand docking program which approximates a complete 
systematic search over ligand positions, orientations and conformations in the 
receptor site.14 A series of hierarchical filters are used to identify the possible 
locations of the ligand into the active site of the receptor which is represented 
as a grid derived by different sets of fields for the accurate scoring of any ligand 
pose.14 To summarize, the search algorithm performs an initial rough positioning 
and scoring to reduce the search then a torsionally flexible energy optimization 
using the OPLS-AA15 force field for a few hundred surviving candidate poses.14 
Only the best candidates are further refined via Monte Carlo sampling of pose 
conformation.14 The best docked poses are selected by the scoring function 
(Glide Score) that combines empirical and force-field based terms.14 
Glide XP
16
 represents an extra precision mode in Glide which consists of 
an optimized search algorithm and scoring function. The goal of this 
methodology is to semi-quantitatively rank the ability of a candidate ligand to 
bind to a specified conformation of the protein receptor.16 






XP Glide Score = Ecoul + EwdW + Ebind + Epenalty  (2.2) 
 
Ebind = Ehyd_enclosure + Ehb_nn_motif + Ehb_cc_motif + EPI + Ehb_pair + Ephobic_pair 
Epenalty = Edesolv + Eligand_Strain 
 
Where Ehyd_enclosure = hydrophobic enclosure interaction; Ehb_cc_motif = charged-
charged hydrogen bond interaction motif; Ehb_nn_motif = neutral-neutral hydrogen 
bond interaction motif; EPI = reward for pi-stacking and pi-cation interactions. 
  The key features of this scoring function16 are:  
1) the application of large desolvation penalties to both ligand and protein 
polar and charged groups. 
2) the identification of specific structural motifs which contribute to binding 
affinity. 
 
2.4 F.R.E.D. (Fast Rigid Exhaustive Docking) 
17,18 
F.R.E.D. is a protein-ligand docking program which: a) takes a multi-
conformer database and receptor file as input, b) performs a systematic, 
exhaustive, non-stochastic evaluation of all possible ligand poses within the 
protein active site, c) filters for shape complementarity and pharmacophoric 
features (if a known inhibitor is prompted) d) and finally select and optimize 
poses using the Chemgauss3 scoring function.17,18,19 The protein is held rigid 
during the docking process as well as the conformers of the ligand. Ligand 
flexibility, however, is implicitly taken into account by docking the conformer 
ensemble of each molecule.17,18  
The protein receptor is represented as the complementary image of the 
active site and it is created by contouring a shape potential field that 
complements the active site.17,18 
The Chemgauss3 scoring function uses Gaussian smoothed potentials to 
measure the complementarity of ligand poses within the active site and it is 
shown below (Equation 2.3):18,19 
 




Where Eshape = shape interaction between the negative image of the 
protein and the ligand; Ehblp = Hydrogen bonding interaction between ligand and 






AutoDock is a suite of automated docking tools and consists of two main 
programs: AutoDock performs the docking of the ligand to a set of grids 
describing the protein while autogrid pre-calculates these grids.20,21 AutoDock 
combines an empirical free energy force field with a Lamarckian Genetic 
Algorithm, giving a prediction of poses and free energies of binding.20,21,22 The 
Lamarckian genetic algorithm provides the conformational search of the ligands 
creating a population of trial conformations, then genetic operators (mutations, 
crossovers etc.) are applied to exchange conformational parameters and to 
select conformations with the lowest binding energy.22 The ‘Lamarckian’ feature 
allows individual conformations to search their local conformational space, 
finding local minima, and then to pass this information to later generations.22  
The target protein is embedded in a grid representing the energy of 
interaction between a probe placed at any grid point and the target protein.22 
The scoring function consists of a semi-empirical free energy force field 
designed to predict binding free energies of small molecules to macromolecular 
targets.22 The free energy of binding is estimated to be equal to the difference 
between the energy of the ligand and the protein in a separated unbound state 
and the energy of the ligand–protein complex.22 The force field includes six pair-
wise evaluations (V) and an estimate of the conformational entropy lost upon 
binding (ΔSconf) as shown below (Equation 2.4):
22 
 
ΔG = (VL-L bound – V L-L unbound) + (VP-P bound – V P-P unbound) +  
(VP-L bound – V P-L unbound + ΔSconf)  (2.4) 
 
In the above equation L refers to the ligand and P refers to the protein in a 
protein–ligand complex and the pair-wise atomic terms (V) include evaluations 





 (electronic high-throughput screening) 
eHiTS is a docking program performing an exhaustive conformational and 
positional search of the space of the ligand, compatible with steric and chemical 
constraints, at a speed practical for virtual high-throughput screening.23,24 A 
statistically derived empirical scoring function evaluates the score of each ligand 
pose during the docking sequence.23,24 
A steric grid is built within the binding pocket, identifying pockets and 
possible interaction sites using thousands of geometric shapes (polyhedra) to 
describe cavities.23,24  
The ligand is broken into rigid fragments while connecting flexible chains 
and all rigid fragments are docked independently.23,24 A fast graph-matching 
algorithm identifies all matching solutions and reconstructs the original molecule 
by fitting flexible chains between the rigid fragments and satisfying all the 
sterical constraints.23,24 The resulting poses are refined by a local energy 
minimization in the active site of the receptor and ranked by the scoring function 
which is constituted by the following terms:  
 Hydrogen-bonding (distance and angle dependent energy function) 
 Hydrophobicity (applied to surface contact points) 
 Aromatic pi-stacking (applied to surface contact points) 
 Electrostatic potential (based on Coulomb’s law) 
 Van der Waals contact energy (Lennard–Jones potential) 
 Metal ion interactions (distance and angle dependent energy function) 
 Penalty for incompatible contacts (e.g. polar–hydrophobic or same charge) 
 Interaction energy of exposed surface atoms with solvent properties 




 (Genetic Optimization for Ligand Docking) 
 GOLD27,28 uses a genetic algorithm for identifying the global minimum of 
the energy of interaction between the ligand and the protein receptor.27 
 A genetic algorithm mimics the natural evolution process where the 
conformation of a ligand and the mapping of interaction points between ligand 
and receptor atoms are codified into a chromosome.27,29 After the application of 
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genetic operators (mutations, crossovers and migrations), only the individuals 
with the best fitness are conserved.27,29 The population of individuals is divided 
into smaller groups employing an island model and the fitness of each individual 
is assessed using the available scoring functions present in the software.27,29  
 The placing of the ligand in the binding site is based on fitting points which 
are generated on hydrogen bonding groups of protein and ligand where 
acceptor or donor points are mapped.27,29 Additionally, hydrophobic fitting points 
in the protein cavity and ligand CH groups are mapped.27,29  
 For the purposes of this thesis, two out of the four available scoring 
functions were considered: GoldScore27 and ChemScore.27, 30 
 The Goldscore27 is a molecular mechanics–like scoring function 
with four terms (Equation 2.5): 
 
Goldscore Fitness = Shb_ext + Svdw_ext + Shb_int + Svdw_int  (2.5) 
 
where Shb_ext is the protein–ligand hydrogen bond score, Svdw_ext is the 
protein-ligand van der Waals score, Shb_int is the contribution to the Fitness due 
to intramolecular hydrogen bonds in the ligand and Svdw_int is the contribution to 
the Fitness due to intramolecular ligand van der Waals score. 
 The Chemscore14,17 is an empirical based scoring function and estimates 
the free energy of binding of a ligand to a protein as follows (Equation 2.6): 
 
Chemscore Fitness = ΔGbinding + ΔGhbondShbond + ΔGmetalSmetal + ΔGlipoSlipo + 
ΔGrotHrot  (2.6) 
 
where Shbond, Smetal, and Slipo are scores for hydrogen bonding, acceptor-metal, 
and lipophilic interactions, respectively. Hrot is a score representing the loss of 
conformational entropy of the ligand upon binding to the protein. 
 The Chemscore14,17 scoring function is up to three times faster than 
Goldscore14 to dock molecules, but the latter is more accurate in predicting 
binding modes with big ligands.27 Combining both scoring functions has been 
shown to give better results than using a single function thanks to the 
complementarity of their parameters.27 No case study has ever identified the 
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 DOCK Blaster,31 is a fully automated docking system which includes self-
assessment. The software has been tested for reproducing experimental 
observed poses and for enrichment, defined as the ability to find active 
molecules included in a database of decoys. A decoy is a member of the 
database that does not bind to the target but shares similar physico-chemical 
properties with active molecules.31 DOCK Blaster is accessible via a web-
enabled user interface32 and the docking program used is DOCK 3.6.33 The 
DOCK Blaster pipeline is composed of six modules:31 a) the parser, which 
identifies the receptor and ligand from a PDB file, b) the scrutinizer, which 
attempts to correct structural problems of supplied pdb structures, c) the 
preparer which assigns atomic parameters, calculates protonation states, ‘hot 
spots’ and grids, d) the calibrator, which assess docking performance and 
suggests optimal docking parameters, e) the docker, which performs the 
screening f) the assessor, which interprets and give results as a spreadsheet.  
 The docking is based on an incremental construction algorithm where the 
ligand is decomposed into single fragments and incrementally reconstructed 
inside the active site.34 The shape characteristics of the protein active site are 
described as a series of overlapping spheres filling the available volume and an 
anchor fragment of the ligand is oriented independently from the other rigid 
fragments by matching its atoms with sphere centers.34 The best scored anchor 




The DOCK blaster scoring function33 is force field based and it is expressed as 
shown below (Equation 2.7) : 
 
Escore = EVdW + Eelec + ΔG
L
desol  (2.7) 
 
where EVdW represents the van der Waals term based on the AMBER united-
atom force field35, and Eelec is the electrostatics term that is based on Poisson 
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Boltzmann calculations performed by DELPHI software36 and ΔGLdesol is the 
polar and apolar desolvation term for each ligand atom. 
 
2.9 Ligand-based virtual screening 
Ligand-based approaches are complementary to structure-based methods 
and are often applied when structural information on the protein target is 
missing or scarce and are focused on the biological and chemical properties of 
ligands.37,38  
Ligand-based methods often use explicit parameters reflecting molecular 
properties and rely on the principle that ligands similar to an active molecule are 
more likely to be active than random ligands.37,38  
Ligand-based approaches generally start from a series of active molecules 
targeted at a specific biological target which are then used to generate a query 
for ranking databases of molecules with a lower computational cost when 
compared with structure-based methods.37,38 They include pharmacophores, 
quantitative structure activity relationship (QSAR) models as well as 3D or 2D 
similarity calculations based on physicochemical properties and molecular 
shapes.37  
One of the advantages of shape-based approaches used for this thesis is 
that multiple active compounds and explicit parameters are not strictly required, 
resulting in limited computational time for screening large databases.37,38 The 
most common drawbacks of ligand-based methods are derived from the fact 
that they 1) do not take into account the protein structure; 2) are biased towards 
existing ligands; 3) chemical and shape descriptors are dependent on input 
conformation; 4) results rely on the quality of training sets; 5) in shape-based 
approaches the problem of the false negatives is not uncommon since 
compounds showing unforeseen binding modes but structurally dissimilar to a 








2.9.1  ROCS38 (Rapid Overlay of Chemical Structures) 
 ROCS is a shape similarity ligand-based software which evaluates the 
molecular shape and the chemical features of one or more active molecules 
defined as a query.38 Molecules are described as atom-centered Gaussian 
functions and the searching algorithm overlays molecular shapes by 
overlapping the centers of mass of the query molecule with a screening 
database of conformers.38 After this preliminary overlay, the principal moments 
of inertia are aligned and the final overlapping is evaluated by the combined 
shape and chemistry (color) score defined as the combo score.38 This score is 
expressed as the sum of the Tanimoto
19
 coefficients for shape and chemical 
(color) similarity and it is a number between 0 and 2 of which 2 represents the 
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3. Critical assessment of the available docking software 
 The priority for developing a VS protocol and, more generally, for ligand-
protein docking, is to critically assess, amongst the available docking software 
implementing different search and evaluating algorithms, which are the ones 
capable of reproducing co-crystal structures, when available, of a ligand with its 
protein. In particular, the success of a docking program is usually measured by 
the root-mean-square deviation (RMSD) between the predicted and the 
experimentally observed heavy atom positions.1 Generally a successful result is 
obtained when docking solutions have RMSD < 2 Å but other authors2,3 
consider RMSDs which lie between 2 and 3 Å as a partial success.4 Another 
important aspect is to consider the reproducibility of the protein-ligand 
interactions and in fact, an acceptable RMSD that lacks this requirement is not 
considered as a good result according to some authors.5 Typically, no single 
docking algorithm works best for all targets and it is necessary to establish the 
optimal docking algorithm on the specific target of interest.1  
For the purposes of this thesis, an RMSD < 3 Å was used as a ‘rule-of-
thumb’ for evaluating docking performance and in addition, the reproducibility of 
the protein-ligand interactions limited to conserved hydrogen bond networks 
between protein-ligand H-Bond donors and acceptors was considered. 
In this thesis, the following software were evaluated: GLIDE,6 F.R.E.D,7,8 
Autodock,9,10 eHiTS,11,12,13,14 GOLD15,16 and Dockblaster.17 
 
3.1 Protein and ligand preparation protocol 
Two crystal structures of the T. thermophilus RNA polymerase (RNAP) 
holoenzyme in complex with the antibiotic myxopyronin 1.25 (PDB id: 3DXJ18 
and PDB id.: 3EQL19) were available from the Protein Databank20 and were 
both evaluated in the docking software assessment.  
In particular, two different chemical forms of myxopyronin were present in 
the two crystal structures: myxopyronin A 1.25 for PDB id: 3DXJ18 and 7-
desmethylmyxopyronin B 1.27 for PDB id.: 3EQL.19 
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The binding site within the RNAP for both myxopyronin A and 7-
desmethylmyxopyronin B was defined as a 20 Å spherical cut of the protein 
surrounding the co-crystallized ligand from the two previously mentioned crystal 
structures. 
The two antibiotic molecules were manually built using Maestro 
(Schrödinger, LLC, New York, NY) and the resulting molecular structures were 
geometrically optimized and energy minimized using the software module 
Macromodel by applying the OPLS2005 force field in a simulated water 
dielectric. Ionization states were defined for a neutral pH using the Epik module 
and partial charges were assigned by applying the OPLS2005 force field.  
Protein structures were prepared using the ‘Protein preparation wizard’ 
module included in Maestro. Preparation consisted of assigning bond orders, 
deleting water molecules, adding hydrogen atoms and optimizing hydrogen 
bond networks assuming neutral pH, using PROPKA. Finally, protein structures 
were subjected to a restrained energy minimization using the OPLS2005 force 
field with heavy atoms allowed to deviate up to 0.3 Å from their experimental 
positions. 
 
3.2 Docking protocol used with Glide
6
  
From the previously prepared ligand and protein structures, a 10 Å3 box 
centered on the mass-center of the crystallographic ligand was considered for 
calculating the docking grid. A fully flexible torsional geometry was allowed for 
the ligand, and 100 poses were generated using the Glide XP scoring function. 
Cluster analysis with an average linkage method was performed using 
clustering scripts implemented within Maestro. The docking conformations were 
clustered on the basis of RMSD applying a cutting rule at 1.5 Å between the 
cartesian coordinates of the ligand atoms. 
The best ranked pose of the most populated cluster was selected as a 
result and RMSD values between predicted and the experimentally observed 
heavy atom positions were calculated using Maestro. 
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3.3 Docking protocol used with eHiTS
11,12,13,14
 
eHiTS v9.0 automatically evaluates all of the possible protonation states 
for ligand and enzyme and for this reason, previously prepared structures were 
not used. Active-site detection was carried out using the ‘-complex’ parameter 
and docking was performed using the highest accuracy setting (set to 6). For 
allowing a more accurate scoring and conformational sampling of the known 
inhibitors myxopyronin A 1.25 and 7-desmethylmyxopyronin B 1.27, the ‘-
bindener’ parameter was used for scoring with the eHiTS scoring function. The 
best ranked pose of the most populated cluster was selected as a result. 
Cluster analysis with an average linkage method was performed using 
clustering scripts implemented in Maestro. The docking conformations were 
clustered on the basis of RMSD applying a cutting rule at 1.5 Å between the 
cartesian coordinates of the ligand atoms. The best ranked pose of the most 
populated cluster was selected as a result and RMSD values between the 
predicted and the experimentally observed heavy atom positions were 
calculated using Maestro. 
 
3.4 Docking protocol used with Autodock
9,10
 
Autodock v.4.2.5.1 was used for docking calculations while ligand and 
protein structures were prepared with Autodock Tools v. 1.5.6 module. The 
docking area was defined using a box, centered on the cartesian coordinates of 
crystallographic myxopyronin A 1.25 and 7-desmethylmyxopyronin B 1.27. A 
grid point box of 60 × 60 × 60 with 0.375 Å spacing was calculated around the 
docking area for all the ligand atom types using AutoGrid4. For each ligand, 100 
separate docking calculations were performed using the Lamarckian Genetic 
Algorithm. All the other docking parameters were applied with the default 
settings. The docking conformations were clustered using Autodock Tools v. 
1.5.6 module applying an average linkage rule on the basis of RMSD using a 
cutting rule at 1.5 Å between the cartesian coordinates of the ligand atoms and 
were ranked based on the AutoDock scoring function. RMSD values between 
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the predicted and the experimentally observed heavy atom positions were 
calculated using Maestro. 
 
3.5 Docking protocol used with F.R.E.D
7,8
 
F.R.E.D v.2.2.5 was used for docking calculations. The receptor file was 
set up interactively using a GUI supplied with the software, specifying the 
location of the active site as a box of 20 Å3 centered on the cartesian 
coordinates of crystallographic myxopyronin A 1.25 and 7-
desmethylmyxopyronin B 1.27. Ligand conformers were generated using 
OMEGA version 2.3.2 prior to running the docking and applying the default 
settings. All the default docking parameters were used with the only exception 
of the number of poses generated, which were set to 100. The Chemgauss 
scoring function was used for the exhaustive search, optimization, and final 
scoring. Cluster analysis with an average linkage method was performed using 
clustering scripts implemented in Maestro. The docking solutions were clustered 
on the basis of RMSD applying a cutting rule at 1.5 Å between the cartesian 
coordinates of the ligand atoms. The best ranked pose of the most populated 
cluster was selected as a result and RMSD values between the predicted and 
the experimentally observed heavy atom positions were calculated with 
Maestro. 
 
3.6 Docking protocol used with GOLD
15,16
 
 From the previously prepared ligand and protein structures as described in 
Section 3.1, the docking area was defined using a sphere of 20 Å diameter 
centered on the Cartesian coordinates of crystallographic myxopyronin A 1.25 
and 7-desmethylmyxopyronin B 1.27. Docking was performed using GOLD 
v4.0.1 applying 200% of accuracy for the genetic algorithm and 100 poses of 
the ligand were generated and ranked separately with both scoring functions, 
Goldscore and Chemscore. 
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Cluster analysis with an average linkage method was performed using a 
module implemented in GOLD. The docking solutions were clustered on the 
basis of RMSD applying a cutting rule at 1.5 Å between the cartesian 
coordinates of the ligand atoms. The best ranked pose of the most populated 
cluster was selected as a result and RMSD values between the predicted and 
the experimentally observed heavy atom positions were calculated with 
Maestro. 
 
3.7 Docking protocol used with DOCK Blaster
17
 
The graphical interface of DOCK Blaster was accessed online and the 
PDB id of the enzyme (3DXJ18 and 3EQL19) were submitted specifying the 3-
letter code of the ligand (NE6 and MXP respectively). A job query number was 
assigned for the docking runs and results of the best docked poses with scoring 
values were generated automatically. No cluster analysis is available for this 
automated docking interface. RMSD values between the predicted and the 
experimentally observed heavy atom positions were automatically calculated.  
 
3.8 Critical evaluation of results 
 With regard to the docking of myxopyronin A 1.25 inside its native co-
crystal complex with PDB id: 3DXJ,18 the results in terms of RMSD between the 
predicted and the experimentally observed heavy atom positions and 
reproducibility of original protein-ligand interactions are summarized in Table 








Table 3.1 Results for the docking of myxopyronin A 1.25 inside its native co-
crystal complex with PDB id: 3DXJ.18 
Docking software RMSD 
Conserved 
interactionsC 
Autodock 6.44 Å 1 out of 4 
Dockblaster 5.38 Å 2 out of 4 
eHiTS 3.00 Å 1 out of 4 
F.R.E.D 5.91 Å 2 out of 4 
GLIDE 8.60 Å 0 out of 4 
GOLDA 1.28 Å  3 out of 4 
GOLDB 1.40 Å 3 out of 4 
 
A Goldscore scoring function 
B Chemscore scoring function 
C Conserved interactions intended as polar contacts of docked ligand with same amino-
acidic   residues contacted in native co-crystal complex.  
 
 
Figure 3.1 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 




Figure 3.2 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 
green) and docking solution obtained with Dockblaster (C atoms in yellow). 
     
Figure 3.3 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 




Figure 3.4 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 
green) and docking solution obtained with F.R.E.D (C atoms in yellow). 
 
 
Figure 3.5 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 
green) and docking solution obtained with GLIDE (C atoms in yellow). 
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Figure 3.6 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 
green) and docking solution obtained with GOLD (C atoms in yellow) using 
Goldscore as a scoring function. 
   
Figure 3.7 Overlay between crystallographic myxopyronin A 1.25 (C atoms in 
green) and docking solution obtained with GOLD (C atoms in yellow) using 




 With regard to the docking of 7-desmethylmyxopyronin B 1.27 inside its 
native co-crystal complex with PDB id.: 3EQL,19 the results in terms of RMSD 
between the predicted and the experimentally observed heavy atom positions 
and reproducibility of the original protein-ligand interactions are summarized in 
Table 3.2 and docking poses are reported in Figures 3.8-3.14. 
 
Table 3.2 Results for the docking of 7-desmethylmyxopyronin B 1.27 inside its 
native co-crystal complex with PDB id.: 3EQL.19 
Docking software RMSD 
Conserved 
interactionsC 
Autodock 6.30 Å 0 out of 5 
Dockblaster 8.87 Å 1 out of 5 
eHiTS 3.26 Å 1 out of 5 
F.R.E.D 8.96 Å 2 out of 5 
GLIDE 6.80 Å 2 out of 5 
GOLDA 1.76 Å 3 out of 5 
GOLDB 2.29 Å 4 out of 5 
 
A Goldscore scoring function 
B Chemscore scoring function 
C Conserved interactions intended as polar contacts of docked ligand with same amino-







Figure 3.8 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 




Figure 3.9 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 





Figure 3.10 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 
(C atoms in green) and docking solution obtained with eHiTS (C atoms in 
yellow). 
 
     
Figure 3.11 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 





Figure 3.12 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 




Figure 3.13 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 
(C atoms in green) and docking solution obtained with GOLD (C atoms in 




Figure 3.14 Overlay between crystallographic 7-desmethylmyxopyronin B 1.27 
(C atoms in green) and docking solution obtained with GOLD (C atoms in 
yellow) using Chemscore as a scoring function. 
 
3.9 Conclusions 
 From the analysis of the docking results, it was possible to conclude that 
GOLD is the most suitable docking software for both crystal structures in terms 
of RMSD values and reproducibility of original hydrogen bond interactions, with 
a slightly better performance observed for the Goldscore scoring function over 
the Chemscore. Redocking of myxopyronin A 1.25 inside its native co-crystal 
complex (PDB id: 3DXJ18) has delivered slightly better results. 
eHiTS can be considered as a second choice software in terms of RMSD 
values but as a consequence of the low reproducibility of the original hydrogen 
bond interactions, a different binding orientations are suggested for 
myxopyronin A 1.25 and 7-desmethylmyxopyronin B 1.27 to that observed in 
the co-crystal structures. 
Interestingly, following comparison of RMSD values for both co-crystal 
structures, the majority of the tested software are performing better with 
myxopyronin A 1.25 co-crystal complex (PDB id: 3DXJ18) which has a slightly 
82 
 
lower resolution (3.0 Å) when compared to that for the 7-desmethylmyxopyronin 
B 1.27 co-crystal complex with PDB id.: 3EQL19 (resolution 2.7 Å). 
On the basis of these considerations, GOLD was used for performing 
docking studies and structure-based virtual screening protocols. Both scoring 
functions (Goldscore and Chemscore) were used alone or in combination for 
consensus scoring approaches and the crystal structure of the T. thermophilus 
RNA polymerase (RNAP) holoenzyme in complex with the antibiotic 
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4.  Design of small molecule libraries as putative bacterial 
RNAP inhibitors  
 
4.1 Reported inhibitors of bacterial RNAP 
A high-throughput screen designed to discover novel inhibitors of E. coli 
RNA polymerase has been reported on Pubchem1 by Penn Center for 
Molecular Discovery.2  
The screen was based on an end-point assay monitoring the release of 
umbelliferone (Um), a fluorescent molecule. RNA polymerase catalyses the 
polymerization of RNA on a DNA template by incorporating nucleotide 
triphosphates, ATP, CTP, GTP, and UTP, with concomitant release of 
pyrophosphate (pp). For this assay, GTP was replaced with Um-pppp-G, which 
releases Um-ppp upon incorporation of guanosine into RNA. The subsequent 
addition of alkaline phosphatase cleaves Um-ppp to release the Um fluorophore 
which is fluorometrically detected.  
A total of 62,232 compounds were screened and seventeen active 
molecules were reported. No putative binding site on RNAP was proposed for 
the active compounds and no synthetic chemistry has been developed to 
assess structure activity relationships. 
It was envisaged that these inhibitors were attractive in terms of forming 
the basis of a study directed towards identifying the potential binding site within 
RNAP and therefore the development of more potent inhibitor scaffolds. Within 
this small set of reported inhibitors, the compound 4.1 (Figure 4.1) was selected 
on the basis of the RNAP in vitro inhibitory activity (18 µM), synthetic 
accessibility, drug-likeness and suitability for designing small libraries to 





Figure 4.1 Structure of 4.1. 
 
In order to probe the potential binding region of the reported inhibitor 4.1 
and to eventually allow structure-based rational design based upon its structure, 
docking studies were performed using the available X-Ray crystal structures of 
RNAP for the identification of its putative binding site. Two small libraries based 
on sulphonamide and urea scaffolds were designed, docked and synthesized 
as described below. 
 
4.2  In Silico docking studies of reported inhibitors 
In order to identify the putative binding site of molecule 4.1, an extensive 
docking study using GOLD was performed focussing on all the known inhibitor 
binding sites of RNAP and in particular, on the ansamycins,3 streptolydigin,4 
myxopyronin,5 tagetitoxin6 and CBR7 binding regions respectively. An X-Ray co-
crystal structure is available for all these binding sites with the exception of the 
CBR703 class of inhibitors, where the putative binding site was hypothesized on 
the location of amino acid changes that yield altered sensitivity to CBR703 on E. 
coli tolC mutants.7 The choice of docking parameters reflected the validation 
studies reported in Chapter 3. 
 
4.3  General docking protocol 
The crystal structures of the T. thermophilus RNA polymerase holoenzyme 
in complex with the antibiotics streptolydigin (PDB id: 2A6H), myxopyronin (PDB 
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id: 3DXJ), and tagetitoxin (PDB id: 2BE5) were downloaded from the Protein 
Databank (www.rcsb.org).   
The binding sites within the RNAP for streptolidydigin, myxopyronin, 
tagetitoxin respectively were defined as a 20 Å cut of the protein surrounding 
the co-crystallised ligand from the structures with PDB code 2A6H, 3DXJ and 
2BE5. 
The binding site for the ansamycins is included within the 20 Å cut of the 
protein surrounding the streptolydigin molecule while the binding region for the 
CBR703 based inhibitors was specified as a 20 Å cut of the protein surrounding 
the amino acid residue 720 into the X-ray crystal structure with PDB code 
2A6H.  
The hit molecule 4.1 was manually built using Maestro and the resulting 
molecular structure was geometrically optimised and energy minimised using 
the software module Macromodel by applying the OPLS2005 force field in a 
simulated water dielectric. 
The docking runs were performed using GOLD8 v4.0.1 (CCDC, 
Cambridge, UK) docking software by using the default settings for the genetic 
searching algorithm generating 100 poses for each compound and these were 
ranked with the Chemscore and rescored with Goldscore scoring function. 
Due to the relatively large volumes of all the chosen binding regions as 
expected, the docking software gave plausible solutions for each binding site 
investigated and therefore in order to discriminate between the various 
possibilities  a post-docking analysis was performed in each case. 
Among the different docking solutions, a cluster analysis using an average 
linkage rule was performed using an internal command within the software. 
Only the best ranked poses of the most populated cluster were considered as 
the most likely and representative ones. In addition, the docked poses within 
each considered binding pocket were analysed in terms of overall score, shape 
complementarity to the cavity, possibility to establish specific H-bonds to the 
protein in addition to the less specific hydrophobic contacts, minimal exposure 
of hydrophobic groups to solvent and absence of an excessive torsional strain 
into the docked conformer. Following post-docking analysis of the results, it was 
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concluded that the predicted binding site for compound 4.1 is within the 
myxopyronin binding region of RNAP. The predicted binding mode of compound 





Figure 4.2 Predicted binding mode of compound 4.1. 
 
In particular, the following interactions between the ligand and the 
myxopyronin binding site were predicted: the NH group belonging to the 
sulphonamide moiety is predicted to H-bond to the Leu619 backbone carbonyl, 
the two sulphonamide oxygen atoms interact via H-bonds with the Gln1019 side 
chain and Gly620 backbone; the oxygen belonging to the methoxy group is 
predicted to make an H-bond with the hydroxyl of Ser1084, and the phenolic 
OH is predicted to form an H-bond with the side chain of Lys610. Additionally, 
the 4-amino-1-naphthol group is predicted to be involved in hydrophobic 
interactions with Val1087, Ile606 and Leu618 side chains.  
4.4  Design of analogues of compound 4.1 
In order to probe the validity of the predicted binding mode of compound 
4.1 within the myxopyronin binding pocket of RNAP, a series of analogues of 
4.1 was designed to probe these potential interactions.  
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In particular, following careful analysis of the predicted binding mode, it 
was reasoned that, although the sulphonamide moiety of the inhibitor is 
predicted to make a number of interactions with the protein, it may be possible 
to replace this moiety with other groups such as an urea and still maintain at 
least some of the predicted interactions with the protein. Additionally, inclusion 
of a thiourea spacer in place of the sulphonamide would test the importance of 
the oxygen atom predicted to act as an H-bond acceptor (Figure 4.3).  
The hydroxyl group present in molecule 4.1 is not predicted to be essential 
and it can be removed or modified into an alkyl or phenyl ether which could 
establish additional interactions with the hydrophobic side chains of Val1087 
and Ile1016. The two aromatic rings in 4.1 are predicted to be important for the 
binding although the naphthalene ring could be partially reduced to give a 
tetrahydro-derivative or simplified into a single aromatic ring. With regard to the 
two methoxy groups, modelling indicated that it is possible to vary their number 
or position within the ring or to substitute them with bioisoteres for obtaining 
useful structure activity relationships. This general analogues design strategy 








Following the above analysis and with reference to the ease of synthesis, 
two small libraries of sulphonamide and urea derivatives of 4.1 (Table 4.1) were 
designed. In order to obtain rapid SAR exploration, the composition of the 
planned libraries was fine-tuned following docking-based prioritization of a 
designed combinatorial library generated from selected commercially available 
starting materials (Figures 4.4 and 4.5). 
 
4.4.1  Design of the library and docking studies 
A library of 40 compounds was designed from starting materials reported 
in Figures 4.4 and 4.5 and each molecule in the library was docked into the 
myxopyronin binding site following a similar docking protocol and post-docking 
analysis as reported above (Section 4.3). In particular, the docking protocol in 
the present case was more accurate than that used earlier in order to prioritize 
the synthesis of the more promising candidates. The docking runs were 
performed using GOLD8 v4.0.1 (CCDC, Cambridge, UK) docking software by 
using the best accuracy settings for the genetic searching algorithm which 
corresponded to the 200% of the default parameter values in order to get a 
more exhaustive search inside the binding cavity. 100 poses were generated for 
each compound and these were ranked using independently both the available 
scoring functions, Goldscore and Chemscore. Only compounds predicted to 
form at least two hydrogen bonds with binding site residues were progressed for 
visual inspection. A summary of the best ranked molecules selected for 







Figure 4.4 Available starting materials for sulphonamide derivatives 
 
 
Figure 4.5 Starting materials for urea and thiourea derivatives 
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Among the designed structural analogues, compounds 4.20 and 4.30 
appeared to be the most representative and promising ones in terms of overall 
score (Table 4.1) and binding mode analysis. 
 
Table 4.1 Overall score values and number of H-bonds of the best ranked 
compounds selected for synthesis. 
Comp. 
number 







26 47 3 
4.17 
 
28 46 2 
4.18 
 
29 43 2 
4.19 
 
24 45 3 
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Table 4.1 continued 
4.20 
 
29 58 3 
4.219 
 
25 42 3 
4.22 
 
25 44 3 
4.239 
 
23 45 3 
4.24 
 






Table 4.1 continued 
4.25 
 
28 49 3 
4.26 
 
28 50 3 
4.2710 
 
26 53 3 
4.28 
 
25 51 3 
4.2911 
 
24 46 3 
4.30 
 
26 56 3 
4.3112 
 
24 48 2 
4.3213 
 




Table 4.1 continued 
4.33 
 
25 43 3 
4.34 
 
25 49 3 
 
Interestingly, after visual inspection of the docked molecules it was 
possible to conclude that all the sulphonamide-based analogues are binding 
into a region close to that predicted for the binding of molecule 4.1 while the 
urea and thiourea derivatives are predicted to bind within a region which is 
distinct from that for compound 4.1 and the sulphonamide derivatives. An 
overlay within the myxopyronin binding site of the most promising sulphonamide 
and urea compounds, 4.20 and 4.30 respectively, along with the sulphonamide 
hit 4.1 is shown in Figure 4.6.  
 
Figure 4.6 Overlay of compound 4.1 (green sticks), 4.20 (purple sticks) and 
4.30 (orange sticks) within myxopyronin binding site. 
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4.4.2  Putative binding mode of compound 4.20 
From the analysis of the proposed binding mode of compound 4.20 (Figure 
4.7), the following interactions between the ligand and the myxopyronin binding 
site were predicted: the NH group belonging to the sulphonamide moiety H-
bonded to Ser1084 side chain, the sulphonamide oxygen interacts via an H-
bond with the Lys621 side chain; the aromatic ring belonging to the sulphonyl 
group is establishing hydrophobic interactions with the side chains of Val1466, 
Val1037 and Leu1053. The oxygen atom belonging to the benzyloxy moiety is 
H-bonding with the side chain of Gln611, while the aromatic portion of the 
benzyloxy group is establishing hydrophobic interactions with the side chains of 
Ile1467, Leu1088, Leu607 and Ala1438. The central aromatic ring bearing the 
benzyloxy substituent is establishing hydrophobic interactions with the side 








4.4.3  Putative binding mode of compound 4.30 
From the analysis of the proposed binding mode of compound 4.30 (Figure 
4.8), the following putative interactions between the ligand and the myxopyronin 
binding site of RNAP were predicted: the NH groups belonging to the urea 
moiety are H-bonded to Glu1034 side chain, the carbonyl oxygen interacted via 
H-bond with the Lys1463 and Ser1439 side chains while the aromatic ring 
belonging to the 3,5-dichlorophenyl moiety is establishing hydrophobic 
interactions with the side chains of Val1466, Val1037, Trp1038 and Leu619. 
The other phenyl ring is establishing cation-π interactions with the positively 
charged side chains of Arg1096 and Lys1463 and additionally, it is predicted to 




Figure 4.8 Predicted binding mode of 4.30. 
 
4.5  Synthesis of the sulphonamide-based library 
Sulphonamides 4.16―4.23 were synthesized in good yield by adding 
dropwise the appropriate sulphonylchloride (4.6―4.9) to an excess of amine 
 98 
 
(4.2―4.5) in presence of pyridine keeping the reaction mixture at 0 °C for 2h 




Scheme 4.1 Synthesis of sulphonamides 
 
Table 4.2 Sulphonamide-based library 






































4.6  Synthesis of the urea-based library 
The urea derivatives 4.24―4.32 and 4.34 were obtained in good yields by 
adding dropwise a dichloromethane solution of appropriate amine (4.2, 4.3, 4.5, 
4.10) into a solution of aryl isocyanate (4.11―4.15a) in dichloromethane using a 










Table 4.3 Urea-based library 








































4.7  Synthesis of the thiourea analogue 
The thiourea 4.33 was obtained in moderate yield by adding dropwise a 
dichloromethane solution of amine 4.3 into a solution of aryl isothiocyanate 
4.15b in dichloromethane using a slight excess of the latter at room temperature 
(Scheme 4.3). 
 
Scheme 4.3 Synthesis of thiourea analogue 4.33. 
 
4.8  Biological evaluation of small molecule inhibitors 
The synthesized analogues derived from 4.1 were evaluated for their in 
vitro RNAP activity against isolated E. coli RNAP using the SYBR Green assay 
(please see Appendix I for details) and the inhibitory activity is summarized 
below (Table 4.4). Disappointingly none of the molecules in this initial series of 
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derivatives were active against RNAP with the only exception being weak 
activity displayed compounds 4.19, 4.22 and 4.32.13 
 




% of inhibition of RNAP 




% of inhibition of 
RNAP at the 
concentration of 100 
µM 
4.16 0 4.26 0 
4.17 0 4.27
10 3.4 
4.18 0 4.28 4.0 
4.19 7.7 4.29
11 2.9 





4.239 0 4.33 0 
4.24 0 4.34 0 
4.25 3.2   
 
These negative preliminary results may reflect the intrinsic limitations of 
the docking software algorithms used and the limited resolution within the 
available X-ray crystal structure of E. coli RNAP, which may lead to predictions 
affected by a significant margin of error. Therefore it was decided to re-
synthesize the original hit molecule 4.1 and to evaluate it in the assay. It should 
also be noted that the original hit molecule 4.1 was identified using a different 
assay14 to that used at Leeds, which differs in several aspects when compared 





4.9  Synthesis and biological evaluation of the sulphonamide 
hit 
Compound 4.1 was synthesised in low yield by drop-wise addition of the 
aromatic sulphonylchloride 4.8 to an excess of amine 4.35 at 0 °C in the 
presence of pyridine (Scheme 4.4). 
 
 
Scheme 4.4 Synthesis of 4.1 from 4.35 and 4.8. 
 
Following the biological evaluation of compound 4.1 with the SYBR Green 
assay15 (please see Appendix I for details) surprisingly, no inhibition activity of 
RNAP at the concentration of 100 µM was observed. This is consistent with the 
lack of any inhibitory activity observed for the two synthesized analogue 
libraries and confirms the dependency of inhibitory activity for this compound 
series on the precise assay used. Specifically, the SYBR Green assay,15 as 
opposed to the assay reported14 for the RNAP inhibitory activity of compound 
4.1, utilizes core RNAP in the absence of promoter sequences, primers and 
sigma factors and for these reasons, this assay has a limited capacity to 
evaluate inhibitors acting on the initiation step of the transcription or inhibitors 
interfering with the protein-protein interactions between the core enzyme and 
the sigma factor to form an holoenzyme which can bind a promoter. This may 
lead to the conclusion that literature hit 4.1 is potentially an initiation or protein-
protein interaction inhibitor. 
Unfortunately, the previously reported assay was not available to us for 
evaluation of the library of analogues of compound 4.1.  
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4.10  Conclusions 
As a direct result of the ability to very rapidly generate analogues, a SAR 
study on a reported RNAP inhibitor was performed using a combination of in 
silico studies followed by synthesis. Although the in silico studies have predicted 
a putative binding site for the original hit molecule, compound 4.1, the two 
synthesized libraries obtained by combining docking studies with classical 
medicinal chemistry approach unfortunately did not possess significant 
biological activity in the Leeds RNAP inhibition assay. Following synthesis of the 
original hit molecule 4.1 and its biological evaluation revealed the absence of 
inhibitory activity in our assay which may be explained by the fact that the 
original hit molecule 4.1 was identified using a different assay14 which differs in 
several aspects when compared to the SYBR Green assay.15 Whilst both 
assays were validated for HTS studies on the same biological target, 
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5. Scaffold-hopping and ligand-based virtual screening to 
assist the design and synthesis of small molecule 
inhibitors of the myxopyronin binding region 
5.1  Physico-Chemical limitations of myxopyronin A 
Myxopyronin A (Myx) 1.251 (Figure 5.1) is a naturally occurring antibiotic 
which inhibits the initiation of transcription by interacting with the RNAP ‘switch 
region’, a hinge mediating the opening and the closure of the RNA ‘clamp’ 
which determines the open or closed state of the active centre cleft of the 
enzyme. 
 
Figure 5.1 Structures of 1.25 and 1.27. 
 Myx 1.25 does not share cross-resistance with rifamycins. Unfortunately 
Myx 1.25 is not a viable drug lead because it does not possess suitable 
physicochemical properties. In particular, the dienone terminal side chain 
portion of the molecule which binds in a large hydrophobic pocket in the 
enzyme (Figure 5.2) results in poor pharmakokinetic properties due to the high 
LogP value and consequent strong binding to plasma proteins.2 A previous 
study3 revealed that binding to serum proteins significantly reduces the 
antibacterial activity of these compounds in vivo. The same authors3 also 
underline issues with compound stability, in fact the Myx structure contains a 
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reactive Michael acceptor and a metabolically unstable carbamate group. The 
chemical synthesis of Myx analogues reported to date,1,4,5 with the only 
exception of 7-desmethylmyxopyronin B derivative 1.27 (Figure 5.1), did not 
lead to more potent analogues and the design of more potent molecules has, 
until recently, been hampered  by the lack of a high resolution structure of the 
RNAP-Myx complex.6   
 In the current project, in order to address the physico-chemical limitations 
of Myx, a scaffold hopping strategy was explored and the derived 
pharmacophoric hypothesis was used for a ligand-based virtual screening of 
commercial and in-house chemical libraries. The top ranking compounds were 
selected for biological evaluation on the basis of visual inspection and docking 
studies.  
5.1.1  Scaffold-hopping strategy 
 Analysis of the X-ray co-crystal structure of 7-desmethylmyxopyronin B 
1.27 in complex with RNAP (PDB id: 3EQL7) reveals that 7-
desmethylmyxopyronin B 1.27 is bound within an almost completely enclosed, 
predominantly hydrophobic crescent-shaped binding pocket (Figure 5.2). 
 
Figure 5.2 Co-crystal structure of 1.27(PDB 3EQL). 
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 Globally, there is a prevalence of hydrophobic interactions with the only 
exception being the α-pyrone ring of 7-desmethylmyxopyronin B 1.27, which is 
involved in key interactions near the cavity entrance via hydrogen bonds with 
Ser1084 and Gly620, while the carbonyl of the ene-carbamate side-chain is 
contacting Trp1038, Glu1041 and Lys1463 (Figure 5.2). 
 The scaffold-hopping strategy adopted in this project involved the 
preservation of the key specific hydrogen bonds at the level of the α-pyrone ring 
and ene-carbamate side-chain and the replacement of the dienone side-chain 
with other suitable lipophilic residues. The key interaction points of the hydrogen 
bond network of 7-desmethylmyxopyronin B 1.27 (Figure 5.3) involve the 
hydroxyl group of the α-pyrone which could be replaced by an hydrogen bond 
donor and/or acceptor and by the ring oxygen where an alternative hydrogen 
bond acceptor could be tolerated. With regard to the ene-carbamate moiety, it 
was reasoned that carbonyl oxygen could be replaced by any other suitable 
hydrogen bond acceptor as well as the methoxy group while the carbamate 
nitrogen could be substituted with any other suitable hydrogen bond donor 
capable of interacting with Glu1041 (Figure 5.2). 
 
 
Figure 5.3 Key interaction points of the hydrogen bond network of 1.27. 
 
 A plausible scaffold-hopping strategy could involve the replacement of the 
α-pyrone core with an alternative aromatic or heteroaromatic moiety derived 
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from the ring fusion of the α-pyrone at position 2 or alternatively, at position 4 
with the concurrent substitution of the carbonyl belonging to the dienone with a 
carbon atom (Figure 5.4). 
 
 
Figure 5.4 Design strategy based on 1.27. 
 
 As an example of this strategy, ring fusion at position 2 of the α-pyrone 
could result in a 4H-benzo[d][1,3]oxazin-4-one or a quinazolin-4(3H)-one based 
heterocyclic core as shown in 5.1 and 5.2 (Figure 5.5). In particular, the ring 
nitrogen replaced the ring oxygen of 7-desmethylmyxopyronin B 1.27. 
 
 
Figure 5.5 Structures of 5.1 and 5.2, original α-pyrone core shown in blue, 
closure points and modified atoms in red. 
 
 Alternatively, following ring fusion at the position 4 of the α-pyrone, a 4H-
pyrido[2,3-d][1,3]oxazin-4-one or a pyrido[2,3-d]pyrimidin-4(3H)-one based 
heterocyclic core as shown in 5.3 and 5.4 could replace the α-pyrone core 
(Figure 5.6) where a nitrogen atom replaced the hydroxyl of 7-





Figure 5.6 Structures of 5.3 and 5.4, original α-pyrone core shown in blue, 
closure points and modified atoms in red. 
 
 In order to apply the previously outlined scaffold-hopping strategy, a 
pharmacophore and shape-based query was elaborated within the graphical 




Figure 5.7 Shape query elaborated in vROCS represented as a grey cloud, 




Figure 5.8 Pharmacophore query elaborated in vROCS represented as 
coloured spheres centred on 7-desmethylmyxopyronin B 1.27 structure 
represented as sticks. 
5.1.2  Ligand-based virtual screening protocol 
 Ligand-based virtual screening was performed for the specified chemical 
query taking in account the overall shape and volume of 7-
desmethylmyxopyronin B 1.27 in addition to matching the pharmacophoric 
points. 
 The in-house medicinal chemistry and chemical biology technology group 
database (MCCB database) comprising 26,493 molecules from Albany 
Molecular Research Inc. (AMRI), Chembridge and Asinex commercial 
databases along with another two commercial databases, the Peakdale (15,339 
molecules) and the Specs diversity set (17,520 structures with molecular 
similarity expressed as Tanimoto coefficient not greater than 0.7), were 
downloaded from the ZINC database.8 
 A library of conformers was generated from the previously downloaded 
databases using OMEGA software version 2.3.2, limiting the maximum number 
of conformers per molecule to 50 using the default settings. 
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 The biologically active conformation of 7-desmethylmyxopyronin B was 
extracted from its crystallographic complex with RNAP (PDB id: 3EQL7) and 
atom types and bond orders were amended when necessary with Maestro 
software. The molecular structure was imported into vROCS version 3.1.2 
where the pharmacophoric features were manually specified over the key atoms 
identified from the previous analysis (Section 5.1.1), and the overall shape and 
volume were automatically perceived by the software.  
 The previously prepared library of conformers was screened on the 
generated query using an Explicit Mills Dean9 colour force field and leaving all 
the other settings to their default values. ROCS automatically ranked the top 
500 molecules using the TanimotoCombo scoring function and the result was 
visually inspected using vROCS to assess the quality of overlapping to the 
shape and chemical features of the query molecule. 
 A short list of around 100 molecules was selected for further analysis and 
filtering via docking studies. The aim of these studies was to verify that 
compounds with good chemical and shape complementarity were also 
predicted to adopt a reasonable binding mode inside the targeted site, avoiding 
steric clashes and reproducing as much as possible the 7-
desmethylmyxopyronin B interaction pattern. 
5.1.3  General docking protocol 
The crystal structure of the T. thermophilus RNA polymerase 
holoenzyme in complex with the antibiotic 7-desmethylmyxopyronin B (PDB id: 
3EQL7) was downloaded from the Protein Databank (www.rcsb.org). 
The binding site within the RNAP for Myx was defined as a 15 Å cut of 
the protein surrounding the co-crystallised ligand. 
The dockings runs were performed using GOLD10 v4.0.1 (CCDC, 
Cambridge, UK) docking software by using the default settings for the genetic 
searching algorithm generating 100 poses for each ligand and the compounds 
were ranked with the Chemscore scoring function. 
A post-docking analysis was performed on the different docking solutions 
for each ligand. Cluster analysis using an average linkage rule was performed 
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using an internal module within the software. Only the best ranked poses of the 
most populated cluster were considered as the most likely and representative 
ones. In addition, the docked poses were analysed in terms of overall score, 
good shape complementarity to the cavity, possibility to establish specific H-
bonds to the protein in addition to the less specific hydrophobic contacts, 
minimal exposure of hydrophobic groups to solvent and absence of an 
excessive torsional strain into the docked conformer. 
5.1.4  Results 
 The list of selected compounds for biological evaluation along with 
predicted properties and docking score is reported in Table 5.1. Interestingly, 
the results are, in part, concordant with the previously mentioned scaffold 
hopping considerations (Section 5.1.1) and the number of 4H-
benzo[d][1,3]oxazin-4-one and quinazolin-4(3H)-one-based scaffolds in the 
best-ranked virtual hits list could not be ignored when prioritizing the 
compounds for biological evaluation. 
 Compounds 5.15―5.21 were not available for purchase but because of 
their fair synthetic accessibility, good final ranking and relevant putative binding 
mode, were synthesized (Section 5.2). 
 













336 3.23 36.4 0 
5.6 
 
364 2.36 30.9 0 
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Table 5.1 Continued 
5.7 
 
335 2.97 33.1 0 
5.8 
 
363 3.90 32.9 0 
5.9 
 
376 2.49 31.8 0 
5.10 
 
420 4.04 32.1 0 
5.11 
 
431 4.09 30.4 0 
5.12 
 




Table 5.1 Continued 
5.13 
 
378 4.48 34.3 0 
5.14 
 
451 2.92 35.6 0 
5.1511 
 
206 -0.42 29.5 0 
5.1612 
 
238 1.72 23.7 0 
5.1713 
 
207 2.09 25.5 0 
5.1814 
 
257 3.49 29.7 0 
5.1915 
 





Table 5.1 Continued 
5.2014 
 
213 2.41 27.2 0 
5.21 
 
269 1.75 28.9 0 
5.22 
 
417 3.02 26.1 0 
5.23 
 
349 2.21 24.2 0 
5.24 
 
326 1.96 24.6 0 
5.25 
 
388 4.14 30.4 0 
5.26 
 
293 0.63 24.6 0 
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Table 5.1 Continued 
5.27 
 
313 4.93 30.7 0 
5.28 
 
330 2.91 27.3 0 
5.29 
 
359 2.81 36.3 0 
 
 (A) ALogP calculated with ALOGPS 2.1 software
16
  
(B) Rule of five defined as reported in Lipinski’s paper,
17




150 ≤ M.W. ≤ 500 
ALogP ≤ 5 
Hydrogen bond donors ≤ 5 
Hydrogen bond acceptors ≤ 10 
Rotatable bonds ≤ 7 
Polar surface area ≤ 150 
  
 Examples of predicted binding mode for the most relevant and best ranked 
compounds are shown below. 
 The predicted binding mode of compound 5.8 is shown in Figure 5.9. The 
following interactions between the ligand 5.8 and the myxopyronin binding site 
were identified: the NH of the indole ring is predicted to form an H-bond with the 
side chain of Glu1041 while the carbonyl of the amide bond is interacting via an 
H-bond with the backbone NH of Gly620. The nitrogen of the pyridyl ring is 
predicted to form an H-bond with the side chain of Gln1019 while the oxygen of 
the methoxy group is interacting via an H-bond with the side chain of Gln1019. 
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The side chains of Leu1049, Leu1053, Val1466, Ile1467, Val1037 and Trp1038 
are predicted to be involved in hydrophobic interactions with the indole and the 
piperidine ring. Notably, H-bond interactions with Glu1041 and Gly620 are also 
present in the X-ray co-crystal structure of 7-desmethylmyxopyronin B 1.27 in 




Figure 5.9 Predicted binding mode of 5.8. 
 
 The binding mode of compound 5.1511 was predicted as shown in Figure 
5.10. The following interactions between the ligand 5.1511 and the myxopyronin 
binding site were identified: the carboxylate is predicted to form an H-bond with 
the side chain of Ser1084, the carbonyl of the semicarbazide moiety is 
predicted to make an H-bond with the side chain of Gln1019 and Lys621 while 
the amidic nitrogen and the neighbouring azomethine nitrogen of the same 
moiety are interacting via H-bonds with the backbone carbonyl of Lys621 and 
the backbone NH of Gly620. The aromatic ring is predicted to be involved in 
hydrophobic interactions with the side chains of Val1466, Val1037 and 
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Leu1619. Interestingly the previously mentioned H-bond interactions with 
Ser1084 and Gly620 are also present in the X-ray co-crystal structure of 7-




Figure 5.10 Predicted binding mode of 5.15.11 
 
 The binding mode of compound 5.1814 was predicted as shown in Figure 
5.11. The following interactions between the ligand 5.1814 and the myxopyronin 
binding site were identified: the carbonyl of the pyrimidinone ring is predicted to 
establish an extended H-bond network with the side chains of Lys621, Ser1084 
while the nitrogen of the same moiety is interacting via H-bond with the 
backbone NH of Gly620. The pyrimidinone and the 2-chlorophenyl moieties are 
involved in hydrophobic interactions with the side chains of Val1466, Leu1053, 
Val1037, Lys621 and Lys610. Interestingly, the two previously mentioned H-
bond interactions are also present in the X-ray co-crystal structure of 7-
desmethylmyxopyronin B 1.27 in complex with RNAP (PDB id: 3EQL
7
) (Figure 




Figure 5.11 Predicted binding mode of 5.18.14 
 
 The binding mode of compound 5.29 was predicted as shown in figure 
5.12. The following interactions between the ligand 5.29 and the myxopyronin 
binding site were identified: the carbonyl of the pyrimidinone ring is predicted to 
establish an H-bond network with the side chains of Ser1439 and Lys1463. 
Notably, the carbonyl of the pyrimidinone ring is mimicking the H-bond of the 
ene-carbamate carbonyl with Lys1463 present in the X-ray co-crystal structure 
of 7-desmethylmyxopyronin B 1.27 in complex with RNAP (PDB id: 3EQL7) 
(Figure 5.2). The nitrogen of the pyridyl ring is predicted to form an H-bond with 
the backbone carbonyl of Leu607; a T-shaped stacked interaction between  the 
side chain aromatic ring of the Phe614 and the pyridyl group is observed while 
the other aromatic rings are predicted to be involved in very extended 
hydrophobic interactions with the side chains of Leu1088, Leu1092, Leu607, 




Figure 5.12 Predicted binding mode of 5.29. 
 
5.2 Synthesis 
 Compound 5.1511 was prepared in high yield following the procedure 
reported by Kumar,19 reacting carboxybenzaldehyde 5.30 with semicarbazide 
hydrochloride 5.31 in a aqueous solution of sodium acetate (Scheme 5.1):  
 
 
Scheme 5.1 Synthesis of 5.15.11 
 The reaction between anthranilic acid 5.32 with an excess of butyryl 
chloride 5.33 in pyridine at room temperature afforded the formation of 5.1713 in 





Scheme 5.2 Synthesis of 5.17.13 
 
 With regard to benzo[e][1,2,4]thiadiazine 1,1-dioxide derivative 5.16,12 this 
was prepared in good yield by reacting a solution of sulphonamide 5.34 in DMA 
with aldehyde 5.35 in presence of an excess of sodium bisulphite under reflux 
as reported by Imai et al20 (Scheme 5.3). 
 
 
Scheme 5.3 Synthesis of 5.16.12 
 
 The synthesis of 2-aryl-4H-benzo[d][1,3]oxazin-4-one derivatives 5.1814 
and 5.2014 was performed (Scheme 5.4) following the literature procedure as 
reported by Bain and Smalley.21  
 The one-pot reaction between equimolar quantities of anthranilic acid 5.32 
with aroylchloride 5.36 or aroylchloride 5.37 in a solution of pyridine and toluene 
under reflux gave, respectively, the benzoxazinones 5.1814 and 5.2014 in 





Scheme 5.4 Synthesis of 5.1814 and 5.20.14 
 
 Quinazolinone 5.1915 was prepared in good yield following the procedure 
reported by Imai et al.20 by refluxing a solution of anthranilamide 5.38 in DMA 





Scheme 5.5 Synthesis of 5.19.15 
 
 The nucleophilic substitution reaction by heating an acetone solution of 
equimolar quantities of 2-mercaptoquinazolin-4(3H)-one 5.39 and 4-
(bromomethyl)pyridine hydrobromide 5.40 in presence of triethylamine afforded 




Scheme 5.6 Synthesis of 5.21. 
5.3 Biological results 
 Compounds 5.5―5.29 were evaluated in the RNAP SYBR green assay22 
(please see Appendix I for details) and weak or no inhibition activity was found 
(Table 5.2). 
 




In vitro RNAP % 
inhibition at 100 μM 
Compound 
number 
In vitro RNAP % 







5.8 13.1 5.21 0 
5.9 1.5 5.22 0 
5.10 0.9 5.23 11.8 
5.11 5.2 5.24 7.2 
5.12 2.6 5.25 5.1 
5.13 4.2 5.26 0 
5.14 0 5.27 0 
5.1511 0 5.28 0 
5.1612 0 5.29 12.3 
5.1713 0   
125 
 
5.4  Conclusions 
 Following the analysis of the X-ray co-crystal structure of 7-desmethyl-
myxopyronin B 1.27 in complex with RNAP (PDB id: 3EQL7) (Figure 5.2), a 
scaffold-hopping strategy has been elaborated and a pharmacophore- and 
shape-based virtual screening approach followed by docking studies has been 
performed in order to overcome the unfavourable pharmacokinetic and 
chemical properties of myxopyronin A (Myx) 1.25.1  
 A series of molecules was selected from commercial databases or 
synthesized for biological evaluation. Whilst all the virtual hits were predicted to 
have improved physicochemical properties, good binding mode and better 
synthetic accessibility when compared to Myx, unfortunately no active 
molecules were identified. A possible reason for the lack of biological activity of 
the selected virtual hits could derive from the nature of the designed protocol. In 
fact, selection of compounds relied mainly on the ligand-based stage while 
docking studies confirmed shape, chemical complementarity and quality of 
binding mode within the targeted site on a narrow number of candidates. Whilst 
the shape screen and the matching of selected pharmacophoric points allowed 
the restriction of the number of candidates, the binding site sampling performed 
at this stage was limited to selected specific interactions of 7-desmethyl-
myxopyronin B 1.27 within RNAP and, for this reason, underestimated the 
possibility of alternative binding modes for chemically dissimilar molecules 
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6. Critical reassessment of a previously reported 
computational study
1
 and development of a combined 
ligand and structure-based virtual screening protocol  
6.1 Limitations of a previously reported computational study
1
 
 A pharmacophore modelling and structure-based virtual screening study 
on the RNAP ‘switch region’ has been recently reported.1 Although a list of 27 
virtual hits out of the 321,374 compounds within the screened database were 
selected and underlined for further study by the authors1 but no biological data 
were reported to support this suggestion or test the validity of the protocol. 
Following detailed inspection of this paper1, several questionable points and 
inaccuracies were found in addition to the lack of a biological validation, and 
these are summarized below: 
A) The screened database, according to the given protocol, was filtered prior 
to hit selection following the Lipinski Rule of five but several selected virtual 
hits have at least one or more violations of this rule. 
B) The developed pharmacophoric query did not include any hydrophobic   
features despite these interactions being important within the targeted 
binding site. 
C) The authors claimed a crystallographic water molecule close to the 
antibiotic molecule was conserved and this was included in the 
crystallographic protein structure used for docking calculations. Following 
analysis of the crystal structure of the T. thermophilus RNAP holoenzyme in 
complex with the antibiotic myxopyronin A 1.25 (PDB id: 3DXJ2), a water 
molecule interacting with the ene-carbamate group is found only in one 
biological assembly out of the two present in the asymmetric unit, while in 
the case of the crystal structure of the T. thermophilus RNAP holoenzyme in 
complex with the antibiotic 7-desmethylmyxopyronin 1.27 (PDB id.: 3EQL3) 





6.2 Critical reassessment of the protocol 
 A critical reassessment of this theoretical study1 has been performed by 
elaborating a new and more rigorous virtual screening protocol which combined 
ligand and structure-based techniques and summarized in Figure 6.1.  
 
 
Figure 6.1 Virtual screening protocol 
 
A conformer database was generated using OMEGA software and an 
initial ligand-based virtual screening run with ROCS was applied with the aims 
of: 





B) prioritizing molecules with similar shape and chemical features to 
myxopyronin, in order to maximize the chance of finding active molecules by 
mimicking the interactions of myxopyronin with RNAP. 
The ligand-based virtual screening strategy was elaborated starting from 
the previously reported analysis (please see Chapter 5, Section 5.1.1) of the X-
ray co-crystal structure of 7-desmethylmyxopyronin B 1.27 in complex with 
RNAP (PDB id: 3EQL3). In summary, pharmacophoric features in terms of 
donor/acceptor and lipophilic atoms were identified and a scaffold hopping 
strategy implying the preservation of key specific hydrogen bonds and 
hydrophobic interactions of 7-desmethylmyxopyronin B 1.27 was formulated, 
with the addition of two more features at the level of the carbonyl group (both at 
the level of the dienone and α-pyrone ring) (Figure 6.2). These two additional 
features were included in order to bias any resulting virtual hits towards 
molecules that contain similar functionality to that within 7-
desmethylmyxopyronin B 1.27, and so to decrease dramatically the number of 








Docking was performed using GOLD docking software inside the 
myxopyronin binding region defined from the crystal structures of the T. 
thermophilus RNAP holoenzyme in complex with the antibiotic myxopyronin A 
(PDB id: 3DXJ2). The highest possible accuracy parameters with regard to the 
searching algorithm were used and consensus scoring was applied to rank the 
molecules. The Chemscore scoring function was used initially for ranking the 
compounds as it was found to be faster than Goldscore in terms of energetic 
evaluation during pose generation and it was even more appropriate because of 
its energetic terms for dealing with a predominantly hydrophobic binding site.6 
The Goldscore scoring function was then applied to re-rank the top scoring 
compounds in order to prioritize the best hydrogen bond network between the 
docked poses, given its superiority in identifying polar contacts when compared 
to Chemscore.6 A post-docking analysis followed the consensus scoring 
strategy and consisted in cluster analysis and visual inspection. 
 
6.2.1  General ligand-based virtual screening protocol 
 The Specs database (206,615 structures) was downloaded from ZINC 
database.4 
 A library of conformers was then generated from the previously 
downloaded databases using the OMEGA software version 2.3.2 limiting the 
maximum number of conformers per molecule to 50 using the default settings. 
 The biologically active conformation of 7-desmethylmyxopyronin B 1.27 
was extracted from its crystallographic complex with RNAP (PDB id: 3EQL3) 
and atom types and bond orders were amended as necessary using Maestro 
software. The molecular structure was imported into vROCS version 3.1.2 
where the pharmacophoric features were manually specified over the key atoms 
identified from the previous analysis (Chapter 5, Section 5.1.1) and the overall 
shape and volume of the molecule were automatically perceived by the 





Figure 6.3 Shape query elaborated in vROCS represented as a grey coloured 
volume. Structure of 7-desmethylmyxopyronin B 1.27 represented as sticks. 
 
 
Figure 6.4 Pharmacophore query elaborated in vROCS represented as 
coloured spheres centred on 7-desmethylmyxopyronin B 1.27 structure 
represented as sticks. 
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 The previously prepared library of conformers was screened on the 
generated query using an Explicit Mills Dean5 colour force field and leaving all 
the other settings to their default values. The top 10% of molecules ranked by 
ROCS using the TanimotoCombo scoring function were selected and after the 
elimination of duplicate conformers, a short list of 5,785 molecules was 
designated for structure-based virtual screening.  
6.2.2  General docking protocol 
Docking settings for the structure-based virtual screening protocol were 
chosen according to the docking validation studies reported in Chapter 3. 
 The crystal structure of the T. thermophilus RNAP holoenzyme in 
complex with the antibiotic myxopyronin A (PDB id: 3DXJ2), was downloaded 
from the Protein Databank (www.rcsb.org). 
All water molecules, cofactors and ions were manually removed using 
Maestro and the binding site within the RNAP was defined as the protein 
comprised in a sphere with a 15 Å radius surrounding the co-crystallised ligand. 
The docking runs were performed using GOLD6 v4.0.1 (CCDC, 
Cambridge, UK) docking software by using the best accuracy settings for the 
genetic searching algorithm which corresponded to the 200% of the default 
parameter values of the genetic algorithm in order to get a more exhaustive 
search inside the binding cavity. Compounds were ranked with the Chemscore 
scoring function generating 100 poses for each ligand. The final docked poses 
were re-ranked using the Goldscore scoring function after energetic 
minimization performed using the simplex algorithm implemented in the GOLD 
docking software.     
A shortlist of 578 compounds corresponding to 10% of the top ranked 
molecules was selected for post-docking analysis which was performed for 
each ligand among its different docking solutions. Cluster analysis using an 
average linkage rule was performed using an internal module within the 
software. Only the best ranked poses of the most populated cluster were 
considered as the most likely and representative ones. In addition, the docked 
poses within the binding pocket were analysed in terms of overall score, shape 
complementarity to the cavity, possibility to establish specific H-bonds to the 
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protein in addition to the less specific hydrophobic contacts, minimal exposure 
of hydrophobic groups to solvent and absence of excessive torsional strain 
within the docked conformer. 
 
6.2.3  vHTS results 
After the post-docking analysis which included the selection of the potential 
virtual hits on the basis of their chemical diversity, 29 molecules were 
purchased for biological evaluation (please see Section 6.2.4 for the biological 
results). Interestingly, 10 out of the 27 virtual hits, 6.1—6.10, reported in the 
previous study,1 were present in the list of the purchased molecules (Table 6.1) 
and some compounds presented one or more violations of the Lipinski rule of 
five. The decision to include such non-Lipinski compliant molecules as part of 
the purchase selection reflected the observation that many existing clinically 
used antibiotics do not conform to this rule.7,8 Moreover, subsequent exploration 
of SAR followed by hit optimization can be used to overcome the initial limitation 
of low oral bioavailability which may be associated with non-Lipinski 
compliance.   
 






















Table 6.1 Continued 
6.2 
 
450 7.19 41.8 1 
6.3 
 
543 5.73 42.2 2 
6.4 
 
495 2.52 42.3 1 
6.5 
 
470 7.45 40.4 1 
6.6 
 




Table 6.1 Continued 
6.7 
 
636 5.97 48.4 3 
6.8 
 
522 4.89 40.9 2 
6.9 
 
476 5.28 37.2 2 
6.10 
 







Table 6.1 Continued 
6.11 
 
466 2.80 33.6 1 
6.12 
 
427 3.07 35.2 0 
6.13 
 
364 3.89 34.5 0 
6.14 
 
458 4.07 35.0 0 
6.15 
 
333 2.04 35.4 0 
6.16 
 




Table 6.1 Continued 
6.17 
 
418 3.71 30.9 0 
6.18 
 
351 3.95 34.9 0 
6.19 
 
395 3.25 38.1 0 
6.20 
 
352 2.86 31.0 0 
6.21 
 
392 1.76 37.3 0 
6.22 
 
455 2.62 37.5 1 
6.23 
 
306 1.47 33.7 1 
6.24 
 




Table 6.1 Continued 
6.25 
 
326 3.81 28.0 0 
6.26 
 
351 2.37 37.3 0 
6.27 
 
338 2.26 37.1 0 
6.28 
 
472 4.03 29.9 0 
6.29 
 
386 5.09 32.1 1 
 
 (A) ALogP calculated with ALOGPS 2.1 software
9
  
(B) Rule of five defined as reported in Lipinski’s paper,
10




150 ≤ M.W. ≤ 500 
ALogP ≤ 5 
Hydrogen bond donors ≤ 5 
Hydrogen bond acceptors ≤ 10 
Rotatable bonds ≤ 7 
Polar surface area ≤ 150 
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6.2.4 Biological results 
 Compounds 6.1―6.29 were evaluated in the SYBR Green assay12 (please 
see Appendix I for details) and the results are summarized in Table 6.2. 
 Compounds 6.3 and 6.10 were found to possess moderate inhibitory 
activity at the concentration of 100 µM on E.coli RNAP core enzyme (compound 
6.10 was not completely soluble under the assay conditions). To probe the 
selectivity of enzyme inhibition, compounds 6.3 and 6.10 were subjected to 
specificity assay analysis using malate dehydrogenase and chymotrypsin 
respectively, as unrelated enzymes, to identify promiscuous activity13 (Table 
6.3). Pleasingly, both compounds did not significantly inhibit these enzymes at 
the concentration of 100 µM (please see Appendix I for details).  
 
Table 6.2 In vitro RNAP percentage inhibition at 100 μM of the virtual hits. 
Compound number 
In vitro RNAP % 
inhibition at 100 μM 
Compound number 
In vitro RNAP % 
inhibition at 100 μM 
6.1 21.7 6.16 0 
6.2 0 6.17 0 
6.3 56.4 6.18 0 
6.4 5.9 6.19 0 
6.5 0 6.20 0 
6.6 0 6.21 0 
6.7 16.4 6.22 0 
6.8 0 6.23 0 
6.9 2.8 6.24 0 
6.10 54.3† 6.25 0 
6.11 0 6.26 0 
6.12 0 6.27 0 
6.13 0 6.28 0 
6.14 0 6.29 17.1 
6.15 0   
 




Table 6.3 Specificity assay on the selected hits on Malate Dehydrogenase and 
Chymotrypsin. 
Compound number 
In vitro Malate Dehydrogenase 
% inhibition at 100 μM 
In vitro Chymotrypsin 
% inhibition at 100 μM 
6.3 2.9 4.3 
6.10 0.3 21.4 
 
From these two hits, acylhydrazone 6.3 was selected for SAR studies on 
the basis of its inhibitory activity, synthetic amenability, chemical stability, 
solubility properties and suitability for analogue design.  
6.2.5 Synthesis of the acylhydrazone hit 
In order to confirm the biological activity of the purchased compound 6.3, 
this acylhydrazone was synthesized as shown below (Scheme 6.1): 
  
Scheme 6.1 Synthesis of 6.3. 
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A DMF solution of ester 6.30 was treated with an excess of benzylbromide 
in presence of an excess of potassium carbonate under reflux to give tri-ether 
6.3114 in low yield. Intermediate hydrazide 6.3215 was obtained in excellent yield 
following the addition of excess hydrazine hydrate to ester 6.3114 and heating to 
reflux in ethanol. Finally, acylhydrazone 6.3 was obtained in good yield by 
reacting an ethanolic solution of hydrazide 6.3215 with aldehyde 6.33 under 
reflux. 
 
6.2.6 Putative binding mode of the acylhydrazone hit 
 From the above mentioned docking studies (Section 6.2.2), the binding 




Figure 6.5 Predicted binding mode of 6.3. 
 
The following interactions between the ligand 6.3 and the myxopyronin 
binding site were identified: the carbonyl oxygen belonging to the acylhydrazone 
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moiety is predicted to H-bond to the side chain of Ser1439 while the nitrogen of 
the pyridyl unit interacts via H-bonding with the side chain NH of Trp1038. The 
protonated nitrogen belonging to the side chain of Lys1463 is performing a 
cation-pi interaction with the pyridyl ring which is also establishing hydrophobic 
interactions with the side chains of Val1466 and Val1037 respectively. The 
aromatic ring of one of the benzyloxy moieties is predicted to establish a OH-pi 
interaction with the hydroxyl moiety belonging to the side chain of Thr1443. All 
three benzyloxy groups are predicted to be involved in extensive hydrophobic 
interactions with the lipophilic side chains of Ala1438, Leu1088, Leu607, 
Leu619, and Leu1053 respectively. 
As reported in Figure 6.6, acylhydrazone 6.3 is partially overlapping 
myxopyronin A 1.25 and the three benzyloxy groups are occupying three 




Figure 6.6 Overlay of predicted binding pose for acylhydrazone 6.3 represented 





Figure 6.7 Myxopyronin binding site represented as a Connolly surface in 
yellow and acylhydrazide 6.3 in green sticks. 
6.2.7 General analogue design strategy 
Based on the above cited putative binding mode a SAR study was 
performed in order to probe the predicted potential interactions and to increase 
potency and drug likeness properties of acylhydrazone 6.3.  




Figure 6.8 General analogue design strategy. 
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In particular, it was reasoned that the partial replacement or complete 
removal of the three benzyloxy groups will help with improvement of the 
physicochemical properties and will also allow exploration of the importance of 
these extended hydrophobic interactions in term of potency. The substitution of 
the 3-pyridyl group with other aromatic or heteroaromatic groups will help the 
optimization and understanding of the hydrogen bonding network. 
In order to optimize the SAR exploration and to maximize the identification 
of biologically active analogues, a similarity searching protocol, based on the 
structure of the virtual hit 6.3, has been conducted using a focused library of 
acylhydrazones designed as shown in the next Section. 
 
6.2.8 Similarity searching on a focused library of acylhydrazones  
Two databases were considered for the preparation of the focused library, 
the ZINC4 and Reaxys16 databases. A chemical structure query was performed 
on both databases with the aim of selecting a chemical space composed of a 
central acylhydrazone scaffold substituted with aromatic or heteroaromatic 




Scheme 6.2 General analogue design strategy. 
 
With regard to the Reaxys16 database, additional filters were specified to 
this query and consisted of selecting only compounds for which a reported 
chemical preparation procedure was available. The above mentioned query 
retrieved 10,375 compounds derived from merging 4,932 compounds from the 
146 
 
ZINC database and 8,901 compounds from the Reaxys database after 
eliminating duplicates. The choice of these databases and the filtering criteria 
for creating the focused library satisfied the objective of short listing 
commercially available and synthetically accessible molecules. A similarity 
searching run using atom environment descriptors (MOLPRINT2D17) was then 
performed on this library using the Canvas module included in the Maestro 
software by using the structure of the acylhydrazone hit 6.3 as a reference 
structure and retrieving only molecules with a Tanimoto18 similarity index ≥ 0.3 
to the reference molecule. The resulting 321 compounds were docked following 
the same protocol reported in Section 6.2.2, using a more accurate post-
docking analysis which selected only compounds showing at least the same 
number of H-bond interactions to that predicted for the parent compound 6.3, 
and an overall Chemscore numerical value in the range of ±15 related to the 
scoring value from the initial hit structure. After the post-docking analysis 17 
molecules were selected and are reported in Table 6.4.  
 













0.73 42.1 3 
6.35 
 
0.71 41.5 2 
6.36 
 
0.62 40.3 3 
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Table 6.4 Continued 
6.37 
 
0.60 42.8 3 
6.38 
 
0.58 43.1 2 
6.39 
 
0.58 44.9 3 
6.4019 
 
0.58 37.7 3 
6.4120 
 
0.52 32.3 2 
6.4221 
 
0.65 28.3 2 
6.4322 
 
0.38 29.5 2 
6.4421 
 




Table 6.4 Continued 
6.4523 
 
0.46 28.1 2 
6.4621 
 
0.41 28.5 2 
6.4721 
 
0.44 28.2 2 
6.4824 
 
0.56 30.4 2 
6.4924 
 
0.33 30.0 2 
6.5024 
 
0.40 29.3 2 
 
 
Interestingly, the selected virtual hits are predicted to share a similar 
binding mode to molecule 6.3 which suggests that the position of the pyridyl ring 
nitrogen is not essential and both the benzyloxy and pyridyl moieties can be 
substituted with other aromatic or heteroaromatic groups. In order to validate 
the similarity searching results, the previously formulated hypothesis concerning 
the position of the pyridyl ring nitrogen and the putative binding mode of 6.3, the 
compounds in Table 6.4, along with other analogues (Table 6.5) bearing the 
generic formula reported in Scheme 6.3, were synthesized (please see Sections 
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6.4 and 6.5 for chemistry) also adopting the previously mentioned analogue 
design strategy (Section 6.2.7). 
 
 
Scheme 6.3 Generic formula of the additional synthesized analogues. 
 
Table 6.5 Additional synthesized analogues. 
Compound number Ar1 Ar2 
6.51  3,4,5-tris(benzyloxy)phenyl 2-pyridyl 
6.52  3,5-bis(benzyloxy)phenyl 2-pyridyl 
6.53  3,5-bis(benzyloxy)phenyl 3-pyridyl 
6.54  3,5-bis(benzyloxy)phenyl phenyl 
6.55  4-(benzyloxy)phenyl 2-pyridyl 
6.56  4-(benzyloxy)phenyl 3-pyridyl 
6.57  4-(benzyloxy)phenyl 4-pyridyl 
6.58  3,4,5-trimethoxyphenyl 2-pyridyl 
6.59  3,4,5-trimethoxyphenyl 3-pyridyl 
6.60  3,4-methylenedioxyphenyl 3-pyridyl 
 
6.2.9 Biological results 
 Compounds 6.34―6.60 were evaluated in the SYBR Green assay12 
(please see Appendix I for details) and results are summarized in Table 6.6. 
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Table 6.6 In vitro RNAP percentage inhibition of the synthesised analogues. 
Compound 
number 
In vitro RNAP % 
inhibition at 100 μM 
Compound 
number 
In vitro RNAP % 







6.37 4.8† 6.51 53.8 
6.38 0† 6.52 15.3‡ 
6.39 36.8† 6.53 31.2‡ 
6.4019 24‡ 6.54 14†‡ 
6.4120 7.2 6.55 2.4 
6.4221 0 6.56 24.3 
6.4322 0 6.57 11.9 
6.4421 0 6.58 2.7 
6.4523 0 6.59 0 
6.4621 3.1 6.60 7.6 
6.4721 4.7  
 
(†) Compounds showing solubility issues in the assay conditions 
(‡) Compounds showing auto-fluorescence in the assay conditions 
 
 Unfortunately compounds 6.35, 6.36, 6.37, 6.38 and 6.39 showed limited 
solubility in the assay conditions (please see Appendix I for details) moreover 
compounds 6.40,19 6.52, 6.53 and 6.54 showed auto-fluorescence. Solubility 
issues and auto-fluorescence exhibited by some compounds have a detrimental 
effect on the percentage of  inhibition at the specified concentration due to the 




6.2.10 Design and synthesis of analogues with partial or total 
removal of benzyloxy groups  
 Solubility problems reported in the previous series of compounds (Tables 
6.4 and 6.5) were addressed by synthesizing structural analogues derived from 
partial or total removal benzyloxy groups (Table 6.7) bearing the generic 
formula reported in Scheme 6.4 (please see Sections 6.4 and 6.5 for 
chemistry). 
 
In vitro RNAP % inhibition at 100  
Scheme 6.4 Generic formula of the synthesized analogues with partial or total 
removal of benzyloxy groups. 
 







6.61  3,4,5-tris(benzyloxy)phenyl 5-nitrofuran-2-yl 
6.62  3,5-bis(benzyloxy)phenyl p-hydroxyphenyl  
6.63  3,5-bis(benzyloxy)phenyl 1H-indol-3-yl 
6.6420  4-(benzyloxy)phenyl p-nitrophenyl  
6.65  4-(benzyloxy)phenyl p-dimethylaminophenyl  
6.66  4-(benzyloxy)phenyl 1H-indol-3-yl 
6.6725  2-naphthyl p-nitrophenyl 
6.68  2-naphthyl p-dimethylaminophenyl 
6.69  2-naphthyl 1H-indol-3-yl 
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6.2.11 Biological results 
 Compounds 6.61―6.69 were evaluated in the SYBR Green assay12 
(please see Appendix I for details) and the results are summarized in Table 6.8. 
 
Table 6.8 In vitro RNAP percentage inhibition of the synthesised compounds. 
Compound number In vitro RNAP % inhibition at 100 μM 
6.61  0† 
6.62  59.5†‡ 
6.63  2.2†‡ 
6.6420  9.8† 




6.6725  30.4 
6.68  13.2† 
6.69  33.1 
 
(†) Compounds showing solubility issues in the assay conditions 
(‡) Compounds showing auto-fluorescence in the assay conditions 
 
 Solubility issues and auto-fluorescence were observed for some 
compounds, which, for these cases, limited the accuracy of measurement of 
inhibition in the assay.  
 Disappointingly, the prediction of LogP and LogSw values using ALOGPS 
2.1 software9 (Table 6.9) for some representative compounds evaluated 
biologically (Tables 6.6, 6.7 and 6.8), was not able to explain why some 




Table 6.9 Prediction of ALogP and LogSw values using ALOGPS 2.1 software9 






6.3419 5.74 -6.63 No 
6.4019 4.51 -6.14 Yes 
6.51 5.95 -6.60 No 
6.52 4.74 -6.12 Yes 
6.53 4.50 -6.11 Yes 
6.62 5.54 -6.12 Yes 
6.68 4.00 -4.95 Yes 
6.69 4.45 -5.68 No 
 
6.2.12 SAR analysis 
 Considering the biological results reported in Sections 6.2.9 and 6.2.11, it 
was possible to conclude preliminary SAR considerations for this library 
(Schemes 6.3 and 6.4, Tables 6.4, 6.5 and 6.7). Replacement of the 3,4,5-
(trisbenzyloxy)phenyl groups with a naphthalene maintains or slightly improves 
activity while complete or partial removal or replacement with other alkyl ethers 
is detrimental to the activity; the position of the nitrogen in the pyridyl ring is not 
essential for the activity. Interestingly, analogues bearing a 3,5-
(bisbenzyloxy)phenyl moiety show auto-fluorescence and for this reason are 
unsuitable for further SAR studies. Whilst compounds 6.35, 6.37, 6.38 and 6.39 
were predicted to be promising compounds on the basis of their putative binding 
mode and overall score, solubility issues in the assay encountered also in their 
less hydrophobic analogues prevented comparison of activity to the parent 
compound 6.3, with the only exception of the soluble 2-naphthyl derivative 
6.67,25 where the presence of the p-nitrophenyl moiety does not impair 
biological activity when compared to analogue 6.4824 bearing a 3-pyridyl moiety. 
Compounds 6.36 and 6.62, despite their solubility problems, reveal that a 
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hydroxyl group in the para position bearing both electron donating properties 
and H-bond donor-acceptor features is tolerated.  
 Putative binding mode of the most active derivative, compound 6.4924 is 
reported in Figure 6.9. 
 
 
Figure 6.9 Predicted binding mode of 6.49.24 
 
 The following interactions between the ligand 6.4924 and the myxopyronin 
binding site were identified: the hydrazone nitrogen bound to the methinic 
carbon and the nitrogen belonging to the pyridyl ring are predicted to form an H-
bond reinforced by the charge with the protonated nitrogen of the side chain of 
Lys1463. The guanidinium moiety belonging to the side chain of Arg1096 is 
predicted to form a cation-pi interaction with the pyridyl ring which is also 
performing a T-shaped displaced pi-stacking interaction with the aromatic ring 
of the side chain of Phe1440. The naphthalenic ring is involved in hydrophobic 
interactions with the side chains of Phe614, Leu619, Leu1088 and Ile1467.      
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6.2.13 Design and synthesis of a new acylhydrazone library with 
improved solubility 
 A new acylhydrazone library (Table 6.10) bearing the generic formula 
reported in Scheme 6.5 was designed to further explore SAR in the light of the 
previous findings and to address some solubility issues encountered (please 
see Sections 6.4 and 6.5 for chemistry).  
 
 
Scheme 6.5 Generic formula of the synthesized analogues with improved 
solubility. 
 







6.70 3,4,5-tris(benzyloxy)phenyl 2-hydroxyphenyl 
6.71 3,4,5-tris(benzyloxy)phenyl 3-hydroxyphenyl 
6.72 3,4,5-tris(benzyloxy)phenyl 2,4-dihydroxyphenyl 
6.73 3,4,5-tris(benzyloxy)phenyl 2-carboxyphenyl 
6.74 3,4,5-tris(benzyloxy)phenyl 3-carboxyphenyl 
6.75 3,4,5-tris(benzyloxy)phenyl 4-carboxyphenyl 
6.76 2-naphthyl 2-carboxyphenyl 
6.77 2-naphthyl 3-carboxyphenyl 




Table 6.10 Continued 
6.79 3,4,5-tris(benzyloxy)phenyl 2-cyanophenyl 
6.80 3,4,5-tris(benzyloxy)phenyl 3-cyanophenyl 
6.81 3,4,5-tris(benzyloxy)phenyl 4-cyanophenyl 
6.82 3,4,5-tris(benzyloxy)phenyl 1H-pyrrol-2-yl 
6.83 2-naphthyl 1H-pyrrol-2-yl 
6.84 1-naphthyl 3-pyridyl 
6.85 quinolin-6-yl 3-pyridyl 
6.86 quinoxaline-6-yl 3-pyridyl 
6.87 1H-indol-3-yl 3-pyridyl 
6.88 1H-indol-5-yl 3-pyridyl 
6.89 1H-indol-6-yl 3-pyridyl 
6.90a 3-morpholinophenyl 3-pyridyl 
6.91a 4-(1H-imidazol-1-yl)phenyl 3-pyridyl 
 
 The following structural variations were probed: 
 As compound 6.36 showed good inhibitory activity despite its solubility 
problems, other positions for the placement of an hydroxyl group on the phenyl 
ring were explored via compounds 6.70 and 6.71, moreover a more soluble 
analogue, 6.72, was prepared.   
3,4,5-(Trisbenzyloxy)phenyl derivatives 6.73, 6.74, 6.75 and 2-naphthyl 
based analogues  6.76, 6.77, 6.7825 with the carboxylate group inserted in 
various positions of the phenyl ring were prepared with the aim of performing a 
bioisosteric replacement of the nitro group and to obtaining more soluble 
derivatives. 
Compounds 6.79, 6.80 and 6.81 were prepared to evaluate the inhibitory 
potency of derivatives bearing a substituent with electron withdrawing and H-
bond acceptor properties. 
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Substitution of the pyridyl group with a smaller ring was tested via 
synthesizing compounds 6.82 and 6.83.   
Compound 6.84 was prepared to assess whether a 2-naphthyl group is 
essential for the biological activity or if a 1-naphthyl substituent is tolerated. 
 Heteroaromatic derivatives 6.85, 6.86, 6.87, 6.88, 6.89, 6.90a, 6.91a were 
synthesized to improve solubility and to explore the effects of H-bond donors 
and acceptors on the putative binding region occupied by the 3,4,5-
(trisbenzyloxy)phenyl group of parent compound 6.3. 
Compounds 6.90a and 6.91a were specifically shortlisted from a series of 
possible structural analogues (Table 6.11) following prediction from docking 
studies that they may undergo favourable binding to RNAP following the 
protocol reported in Section 6.2.2. The overall score value, putative binding 
mode and number of H-bond interactions were considered in prioritizing the 
synthesis of 6.90a and 6.91a as reported in Table 6.11. 
 































6.2.14 Biological results 
 Compounds 6.70―6.91a were evaluated in the SYBR Green assay12 
(please see Appendix I for details) and results are summarized in Table 6.12. 




In vitro RNAP % 
inhibition at 100 μM 
Compound 
number 
In vitro RNAP % 
inhibition at 100 μM 
6.70 0 6.81 17.1† 
6.71 15.1 6.82 9.7 
6.72 5.9† 6.83 0 
6.73 53.8 6.84 0 
6.74 18.7 6.85 7.9 
6.75 72.7 6.86 0 
6.76 11.8 6.87 13.3† 
6.77 16.4 6.88 0 
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Table 6.12 Continued 
6.7825 30.1 6.89 7.5 
6.79 0† 6.90a 0 
6.80 36.9 6.91a 0 
 
(†) Compounds showing solubility issues in the assay conditions 
 
 
Compounds 6.72, 6.79, 6.81 and 6.87 showed limited solubility in the buffer 
solution used for the assay, which would likely compromised their measured 
biological activity in the assay. As mentioned earlier, prediction of ALogP and 
LogSw values using ALOGPS 2.1 software9 for some representative 
compounds (Table 6.13) was again not able to account for why some 
compounds with better predicted solubility showed solubility issues in the assay. 
 
Table 6.13 Prediction of ALogP and LogSw values using ALOGPS 2.1 






6.70 6.45 -6.50 No 
6.71 6.46 -6.56 No 
6.72 6.36 -6.18 Yes 
6.79 6.42 -6.08 Yes 
6.80 6.43 -6.08 No 
6.81 6.44 -6.08 Yes 
6.87 2.37 -3.89 Yes 
6.88 2.37 -3.98 No 




6.2.15 SAR analysis 
 In light of the biological results reported in Section 6.2.14, it was possible 
to make a number of deductions regarding SAR within this library (Scheme 6.5 
and Table 6.10): with regard to 3,4,5-(trisbenzyloxy)phenyl-based derivatives, 
introduction of the hydroxyl group in the phenyl ring belonging to the 
benzylidene moiety in positions other than para, as in compounds 6.70 and 6.71 
is detrimental for activity, while introduction of two hydroxyl groups somewhat 
surprisingly leads to solubility problems as in compound 6.72. Introduction of a 
carboxyl group in either the ortho or para positions of the benzylidene unit 
increases the biological activity (compounds 6.73 and 6.75 respectively), whilst 
the placement of carboxyl at the meta position as in compound 6.74 reduces 
the biological activity relative to the parent compound 6.3. Notably, introduction 
of a less strong H-bond acceptor and weaker electron withdrawing group 
relative to the carboxyl as in the cyano-substituted compounds 6.79, 6.80 and 
6.81, is negative for the biological activity. With regard to the 2-naphthyl based 
derivatives, introduction of a carboxyl group in the same previously mentioned 
positions does not lead to more potent analogues in comparison with the parent 
compound 6.3 but, by analogy with compounds 6.37, 6.38 and 6.39, substitution 
at the para position of the benzylidene moiety is the most favorable in terms of 
biological activity. Interestingly, the 1-naphthyl based derivative 6.84 is inactive 
and this suggests that this scaffold is not amenable in contrast with 2-naphthyl 
based isomer. Substitution of the pyridyl group with a smaller ring system as in 
compounds 6.82 and 6.83 is detrimental for biological activity in both the 3,4,5-
(trisbenzyloxy)phenyl and 2-naphthyl based derivatives. Substitution of the 
3,4,5-(trisbenzyloxy)phenyl group of the parent compound 6.3 with other 
heteroaromatic derivatives conferring higher predicted solubility and the 
possibility to establish additional H-bond interactions led to inactive molecules 
as observed for compounds 6.85, 6.86, 6.87, 6.88, 6.89, 6.90a, 6.91a. 
 The putative binding mode of the most active analogue, compound 6.75, is 





Figure 6.10 Putative binding mode of 6.75. 
 The following interactions between the ligand 6.75 and the myxopyronin 
binding site were predicted: the protonated nitrogen of the Lys1097 side chain is 
predicted to form an H-bond/ionic interaction with the carboxylate moiety of 
6.75, while the hydrazone carbonyl is establishing an H-bond reinforced by 
charge with the protonated nitrogen belonging to the side chain of Lys1463. 
Hydrophobic interactions are predicted between the benzylidene aromatic ring 
and the side chain of Phe1440. A T-shaped pi-stacking interaction is 
established between the side chain of Phe614 and one benzyloxy group while 
the side chains of Leu1447, Leu607, Leu1088, Leu619, Leu1053, Ile1466, Ile 
1467 and Val1037 are performing hydrophobic interactions with the three 
benzyloxy groups. 
 
6.2.16 Attempted evaluation of IC50 values and antibacterial activity 
for selected compounds. 






 6.51 and 6.75 exhibited 
the best percentage inhibition activity at the concentration of 100 μM, attempts 
were made to establish IC50 values using E. coli RNA polymerase and also to 
162 
 
probe antibacterial activity on selected bacterial strains (please see Appendix I 
for details). 
 With regard to IC50, unfortunately a full dose response curve could not be 
determined for any of the compounds under study. This was due to the lack of 
100% inhibition when compounds reached the saturation concentration in the 
assay conditions. This observation may reflect the relative poor solubility of 
these compounds at higher concentrations as coupled with the rather modest 
inhibitory activity. 
 Antibacterial activity for selected compounds is summarized in Table 6.14. 
 
Table 6.14 MIC determination for selected compounds. a MIC values in μg/mL b 
E. coli TolC deficient strain. 




6.3           >128 >128 
6.36 >128 >128 
6.4824 >128 >128 
6.4924 32 >128 
6.5024 >128 >128 
6.51 >128 >128 
6.75 >128 >128 
 Disappointingly, none of the compounds showed significant antibacterial 
activity with the only exception being compound 6.49,
24
 which showed 
moderate inhibitory activity with the Gram positive bacterial strain of S. aureus 
SH1000. 
6.3 Synthesis of intermediate 6.93 
 An acetone solution of ester 6.92 was treated with an excess of 
benzylbromide in presence of an excess of potassium carbonate under reflux to 
give di-ether 6.93




Scheme 6.6 Synthesis of 6.93.26 
6.4 Synthesis of the hydrazides 
 The intermediate hydrazides were readily prepared in excellent yields by 
adding an excess of hydrazine hydrate to an ethanolic solution of an 
appropriately prepared (6.93)26 or commercially available ester (Table 6.15, 
Appendix II, Section A) and heating to reflux for 12 hours (Scheme 6.7). 
Recrystallization from a suitable solvent afforded the corresponding hydrazides 
(Table 6.16, Appendix II, Section B). 
 
 
Scheme 6.7 Synthesis of 6.103―6.111. 
 
6.5 Synthesis of the acylhydrazone library 
 A library of acylhydrazone analogues has been synthesized in good yield 
(Scheme 6.8) by heating to 50 °C for 8 hours an ethanolic solution of equimolar 
quantities of the prepared (6.94-6.111) or commercially available 6.112-6.116 
hydrazide (Table 6.17, Appendix II, Section C) and commercially available 
aldehyde (Table 6.18, Appendix II, Section D). Recrystallization from a suitable 
solvent or purification via mass-directed preparative HPLC afforded the 





Scheme 6.8 Synthesis of the hydrazones. 
6.6 Conclusions 
Following the application of a rigorous and accurate docking study, 
amongst the two discovered bacterial RNAP inhibitors, acylhydrazone 6.3 was 
selected on the basis of its RNAP inhibitor activity (56% of inhibition at the 
concentration of 100μM), synthetic amenability and suitability for analogue 
design. Based upon the predicted binding mode of this compound within RNAP, 
a SAR study was conducted in order to increase potency and drug likeness 
properties. A library of acylhydrazone analogues was synthesized after 
similarity searching and docking  studies which allowed the exploration of the 
chemical space around the initial hit and to prioritize the synthesis of analogues 
on the basis of the predicted binding mode. 
The biological results underlined the importance of hydrophobic 
interactions for the binding. In fact, any attempt to improve drug likeness by 
preparing compounds with predicted increased aqueous solubility, led 
systematically to inactive compounds or to derivatives with improved biological 
activity but which still suffered from poor solubility at higher concentrations 
which prevented the establishment of full IC50 determination. Notably, the 
calculation of physicochemical descriptors like LogP and LogSw during the 
analogue design failed in some cases to predict empirical solubility in the 
specific assay conditions. It was possible to conclude from the SAR studies that 
effectively targeting a highly lipophilic binding site via designing compounds with 
better physicochemical properties when compared to myxopyronin antibiotics is 
very challenging.  
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Interestingly, compounds 6.36, 6.49,24 6.62 and 6.75 showed better 
inhibition activity when compared to the parent acylhydrazone 6.3 but 
disappointingly none of them showed antibacterial activity with the only 
exception being derivative 6.49,24 which possessed moderate activity towards a 
Gram-positive bacterial strain of S. aureus SH1000. It is clear that inhibiting a 
whole bacterial cell implies crossing biological barriers and in the case of Gram 
negative strains, additional barriers and active mechanisms of resistance are 
operating and this explains why it is more easier to obtain inhibitors active in the 
isolated enzyme as opposed to also exhibiting cellular activity.  
With regard to the vHTS protocol, it was possible to conclude that this 
showed a reasonable hit identification ratio. The presence of false positives in 
the shortlist and the lack of correlation, in some cases, between the scoring 
values and the biological activity, underlined the actual limits of scoring 
functions in evaluating the free energy of binding. In addition, putative binding 
modes allowed to guide the design process and to explain the biological activity 
of some analogues, but the well known difficulties of search algorithms to 
sample a large binding site may lead to inaccuracies in the predictions. The lack 
of a potent inhibitor prevented the confirmation of binding modes with empirical 
data derived from X-ray diffraction studies of co-crystal structures of bound 
inhibitors. 
 In conclusion, none of the synthesized molecules possessed improved 
enzymatic inhibitory activity and antibacterial potency when compared to 7-
desmethylmyxopyronin B 1.27 despite of their improved synthetical amenability, 
better binding energy on the basis of the scoring function and more suitable 
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7. Developing of a novel structure based virtual screening 
protocol  
7.1 Virtual screening strategy 
 As described previously, in the light of the solubility problems and the 
general lack of potency required for future optimisation encountered in the 
previous series of synthesized acylhydrazones (Chapter 6), it was decided to 
develop a novel RNAP inhibitor using a structure-based virtual screening 
protocol.  
 In order to maximise the solubility of the newly predicted virtual hits, a 
preliminary library filtering based on physico-chemical descriptors was 
performed to restrict the number of screening candidates. After this preliminary 
step, a docking was then performed using GOLD docking software focussed 
inside the myxopyronin binding region defined from the crystal structure of the 
T. thermophilus RNA polymerase holoenzyme in complex with the antibiotic 
myxopyronin A 1.25 (PDB id: 3DXJ1). 
 In contrast to the protocol reported in the previous Chapter (Sections 6.2.1 
and 6.2.2), no ligand-based stage was implemented in this virtual screening 
protocol. The definition of key pharmacophoric points based on the active 
conformation of 7-desmethyl-myxopyronin B 1.27 in the ligand-based virtual 
screening protocol reported in Section 6.2.1 permitted the prioritization of 
molecules showing similarity to the natural antibiotic in terms of pharmacophoric 
features and to decrease dramatically the number of molecules to be docked. 
The main disadvantage of this strategy was the identification of molecules 
sampling a limited number of interaction points present in a very large binding 
region. The full sampling of the binding site via docking allowed the selection of 
more structurally diverse molecules which also were predicted to interact with 
different residues when compared to the binding mode observed for the natural 
antibiotic 7-desmethylmyxopyronin B 1.27.     
 In order to counterbalance the increased computational time required for 
screening a database of molecules without a preliminary ligand-based 
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screening, the protocol was limited to a small sized compound library, the 
Medicinal Chemistry and Chemical Biology technology group (MCCB) in-house 
chemical database, composed of 26,493 molecules. With regard composition, 
the MCCB database  comprises selected collections of commercial compounds 
purchased from Albany Molecular Research Inc. (AMRI), Chembridge and 
Asinex databases.  
7.1.1  Database filtering protocol 
 The initial database of 26,493 molecules was filtered using Canvas v.1.6, a 
chemoinformatic module  included into Schrodinger Maestro software suite.  
 The specified parameters for filtering the database were calculated with 
Canvas v.1.6 with the exception of ALogP and LogSw (logarithm of the 
predicted solubility in water)  values which were calculated with ALOGPS 2.1 
software:2 
300 ≤ M.W. ≤ 500 
ALogP ≤ 4.0 
LogSw  ≥ -5.0 
Hydrogen bond donors ≤ 5 
Hydrogen bond acceptors ≤ 10 
Rotatable bonds ≤ 5 
Polar surface area ≤ 150 
 The choice of ALogP and LogSw parameters for filtering the database 
reflected the purpose of considering only molecules with good predicted 
solubility. Use of the specified M.W. range allowed the filtering of molecular 
fragments with a limited possibility to establish interactions within the binding 
site, while limiting the number of rotatable bonds allowed a significant reduction 
of the computational time spent by the searching algorithm for sampling the 
conformational space of the docked molecules.  
 Globally, the above specified physico-chemical parameters used for 
filtering the database were found to select a subgroup of 8,143 molecules which 
all satisfied the Lipinski’s rule of five3 and this database differed in more 
170 
 
restrictive range of values for the M.W., ALogP and the number of rotatable 
bonds. 
7.1.2  Docking protocol 
 Docking settings for the structure-based virtual screening protocol were 
used as described in the docking validation studies reported in Chapter 3. 
 The crystal structure of the T. thermophilus RNA polymerase 
holoenzyme in complex with the antibiotic myxopyronin A 1.25 (PDB id: 3DXJ1), 
was downloaded from the Protein Databank (www.rcsb.org). 
All water molecules, cofactors and ions were manually removed using 
Maestro and the binding site within the RNAP was defined as the protein 
comprised in a sphere with a 15 Å radius surrounding the cocrystallised ligand. 
The docking runs were performed using GOLD4 v4.0.1 (CCDC, 
Cambridge, UK) docking software by initially using accuracy settings for the 
genetic searching algorithm which corresponded to the 50% of the default 
parameters values of the genetic algorithm in order to get a quick and relatively 
accurate search inside the binding cavity. Compounds were ranked using the 
Chemscore scoring function generating 100 poses for each ligand. The top 10% 
of molecules, corresponding to 814 structures, were progressed to a further 
docking evaluation using the best accuracy settings for the genetic search 
algorithm  which corresponded to the 200% of the default parameters values in 
order to get a more exhaustive search inside the binding cavity. The final 
docked poses were re-ranked using Goldscore scoring function after energetic 
minimization performed using the simplex algorithm implemented in GOLD.     
A shortlist of 400 compounds which corresponded to around the 50% of 
the top-ranked molecules in this final step, was selected for post-docking 
analysis, which was performed for each ligand among its different docking 
solutions. Cluster analysis using an average linkage rule was performed using 
an internal module within the software. Only the best ranked poses of the most 
populated cluster were considered as the most likely and representative ones. 
In addition, the docked poses within the binding pocket were analysed applying 
the same post-docking criteria reported in Chapter 6, Section 6.2.2. 
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7.1.3  vHTS results 
 Following post-docking analysis, which included the selection of virtual hits 
on the basis of their chemical diversity, twenty molecules were selected for 
biological evaluation and are reported in Table 7.1 (please see Section 7.1.4 for 
biological results). 
 












340 3.67 -3.86 26.8 
7.2 
 
325 3.24 -3.42 30.2 
7.3 
 
362 2.26 -3.50 30.0 
7.4 
 
371 2.31 -2.53 31.0 
7.5 
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338 1.80 -3.30 33.8 
7.7 
 
445 2.69 -3.39 33.9 
7.8 
 
345 2.43 -3.32 28.3 
7.9 
 
406 3.62 -4.24 37.9 
7.10 
 
398 2.30 -3.55 35.5 
7.11 
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392 2.95 -3.72 35.2 
7.13 
 
348 2.27 -3.75 29.0 
7.14 
 
360 2.05 -4.12 30.2 
7.15 
 
304 3.71 -3.71 33.5 
7.16 
 
352 2.53 -2.60 31.1 
7.17 
 
375 3.65 -3.48 40.7 
7.18 
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7.20 
 




Compound 7.18 was purchased as a racemic mixture and the Chemscore value is referred to its mean 
value of the two single docked enantiomers. 
 
7.1.4 Biological evaluation of the vHTS hits 
 Compounds 7.1―7.20 were evaluated in the SYBR Green assay5 (please 
see Appendix I for details) and the results are summarized in Table 7.2. 
 
Table 7.2 In vitro RNAP percentage inhibition of the vHTS hits 
Compound 
number 
In vitro RNAP % 
inhibition at 100 μM 
Compound 
number 
In vitro RNAP % 
inhibition at 100 μM 
7.1 3.3 7.11 6.4 
7.2 5.2 7.12 6.4 
7.3 7.5 7.13 0 
7.4 0.9 7.14 11.6 
7.5 4.6 7.15 7.8 
7.6 3.0 7.16 3.6 
7.7 9 7.17 0 
7.8 9.8 7.18 57.1† 
7.9 12.1 7.19 1.8 
7.10 18.8 7.20 0 
 
(†) % inhibition value for Compound 7.18 refers to the racemic mixture. 
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 Disappointingly, most of the compounds showed only moderate inhibition 
activity with the only exception being 7.18 which was considered for further 
investigations and possible chemical optimization.  
 
7.1.5 Substructure query-based search and docking of structural 
analogues of compound 7.18 
 In order to explore the close chemical space of the identified hit from the 
previous virtual screening studies, a substructure query based search was 
performed both on the ZINC6 and MCCB database using ZINC substructure 
query tool and Canvas module included in Schrodinger Maestro software 
respectively. Substructure query based search on all atoms was based on a 




Scheme 7.1 Central scaffold used for the substructure query based search 
 
 The substructure query based search of the MCCB library retrieved only 
fourteen compounds and they were all present within the Chembridge 
commercial library. Compounds were then docked following the same settings 
specified in Section 7.1.2 and it was observed that their predicted binding mode 
and overall score value was similar to those for compound 7.18 (Table 7.3). 


















355 2.43 -4.22 29.5 
7.22 
 
325 1.03 -2.78 28.6 
7.23 
 
273 0.51 -2.36 24.3 
7.24 
 
335 1.09 -3.32 28.1 
7.25 
 
311 0.82 -2.75 26.7 
7.26 
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289 -0.05 -2.26 25.0 
7.28 
 
399 2.20 -3.43 28.4 
7.29 
 
355 0.71 -2.92 29.2 
7.30 
 
395 1.47 -3.75 29.3 
7.31 
 
391 1.72 -3.28 31.8 
7.32 
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341 2.01 -4.06 30.6 
7.34 
 




All chiral compounds were purchased as a racemic mixture and the Chemscore value is referred as the 
mean value of the two single docked enantiomers. 
 
7.1.6 Biological results 
 Compounds 7.21―7.34 were evaluated in the SYBR Green assay5 
(please see Appendix I for details) and results are summarized in Table 7.4. 
 
Table 7.4 In vitro RNAP percentage inhibition of 7.18 close structural analogues 
Compound 
number 
In vitro RNAP % 
inhibition at 100 μM 
Compound 
number 
In vitro RNAP % 
inhibition at 100 μM 
7.21 27.8 7.28 30.4 
7.22 0 7.29 11.2 
7.23 0 7.30 11.5 
7.24 6 7.31 4.5 
7.25 8.2 7.32 28.7 
7.26 10.3 7.33 3.6 




 Unfortunately, none of the purchased analogues showed better biological 
activity than the original hit 7.18. In order to explore the potential for 
development of hit 7.18 and possible synthesis of novel analogues, this 
compound was further evaluated for antibacterial activity (Table 7.5) using 
selected bacterial strains (please see Appendix I for details).  
 
Table 7.5 MIC determination for 7.18. a MIC values in μg/mL b E. coli TolC 
deficient strain. 




7.18            >128 >128 
 
 Unfortunately, compound 7.18 did not possess antibacterial activity with 
both Gram positive and Gram negative representative strains which probably 
reflects the poor penetration of bacterial membranes despite the good inhibition 
activity displayed by these compounds in the presence of the isolated enzyme. 
7.1.7 SAR analysis of the purchased analogues 
 On the basis of the previous biological results of the purchased analogues 
of hit 7.18 (Section 7.1.6), SAR were formulated. Globally, the thiophen-2-yl 
moiety along with the N-methoxyethyl chain are essential for the biological 
activity and no alternative moieties conferred better activity. In particular, the 
methoxy group at the level of the N-methoxyethyl chain is critical for the activity 
and N-alkyl derivatives are almost inactive, showing a negative trend of 
biological activity as the length of the chain is decreased as shown in 
compounds 7.21 and 7.33. Interestingly, substitution of the thiophen-2-yl moiety 
with bioisosteres as shown in compounds 7.29 and 7.34, is detrimental for the 
activity. Replacement of thiophen-2-yl moiety with groups showing increased 
steric hindrance in compounds 7.28, 7.30, 7.31 and 7.32 is negative for the 
activity, but the presence of a moderately electron withdrawing group in para 
position of the phenyl ring is better tolerated when comparing biological 
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activities of compounds 7.28 and 7.32 with 7.30 and 7.31. When comparing the 
importance for the biological activity of the thiophen-2-yl and N-methoxyethyl  
moieties in compounds 7.27 and 7.33 respectively, the N-methoxyethyl chain is 
more critical for the activity. Methylation of the NH between the two keto groups 
is detrimental for the activity as shown by compounds 7.24 and 7.26. 
 
7.1.8 Putative binding mode of the identified hit 
 A putative binding mode of the most active derivative, compound 7.18, is 
shown in Figures 7.1 and 7.2 for both the enantiomers, (S) and (R) respectively. 
Whilst compound 7.18 was available only as a racemic mixture from the vendor, 
a different binding mode was found for both enantiomers and a slightly better 
Chemscore value was found for the (R) enantiomer as shown in Table 7.6. 
 
Table 7.6 Chemscore value for both enantiomers of 7.18 
Compound number Enantiomer Chemscore
 
7.18    (S)            28.6 
7.18    (R)            34.6 
 
 The following interactions between the (S) enantiomer of 7.18 and the 
myxopyronin binding site were identified (Figure 7.1): a H-bond was predicted 
between the side chain of Gln1019 and one carbonyl of the pyrimidine ring 
while the carbonyl and the NH of Gly620 are forming a H-bond with the NH and 
the carbonyl of the pyrimidine ring respectively. The N-methoxyethyl chain is 
establishing hydrophobic interactions with the side chain of Val1087 while the 
side chains of Ile1467, Leu619 and Val1037 are performing the same 
interactions with the dihydroisoquinolinone ring and the thiophen-2-yl moiety of 
7.18. Notably, the predicted binding mode for this enantiomer, is able to explain 
some aspects of the previous SAR analysis. The importance of the N-
methoxyethyl chain and the thiophen-2-yl moiety in addition to the lower 
biological activity of shorter N-alkyl derivatives, may be explained by their 
predicted hydrophobic interactions. The detrimental effects upon biological 
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activity of moieties offering steric hindrance that is bigger than that predicted for 
the  thiophen-2-yl group, is predicted by the possible steric clash with the side 
chain of Trp1038. Finally the loss of activity following the methylation of the 
pyrimidine NH is explained by the loss of its hydrogen bond with the backbone 
of Gly620.  
 
 
Figure 7.1 Putative binding mode of the (S) enantiomer of 7.18 
 
 The following interactions between the (R) enantiomer of 7.18 and the 
myxopyronin binding site were identified (Figure 7.2): a H-bond was predicted 
between the side chain of Ser1084 and one carbonyl of the pyrimidine ring 
while the carbonyl and the dihydroisoquinolinone ring is forming H-bonds with 
the side chain of Ser1439 and Lys1463. The N-methoxyethyl chain is 
establishing hydrophobic interactions with the side chain of Val1087 while the 
side chains of Phe614, Val1466, Ile1467 and Val1466 are performing the same 
interactions with the dihydroisoquinolinone ring and the thiophen-2-yl moiety of 
7.18. A T-shaped pi-stacking interaction was predicted between the side chain 
of Trp1038 and the thiophen-2-yl moiety. Interestingly, the predicted binding 
mode for this enantiomer, is able to explain, by analogy with the previous 
182 
 
binding mode, some aspects of the previous SAR analysis. The importance of 
the N-methoxyethyl chain and thiophen-2-yl moiety in addition to the lower 
biological activity of shorter N-alkyl derivatives are explained by their predicted 
hydrophobic interactions. The detrimental effects on biological activity of 
moieties with bigger steric hindrance than the  thiophen-2-yl group is predicted 
by the possible clash with the side chain of Val1466. The T-shaped pi-stacking 
interaction between the side chain of Trp1038 and the thiophen-2-yl moiety 
could explain why analogue 7.29 has lower activity than 7.18, in fact, the 
electron rich furan ring could suffer from repulsion of the neighbouring electron 
rich indole ring while the thiophene moiety of 7.18, having a lower electron 
density, could establish a more favourable interaction with the side chain of 
Trp1038.    
 
 
Figure 7.2 Putative binding mode of the (R) enantiomer of 7.18 
 
 Overlay of the (R) enantiomer of compound 7.18 with myxopyronin A 1.25 
into its binding site (Figure 7.3) revealed that the pyrimidine ring is occupying 
the same region of the central α-pyrone ring performing a similar network of H-
bond interactions while the N-methoxyethyl chain and the thiophen-2-yl moiety 
is predicted to occupy the same hydrophobic regions of myxopyronin A. The 
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dihydroisoquinolinone ring system is involved in some important interactions 
within the binding site (Figure 7.3) and it is also providing the function of a rigid 
spacer for the thiophen-2-yl moiety. This putative binding mode could provide 
useful ideas for future analogue design based on a central N-substituted 
pyrido[2,3-d]pyrimidine-based scaffold linked to a suitable polar group 
mimicking the interactions of the ene-carbamate as shown in Scheme 7.2. 
 
 
Figure 7.3 Overlay between myxopyronin A  1.25 in yellow sticks and the (R) 








 In order to avoid solubility problems in the assay, a structure-based virtual 
screening was conducted on the (MCCB) in-house chemical database applying 
a preliminary library filtering based on physico-chemical descriptors.  
 Application of this virtual screening protocol was successful and identified 
a hit between a short list of twenty molecules which did not show solubility 
issues.  
 In order to explore the close chemical space of the identified hit, a 
substructure query based search and docking studies were conducted on the 
on the ZINC6 and MCCB database, identifying fourteen analogues and SAR 
analysis was performed on these molecules. Interestingly, the putative binding 
modes for both enantiomers of 7.18 were able to explain SAR and this 
appeared to validate the putative binding mode and to confirm the good 
performance of the searching algorithm. On the contrary, the lack of biological 
activity of the selected hit analogues showing a similar score underlines the 
limitations of the scoring function in correlating the biological activity with the 
estimated binding energy.    
 Considering the absence of antibacterial activity showed by the most 
active inhibitor, compound 7.18, in addition to the inability to improve inhibitory 
activity via analysis of structural analogues, compound 7.18 is not a viable 
candidate for future optimisation by synthesis but its putative binding mode 
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8. Conclusions and future work 
The work described in this thesis was directed towards the identification 
of novel bacterial RNAP inhibitors via the application of rational computational 
design, synthesis and biological evaluation. 
In particular, this research was focussed on the myxopyronin binding 
region, the ‘switch region’, a promising ‘hot spot’ which is essential for the 
conformational changes within RNAP required during DNA transcription.   
The computational rational design phase of the work involved the 
combined use of ligand- and structure-based techniques. Given the availability 
of different docking algorithms as well as X-ray co-crystal structures, a 
validation study was conducted in Chapter 3 to identify the optimal software 
parameters and the most appropriate crystal structure for use in the subsequent 
inhibitor design studies. 
Initially, the work was based around a small molecule RNAP inhibitor, 
4.1, reported on Pubchem.1 The absence of information on the putative binding 
site of this molecule and the lack of any SAR data required attempts to be made 
to identify the binding region of this molecule within RNAP via the use of 
extended docking studies on all the known inhibitor binding sites followed by 
SAR exploration. Unfortunately, the apparent inhibitory activity of this compound 
could not be reproduced using the assay system at Leeds which may result 
from differences between the Leeds-based biological assay2 and that reported 
in literature.3 
A scaffold-hopping strategy was then conducted (Chapter 5) on the basis 
of a pharmacophore hypothesis based upon structural elements of 
myxopyronin. Ligand-based virtual screening followed by docking studies were 
performed in order to attempt to identify putative RNAP inhibitors which may 
overcome the unfavourable pharmacokinetic and chemical properties of 
myxopyronin A (Myx) 1.25. Unfortunately, despite of the favourable 
physicochemical properties of the selected hits, no RNAP inhibition was 
observed. These results revealed the limitations of a virtual screening protocol 
relying mostly on ligand based techniques. 
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In Chapter 6, based upon a theoretical study described in the literature,4 
two bacterial RNAP inhibitors were identified via a rigorous and accurate 
combined ligand- and structure-based virtual screening protocol. Acylhydrazone 
6.3 was selected and a SAR study was conducted in order to increase its 
potency and drug likeness on the basis of its putative binding mode. A library of 
acylhydrazone analogues was synthesized after similarity-based virtual-
screening and docking studies, which allowed to explore the close chemical 
space of the initial hit and to prioritize the synthesis of analogues. Compounds 
6.36, 6.49,
5
 6.62 and 6.75 showed better inhibition activity when compared to 
the parent acylhydrazone 6.3 and moreover, derivative 6.49
5
 possessed 
moderate activity towards a Gram-Positive bacterial strain of S. aureus SH1000. 
Unfortunately, during IC50 determination studies, it was found that the most 
active compounds of this series had relatively poor aqueous solubility. 
Nonetheless, the results from the SAR study on this compound series underline 
the importance of hydrophobic interactions for the binding of these molecules to 
the myxopyronin binding site within RNAP and attempts to improve drug 
likeness by preparing compounds with predicted increased aqueous solubility 
(and corresponding decreased hydrophobicity) led systematically to inactive 
compounds or to derivatives with improved biological activity but which were 
poorly soluble. In addition, whilst a successful virtual screening protocol was 
conducted, this work showed that targeting effectively a highly lipophilic binding 
site via the design of compounds with better physicochemical properties than 
myxopyronin is very challenging. Furthermore, it was found that the use of 
physicochemical descriptors for predicting solubility is not always reliable when 
applied in circumstances different from model systems like the specific assay 
conditions. 
In Chapter 7, in order to prevent solubility problems previously 
encountered in the assay, structure-based virtual screening was conducted 
using an in-house (MCCB) chemical database, applying preliminary library 
filtering based on physico-chemical descriptors. Given the small size of the 
screened library, a new structure-based virtual screening protocol was 
successfully applied and a hit, compound 7.18, was identified. In order to 
explore the close chemical space of the identified hit, a substructure query 
188 
 
based search followed by docking studies were conducted identifying fourteen 
analogues and SAR analysis was performed on these molecules. Interestingly, 
the putative binding mode for 7.18 was generally able to explain the observed 
SAR in which appears to validate the modelling and design protocol. In contrast, 
the lack of biological activity of selected analogues showing a similar score to 
the original hit underlines the limitations of the scoring function in correlating the 
biological activity with the estimated binding energy. Compound 7.18 and its 
analogues did not show antibacterial activity and none of the analogues showed 
increased inhibition when compared with the parent molecule 7.18. For the 
previously cited reasons, no additional synthetic exploration was undertaken 
even if the putative binding mode of 7.18 offers useful ideas for future design. 
With the exception of compound 6.49,5 the lack of antibacterial activity 
among the synthesized enzyme inhibitors from this project underlines the 
challenge of crossing bacterial cell membranes and this explains why it is  
easier to obtain inhibitors active against the isolated enzyme as opposed to also 
exhibiting cellular activity.  
Whilst there is no conclusive evidence that the synthesized inhibitors bind 
to the myxopyronin binding region, future work could involve the synthesis of 
new analogues with increased potency for determining a X-ray co-crystal 
complex with bacterial RNAP. These crystallography data would provide 
increased reliability of the predictions via computational studies and will 
represent an excellent starting point for future structure-based design.  
Future analogue design could be based either on the ideas reported in 
Scheme 7.2 in Chapter 7 or applying the successful virtual screening protocols 
reported in Chapters 6 and 7 after preliminary library filtering based on physico-
chemical descriptors. 
 The myxopyronin binding region of bacterial RNAP is a highly lipophilic 
binding site and the design of a ligand with a favourable aqueous solubility 
profile represents a challenge for drug design. A possible strategy to overcome 
these intrinsic limitations could be represented by focussing attention on 
alternative known inhibitor binding regions of bacterial RNAP, e.g. 
streptolydigin6 and tagetitoxin7 binding sites, characterised by a lower 
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hydrophobicity of their key residues which are still unexplored in terms of drug 
design and synthesis.  
With regard to the lack of consensus between different biological assays 
encountered in Chapter 4, an interesting recent paper8 offered useful insights 
into this issue. In fact, the authors
8
 demonstrated that the template choice can 
influence the inhibitory potency of bacterial RNAP inhibitors. In particular, our 
assay, when compared with the other assays described in the paper,8 
underestimates the potency of myxopyronin while in the case of an another 
inhibitor of the same binding region, corallopyronin, gave comparable results. 
The authors8 recommended the use of a double-stranded, preferentially 
prokaryotic promoter-containing DNA template for the determination of inhibitory 
potencies of compounds targeting bacterial RNAP. In the light of these findings 
and considering that the template in our assay is a single strand of circular DNA 
lacking of promoter, it might be useful to develop an alternative assay in future 
for evaluating the synthesized molecules of this thesis which were designed and 
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9. Experimental section 
9.1  General Procedures and Instrumentation 
 
All reagents were obtained from Sigma-Aldrich chemical company and/or 
Acros and/or Alfa-Aesar and/or TCI UK and were not further purified before use.  
 All reactions, unless otherwise specified, were performed under a positive 
pressure of dry, oxygen-free nitrogen. 
 Glassware for reactions carried out under dry conditions was washed with 
acetone, dried overnight at 125 °C and cooled under a stream of dry nitrogen 
prior to use. 
 Solvents were removed under reduced pressure using a Buchi rotary 
evaporator connected to a diaphragm pump. This was followed by drying under 
high vacuum using a rotary oil pump at 0.5 mmHg. 
 Analytical thin layer chromatography (TLC) was performed on Merck 
aluminium backed TLC silica gel 60 F254 sheets and these were visualised using 
ultraviolet lamp (λmax = 254 nm) or other developing agents (potassium 
permanganate, 2,4-dinitrophenylhydrazine or bromo-cresol green) where 
appropriate. Silica gel 60 (particle size 37-70 μm) supplied by E.M. Merck was 
employed for flash chromatography. 
 1H and 13C NMR spectra were measured on a Bruker DPX300, Avance 
500 or on a Bruker DRX500 Fourier transform spectrometer and chemical shifts 
are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) 
in δ units and coupling constants (J) are given in Hertz (Hz). 
 TMS was defined at 0 ppm for 1H NMR spectra and the central peak of 
DMSO-d6 septet was also defined as 39.5 ppm for 13C NMR spectra. 
 The following abbreviations: s, singlet; br s, broad singlet; d, doublet; t, 
triplet; q, quartet; quint, quintet; sext, sextet; sept, septet; m, multiplet; dd, 
double doublet; dt, double triplet; ddd, double double doublet and apparent 
multiplicities (app., e.g. app. d denotes an apparent doublet); Ar, aromatic; qt, 
quaternary; are used when describing the 1H NMR spectra. Where appropriate, 
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proton and carbon assignment has been based on COSY, DEPT 135, DEPT 
90, HMQC, HMBC and NOESY spectra. 
 Infrared spectra (IR) were recorded on a Nicolet Avatar 300 Ft-IR or a 
Bruker Alpha Ft-IR Platinum ATR spectrophotometer. The vibrational 
frequencies are reported in wavenumbers (cm
-1
). 
 Mass spectra were recorded on a GTC Premier Micromass spectrometer 
for impact ionisation (EI) or fast atom bombardment (FAB) while for electron 
spray ionisation (ES), a Bruker Daltonics microTOF or a Micromass LCT-KA11 
spectrometer was used. Isotopic distributions in routine mass spectra were as 
expected. 
 HPLC analyses were carried out using:  
Method A; Agilent 1290 infinity LC system equipped with a column Ascentis 
Express C18 (5 x 2.1mm, 2.7μm) using a diode array detection system. 
Samples were eluted with a gradient of acetonitrile (5-95%) / water in the 
presence of 0.1% TFA at a flow rate of 0.5 ml/min over 5 minutes.  
Method B; Agilent 1290 infinity LC system equipped with a column Ascentis 
Express C18 (5 x 2.1mm, 2.7μm) using a diode array detection. Samples were 
eluted with a gradient of acetonitrile (5-95%) / water at a flow rate of 0.5ml/min 
over 5 minutes. 
Method C; Agilent 1290 infinity LC system equipped with a column Ascentis 
Express C18 (5 x 2.1mm, 2.7μm) using a diode array detection. Samples were 
eluted with a gradient of acetonitrile (50-95%) / water at a flow rate of 0.5 ml/min 
over 5 minutes.  
 Purifications via mass-directed preparative HPLC were carried out on 
Agilent 6100 series single quad mass spectrometer equipped with a XBridge 
Prep C18 (5μm OBD 19x100 mm) column at a flow rate of 20 ml/min using a 
mobile phase consisting of methanol / water at an appropriate gradient in the 
presence of 0.1% formic acid. 
HPLC purity was reported as % values. 




 Combustion analyses were performed with a Carlo Erba elemental 
analyser MOD 1106 instrument. 
 
9.2  General experimental methods 
 
Method A: Synthesis of sulphonamide derivatives 
 A solution of the sulphonyl chloride (1 eq) in dichloromethane (2.5 mL) was 
added dropwise to a stirred solution of the amine (2 eq) in dichloromethane (2.5 
mL) and pyridine (5 mL) cooled in an ice bath. This solution was stirred at 0 °C 
for 2 hours and then allowed to warm to room temperature over 12 hours under 
constant stirring. The reaction mixture was poured into dichloromethane (50 
mL) and the organic layer washed successively with 1M HCl solution (3 x 50 
mL), water (50 mL), brine (50 mL), saturated aqueous NaHCO3 (2 x 50 mL) and 
brine again (50 mL). The resulting solution was dried (MgSO4) and the solvent 
removed in vacuo to give the corresponding sulphonamides, which were 
recrystallised from MeOH / water. 
 
Method B: Synthesis of urea derivatives 
 A solution of amine (1 eq) in dichloromethane (4 mL) was added dropwise 
to a solution of isocyanate (1.1 eq) in dichloromethane (4 mL) at room 
temperature and stirred for 7 hours. The resulting white slurry was cooled at 0 
°C, filtered and washed with cold dichloromethane. The resulting solid was 
recrystallised from dichloromethane.  
 
Method C: Synthesis of hydrazide derivatives 
 To a solution of an appropriate ester (1 eq) in ethanol (10 mL) was added 
an excess of hydrazine hydrate. The mixture was stirred and heated at reflux for 
12 hours unless otherwise specified. The reaction mixture was cooled to room 
temperature and the precipitate formed was removed via filtration and dried. 




Method D: Synthesis of acylhydrazone derivatives 
 To a solution of hydrazide (1 eq) in ethanol (10 mL) was added the 
corresponding aldehyde derivative (1 eq). The mixture was heated to 50 °C and 
stirred for 8 hours unless otherwise specified. The reaction mixture was cooled 
to room temperature and poured into water and the precipitate formed was 
removed via filtration and dried. The resulting residue was recrystallized from a 




























A solution of 2,5-dimethoxybenzenesulphonyl 
chloride 4.8 (236 mg, 1.0 mmol) in dichloromethane 
(5 mL) was added dropwise to a stirred solution of 
4-aminonaphthalen-1-ol hydrochloride 4.35 (220 
mg, 1.1 mmol) in dichloromethane (5 mL) and 
pyridine (10 mL) cooled in an ice bath. This solution 
was stirred for 2 hours and then allowed to warm to 
room temperature over 12 hours under constant stirring. The reaction mixture 
was poured into dichloromethane (50 mL) and the organic layer washed 
successively with 1M HCl solution (3 x 50 mL), water (50 mL), brine (50 mL), 
saturated aqueous NaHCO3 (2 x 50 mL) and brine (50 mL). The resulting 
solution was dried (MgSO4) and the solvent removed in vacuo to give the 
corresponding dark red solid, which was purified using column chromatography 
on silica gel eluting with petroleum ether / EtOAc (80:20) and the resulting dark 
red solid was recrystallised from MeOH / water to give the title compound 4.1 ( 
270 mg, 0.75 mmol, 75%) as light pink plates m.p. 119—121 °C. Rf 0.60 (1:1 
petroleum ether—EtOAc); HPLC (Method B), R.t. 3.17 min, (100%); δH (300 
MHz, DMSO-d6); 10.24 (1H, s, NH or OH), 9.60 (1H, s, NH or OH), 8.04-8.09 
(2H, m, Ar-H5’,8’), 7.38-7.48 (2H, m, Ar-H), 7.12-7.14 (2H, m, Ar-H), 6.94-6.99 
(2H, m, Ar-H), 6.70 (1H, d, J = 8.1, Ar-H2’), 3.87 (3H, s, OCH3), 3.61 (3H, s, 
OCH3); δC (75 MHz, DMSO-d6); 152.2 (4′-C), 151.9 (2-C or 5-C), 150.4 (2-C or 
5-C), 131.7 (Ar-Cqt), 128.1 (Ar-Cqt), 126.1 (Ar-C), 125.2 (Ar-C), 124.7 (Ar-C), 
123.3 (Ar-Cqt), 123.2 (Ar-C), 122.0 (Ar-C), 119.4 (Ar-C), 114.6 (Ar-C), 113.8 (Ar-
C), 107.2 (2′-C), 104.5 (Ar-Cqt), 56.1 (OCH3), 55.5 (OCH3); vmax/cm
-1 (neat); 
3404, 3287, 1610, 1510, 1310, 1280; m/z (ES) 382.1 (100%, MNa+); (Found 











Prepared via general method A using 5,6,7,8-
tetrahydronaphthylamine 4.2 (0.280 mL, 2.0 mmol) and 2,5-
dimethoxybenzenesulphonylchloride 4.8 (238 mg, 1.0 mmol). 
Recrystallization from methanol / water gave the title 
compound 4.16 (205 mg, 0.59 mmol, 59%) as light-pink 
needles m.p. 108—109 °C. Rf 0.40 (40:10 petroleum ether—
EtOAc); HPLC (Method A), R.t. 3.39 min, (100%); δH (300 
MHz, DMSO-d6); 9.07 (1H, s, NH), 7.18-7.19 (2H, m, Ar-H 
benzene), 7.11-7.13 (1H, m, Ar-H benzene), 6.95 (1H, app. t, J = 7.6, Ar-H3′), 
6.88 (1H, app. d, J = 7.6, Ar-H4′), 6.76 (1H, app. d, J = 7.6, Ar-H2′), 3.82 (3H, s, 
OCH3), 3.70 (3H, s, OCH3), 2.60-2.70 (4H, m, 2H5′ and 2H8′), 1.61-1.64 (4H, m, 
2H6′ and 2H7′),δC (75 MHz, DMSO-d6); 152.0 (2-C or 5-C), 150.3 (2-C or 5-C), 
137.7 (1′-C), 134.8 (Ar-Cqt), 133.3 (Ar-Cqt), 128.9 (Ar-Cqt), 127.0 (Ar-C 
tetrahydronaphthalene), 125.2 (Ar-C tetrahydronaphthalene), 123.1 (Ar-C 
tetrahydronaphthalene), 119.4 (Ar-C benzene), 114.5 (Ar-C benzene), 114.0 
(Ar-C benzene), 56.2 (OCH3), 55.7 (OCH3), 29.0 (5′-C), 24.2 (8′-C), 22.3 (6′-C 
or 7′-C), 22.2 (6′-C or 7′-C); vmax/cm
-1 (neat); 3309, 3287, 2945, 1584, 1490, 
1466, 1401, 1222, 1160, 1038; m/z (ES) 370.1 (100%, MNa+); (Found MNa+, 




Prepared via general method A using 5,6,7,8-
tetrahydronaphthylamine 4.2 (0.560 mL, 4.0 mmol) and 
benzenesulphonylchloride 4.7 (0.256 mL, 2.0 mmol). 
Recrystallization from methanol / water gave the title 
compound  4.17 (356 mg, 1.24 mmol, 62%) as orange platelets 
m.p. 151—153 °C. Rf 0.52 (40:10 petroleum ether—EtOAc); 
(Found: C, 76.5; H, 6.75; N, 10.4; C17H18N2O requires C, 76.7; 
H, 6.81; N, 10.5%). HPLC (Method A), R.t. 3.36 min, (100%); δH (300 MHz, 
DMSO-d6); 9.42 (1H, s, NH), 7.63-7.68 (2H, m, Ar-H benzene), 7.54-7.58 (3H, 
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m, Ar-H benzene), 6.98 (1H, app. t, J = 7.6, Ar-H3′), 6.92 (1H, dd, J = 7.6, 1.1,  
Ar-H4′), 6.75 (1H, dd, J = 7.6, 1.1, Ar-H2′), 2.66 (2H, t, J = 6.3, H5′), 2.39 (2H, t, J 
= 6.3, H8′), 1.49-1.60 (4H, m, 2H6′ and 2H7′), δC (75 MHz, DMSO-d6); 140.7 (1-C 
or 1′-C), 137.9 (1-C or 1′-C), 134.4 (Ar-Cqt), 133.4 (Ar-Cqt), 132.6 (Ar-C), 129.1 
(Ar-C), 127.3 (Ar-C), 126.4 (Ar-C), 125.3 (Ar-C), 123.6 (Ar-C), 29.0 (5′-C), 24.2 
(8′-C), 22.2 (6′-C or 7′-C), 22.1 (6′-C or 7′-C); vmax/cm
-1 (neat); 3262, 2940, 1911, 
1783, 1580, 1455, 1397, 1323, 1158, 1090; m/z (ES) 310.1 (90%, MNa+); 





Prepared via general method A using 5,6,7,8-
tetrahydronaphthylamine 4.2 (0.28 mL, 2.0 mmol) and 2,5-
dichlorobenzenesulphonylchloride 4.9 (491 mg, 1.0 mmol). 
Recrystallization from methanol / water gave the title 
compound 4.18 (214 mg, 0.60 mmol, 60%) as orange-yellow 
platelets m.p. 190—191 °C dec. Rf 0.48 (40:10 petroleum 
ether—EtOAc); HPLC (Method A), R.t. 3.88 min, (100%); δH 
(300 MHz, DMSO-d6); 9.90 (1H, br s, NH), 7.78-7.77 (1H, m, Ar-H benzene), 
7.75-7.70 (2H, m, Ar-H benzene), 6.95 (1H, app. t, J = 7.3, Ar-H3′), 6.88 (1H, 
app. d, J = 7.3, Ar-H4′), 6.76 (1H, app. d, J = 7.3, Ar-H2′), 2.61-2.70 (4H, m, 2H5′ 
and 2H8′), 1.61-1.67 (4H, m, 2H6′ and 2H7′), δC (75 MHz, DMSO-d6); 142.5 (2-C 
or 5-C), 141.2 (2-C or 5-C), 137.8 (Ar-Cqt), 133.5 (Ar-C benzene), 133.2 (Ar-C 
benzene), 131.7 (Ar-Cqt), 129.8 (Ar-C benzene), 129.6 (Ar-Cqt), 128.4 (Ar-C 
tetrahydronaphthalene), 126.2 (Ar-Cqt), 125.3 (Ar-C tetrahydronaphthalene), 
122.6 (Ar-C tetrahydronaphthalene), 29.1 (5′C or 8′-C), 24.5 (5′C or 8′-C), 22.4 
(6′-C or 7′-C), 22.1(6′-C or 7′-C); vmax/cm
-1 (neat); 3736, 3325, 1738, 1586, 1450, 
1343, 1145, 1043; m/z (ES) 378.0 (75%, MNa+); (Found MNa+, 378.0097. 






Prepared via general method A using p-anisidine 4.3 (246.3 
mg, 2.0 mmol) and 2,5-dimethoxybenzenesulphonylchloride 
4.8 (236.7 mg, 1.0 mmol). Recrystallization from methanol / 
water gave the title compound 4.19 (236.4 mg, 0.70 mmol, 
70%) as light-pink needles m.p. 119—121 °C. Rf 0.44 (40:10 
petroleum ether—EtOAc); HPLC (Method A), R.t. 2.69 min, 
(100%); δH (300 MHz, DMSO-d6); 9.63 (1H, s, NH), 7.10-7.17 
(3H, m, Ar-H3,4,6), 7.02 (2H, d, J = 9.0, Ar-H2′,6′), 6.78 (2H, d, J = 9.0, Ar-H3′,5′), 
3.86 (3H, s, OCH3 benzenesulfonamide), 3.69 (3H, s, OCH3 
benzenesulfonamide), 3.65 (3H, s, OCH3 in C4′), δC (75 MHz, DMSO-d6); 156.2 
(4′-C), 152.0 (2-C or 5-C), 150.2 (2-C or 5-C), 130.2 (Ar-Cqt), 126.8 (Ar-Cqt), 
122.7 (Ar-C), 119.6 (Ar-C), 115.0 (Ar-C), 114.1 (Ar-C), 113.9 (Ar-C), 56.3 
(OCH3), 55.6 (OCH3), 55.0 (OCH3); vmax/cm
-1 (neat); 3249, 2939, 2840, 1888, 
1612, 1582, 1434, 1273, 1153, 1016; m/z (ES) 324.1 (60%, MH+); (Found MH+, 
324.0914. C15H17NO5S requires MH, 324.0900).   
 
N-(4-phenoxyphenyl)benzenesulfonamide (4.20) 
Prepared via general method A using 4-benzyloxyanilin 
hydrochloride 4.4 (472 mg, 2.0 mmol) and 
benzenesulphonylchloride 4.7 (0.128 mL, 1.0 mmol). 
Recrystallization from methanol / water gave the title compound 
4.20 (273 mg, 0.58 mmol, 58%) as colourless platelets m.p. 98—
100 °C. Rf 0.46 (40:10 petroleum ether—EtOAc); HPLC (Method 
A), R.t. 3.45 min, (100%); δH (300 MHz, DMSO-d6); 9.95 (1H, s, 
NH), 7.68-7.71 (2H, m, Ar-H2,6), 7.59-7.63 (1H, m, Ar-H4), 7.52-
7.56 (2H, m, Ar-H3,5), 7.30-7.42 (5H, m, Ar-H2′′,3′′,4′′,5′′,6′′), 6.98 (2H, 
d, J = 9.0, Ar-H2′,6′), 6.89 (2H, d, J = 9.0,  Ar-H3′,5′), 5.00 (2H, s, 
OCH2), δC (75 MHz, DMSO-d6); 155.6 (4′-C), 139.4 (1-C), 136.9 
(1′-C), 132.7 (4-C), 130.2 (1′′-C), 129.1 (Ar-C), 128.4 (Ar-C), 127.8 (Ar-C), 126.6 
(Ar-C), 123.3 (2′-C, 6′-C), 115.1 (3′-C, 5′-C), 69.3 (OCH2); vmax/cm
-1 
(neat); 
3273, 3063, 2886, 1894, 1610, 1510, 1326, 1157; m/z (ES) 362.1 (100%, 




Prepared via general method A using p-anisidine 4.3 (246 mg, 2.0 
mmol) and benzenesulphonylchloride 4.7 (0.256 mL, 1.0 mmol). 
Recrystallization from methanol / water gave the title compound 
4.21 (189 mg, 0.72 mmol, 72%) as pink needles m.p. 91—92 °C 
(Lit.1 91—92 °C). Rf 0.13 (40:10 petroleum ether—EtOAc); 
(Found: C, 59.2; H, 4.90; N, 5.2; S 12.2; C13H13NO3S requires C, 
59.3; H, 4.98; N, 5.3; S, 12.2%).  HPLC (Method A), R.t. 2.64 min, 
(100%); δH (300 MHz, DMSO-d6); 9.91 (1H, s, NH), 7.67-7.70 (2H, m, Ar-H 
benzenesulphonamide), 7.58-7.63 (1H, m, Ar-H benzenesulphonamide), 7.52-
7.56 (2H, m, Ar-H benzenesulphonamide), 6.97 (2H, d, J = 9.0, Ar-H2′,6′), 6.80 
(2H, d, J = 9.0,  Ar-H3′,5′), 3.67 (3H, s, OCH3 in C4′), δC (75 MHz, DMSO-d6); 
156.4 (4′-C), 139.4 (1-C), 132.7 (Ar-C benzenesulphonamide), 130.0 (1′-C), 
129.1 (Ar-C benzenesulphonamide), 126.6 (Ar-C benzenesulphonamide), 123.4 
(2′-C, 6′-C), 114.2 (3′-C, 5′-C), 55.1 (OCH3); vmax/cm
-1 (neat); 3259, 3004, 1613, 
1506, 1466, 1445, 1333, 1289, 1147; m/z (ES) 286.0 (100%, MNa+); (Found 
MNa+, 286.0510. C13H13NO3S requires MNa, 286.0508).   
 
N-benzyl-2,5-dimethoxybenzenesulfonamide (4.22) 
Prepared via general method A using benzylamine 4.5 
(0.22 mL, 2.0 mmol) and 2,5-
dimethoxybenzenesulphonylchloride 4.8 (236 mg, 1.0 
mmol). Recrystallization from methanol / water gave the 
title compound 4.22 (157 mg, 0.51 mmol, 51%) as light-
yellow platelets m.p. 88—90 °C. Rf 0.82 (40:10 petroleum 
ether—EtOAc); (Found: C, 58.7; H, 5.50; N, 4.4; 
C15H17NO4S requires C, 58.6; H, 5.57; N, 4.6%). HPLC (Method A), R.t. 2.82 
min, (100%); δH (300 MHz, DMSO-d6); 8.19 (1H, t, J = 6.3, NH), 7.16-7.25 (6H, 
m, Ar-H), 7.12 (1H, dd, J = 9.0, 3.1, Ar-H4), 7.06 (1H, app. d, J = 9.0, Ar-H3), 
4.05 (2H, d, J = 6.3, CH2), 3.78 (3H, s, OCH3), 3.75 (3H, s, OCH3); δC (75 MHz, 
DMSO-d6); 152.1 (2-C or 5-C), 150.1 (2-C or 5-C), 137.8 (6′-C), 128.9 (1-C), 
127.9 (Ar-C benzyl), 127.4 (Ar-C benzyl), 126.9 (Ar-C benzyl), 119.3 (Ar-C 
benzenesulphonamide), 114.1 (Ar-C benzenesulphonamide), 114.0 (Ar-C 
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benzenesulphonamide), 56.2 (OCH3), 55.7 (OCH3), 46.2 (CH2); vmax/cm
-1 (neat); 
3326, 1969, 1895, 1446, 1324, 1151, 1092, 687; m/z (ES) 308.1 (70%, MH+); 
(Found MH+, 308.0964. C15H17NO4S requires MH, 308.0951).   
 
N-benzylbenzenesulfonamide (4.23)1 
Prepared via general method A using benzylamine 4.5 
(0.220 mL, 2.0 mmol) and benzenesulphonylchloride 4.7 
(0.128 mL, 1.0 mmol). Recrystallization from methanol / 
water gave the title compound 4.23 (138 mg, 0.56 mmol, 
56%) as colourless needles m.p. 87—88 °C (Lit.1  87—88 
°C) Rf 0.75 (40:10 petroleum ether—EtOAc); (Found: C, 
63.2; H, 5.25; N, 5.6; S 13.0; C13H13NO2S requires C, 63.1; 
H, 5.30; N, 5.7, S 13.0%). HPLC (Method A), R.t. 2.81 min, (100%); δH (300 
MHz, DMSO-d6); 8.17 (1H, t, J = 6.3, NH), 7.81-7.83 (2H, m, Ar-H 
benzenesulphonamide), 7.63-7.66 (3H, m, Ar-H benzenesulphonamide), 7.57-
7.60 (5H, m, Ar-H benzyl), 4.00 (2H, d, J = 6.3, CH2); δC (75 MHz, DMSO-d6); 
140.7 (1-C), 137.6 (6′-C), 132.3 (Ar-C benzenesulphonamide), 129.1 (Ar-C 
benzenesulphonamide), 128.2 (Ar-C benzenesulphonamide), 127.5 (Ar-C 
benzyl), 127.1 (Ar-C benzyl), 126.4 (Ar-C benzyl), 46.1(OCH2); vmax/cm
-1 (neat); 
3338, 2930, 1969, 1896, 1447, 1320, 1150; m/z (ES) 270.1 (100%, MNa+); 
(Found MNa+, 270.0574. C13H13NO2S requires MNa, 270.0559).   
 
1-(4-methoxyphenyl)-3-(5,6,7,8-tetrahydronaphthalen-1-yl)urea (4.24) 
Prepared via general method B using 5,6,7,8-
tetrahydronaphthylamine 4.2 (0.240 mL, 1.68 
mmol) and 4-methoxyphenylisocyanate 4.11 
(0.240 mL, 1.80 mmol). Recrystallization from 
dichloromethane gave the title compound 4.24 
(408 mg, 1.38 mmol, 82%) as colourless needles m.p. 213—214 °C. Rf 0.52 
(40:10 petroleum ether—EtOAc); (Found: C, 73.0; H, 6.70; N, 9.4; C18H20N2O2 
requires C, 73.0; H, 6.80; N, 9.4%). HPLC (Method A), R.t. 3.21 min, (100%); δH 
(300 MHz, DMSO-d6); 8.83 (1H, s, NH1′′′), 7.69 (1H, s, NH3′′′), 7.66 (1H, app. d, J 
= 7.8, Ar-H2), 7.37 (2H, d, J = 9.0, Ar-H2′,6′), 7.03 (1H, app. t, J = 7.8, Ar-H3), 
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6.88 (2H, d, J = 9.0, Ar-H3′,5′), 6.76 (1H, app. d, J = 7.8, Ar-H4), 3.87 (3H, s, 
OCH3), 2.72 (2H, t, J = 6.2, H8), 2.58 (2H, t, J = 6.2, H5), 1.78-1.83 (2H, m, H6), 
1.69-1.73 (2H, m, H7); δC (75 MHz, DMSO-d6); 154.3 (4′-C), 152.8 (C=O), 137.1 
(4a-C or 1-C), 137.0 (4a-C or 1-C), 133.0 (1′-C), 126.5 (8a-C), 125.1 (Ar-C 
tetrahydronaphthalene), 123.4 (Ar-C tetrahydronaphthalene), 119.6 (Ar-C), 
118.4 (Ar-C), 114.0 (3′-C, 5′-C), 55.1 (OCH3), 29.4 (5-C), 24.2 (8-C), 22.4 (6-C 
or 7-C), 22.1 (6-C or 7-C); vmax/cm
-1 (neat); 3854, 3326, 3272, 1873, 1644, 
1560, 1509, 1246; m/z (ES) 319.1 (100%, MNa+); (Found MNa+, 319.1428. 
C18H20N2O2 requires MNa, 319.1417).   
 
1-(3,5-dimethoxyphenyl)-3-(5,6,7,8-tetrahydronaphthalen-1-yl)urea (4.25) 
Prepared via general method B using 5,6,7,8-
tetrahydronaphthylamine 4.2 (0.240 mL, 1.68 
mmol) and 3,5-dimethoxyphenylisocyanate 
4.12 (331 mg, 1.85 mmol). Recrystallization 
from dichloromethane gave the title compound 
4.25 (483 mg, 1.51 mmol, 90%) as colourless needles m.p. 192—193 °C. Rf 
0.72 (40:10 petroleum ether—EtOAc); HPLC (Method A), R.t. 3.38 min, (100%); 
δH (300 MHz, DMSO-d6); 9.01 (1H, s, NH1′′′), 7.75 (1H, s, NH3′′′), 7.64 (1H, app. 
d, J = 7.8, Ar-H2), 7.04 (1H, app. t, J = 7.8, Ar-H3), 6.78 (1H, app. d, J = 7.8, Ar-
H4), 6.69 (2H, d, J = 2.2, Ar-H2′,6′), 6.14 (1H, t, J = 2.2, Ar-H4′), 3.73 (6H, s, 
OCH3 in 5′ and 3′), 2.73 (2H, t, J = 6.2, H8), 2.57 (2H, t, J = 6.2, H5), 1.67-1.84 
(4H, m, H6,7); δC (75 MHz, DMSO-d6); 160.6 (3′-C, 5′-C), 152.5 (C=O), 141.6 
(4a-C or 1-C), 137.1 (4a-C or 1-C), 136.8 (1′-C), 126.8 (8a-C), 125.1 (Ar-C 
tetrahydronaphthalene), 123.7 (Ar-C tetrahydronaphthalene), 118.7 (Ar-C 
tetrahydronaphthalene), 96.2 (2′-C, 6′-C), 93.8 (4′-C), 55.0 (OCH3 in 3′-C and 5′-
C), 29.4 (5-C), 24.2 (8-C), 22.4 (6-C or 7-C), 22.3 (6-C or 7-C); vmax/cm
-1 (neat); 
3852, 3736, 3350, 3294, 1744, 1650, 1605, 1564, 1208, 1151; m/z (ES) 349.1 







Prepared via general method B using 5,6,7,8-
tetrahydronaphthylamine 4.2 (0.240 mL, 1.68 
mmol) and phenylisocyanate 4.13 (0.220 mL, 1.85 
mmol). Recrystallization from dichloromethane 
gave the title compound 4.26 (362 mg, 1.36 mmol, 
81%) as colourless needles m.p. 194—195 °C. Rf 0.75 (40:10 petroleum 
ether—EtOAc); HPLC (Method A), R.t. 3.28 min, (100%); δH (300 MHz, DMSO-
d6); 9.03 (1H, s, NH1′′′), 7.79 (1H, s, NH3′′′), 7.66 (1H, app. d, J = 7.4, Ar-H2), 
7.46 (2H, app. d, J = 7.9, Ar-H2′,6′), 7.28 (2H, app. t, J = 7.9, Ar-H3′,5′), 7.03 (1H, 
app. t, J = 7.4, Ar-H3), 6.95 (1H, app. t, J = 7.9, Ar-H4′), 6.77 (1H, app. d, J = 
7.4, Ar-H4), 2.72 (2H, t, J = 6.0, H5), 2.58 (2H, t, J = 6.0, H8), 1.77-1.83 (2H, m, 
H6), 1.71-1.75 (2H, m, H7); δC (75 MHz, DMSO-d6); 152.6 (C=O), 139.9 (1′-C), 
137.1 (4a-C or 1-C), 136.9 (4a-C or 1-C), 128.8 (3′-C, 5′-C), 126.7 (Ar-Cqt), 
125.1 (2′-C, 6′-C), 123.6 (Ar-C tetrahydronaphthalene), 121.6 (Ar-C 
tetrahydronaphthalene), 118.6 (4′-C), 117.9 (2-C), 29.4 (5-C), 24.2 (8-C), 22.4 
(6-C or 7-C), 22.1 (6-C or 7-C); vmax/cm
-1 (neat); 3309, 2935, 1638, 1560, 1310, 
1244; m/z (ES) 289.1 (100%, MNa+); (Found MNa+, 289.1315. C17H18N2O 
requires MNa, 289.1311).   
 
1,3-bis(4-methoxyphenyl)urea (4.27)2 
Prepared via general method B using p-
anisidine 4.3 (246 mg, 2.0 mmol) and 4-
methoxyphenylisocyanate 4.11 (0.290 mL, 2.2 
mmol). Recrystallization from dichloromethane 
gave the title compound 4.27 (551 mg, 1.84 mmol, 92%) as colourless needles 
m.p. 237—238 °C (Lit.2 238 °C). Rf 0.38 (40:10 petroleum ether—EtOAc); 
(Found: C, 66.2; H, 5.92; N, 10.3; C15H16N2O3 requires C, 66.0; H, 5.90; N, 
10.4%). HPLC (Method A), R.t. 2.47 min, (100%); δH (300 MHz, DMSO-d6); 
8.36 (2H, s, NH1′′′,3′′′), 7.35 (4H, d, J = 9.0, Ar-H2,2′,6,6′), 6.86 (4H, d, J = 9.0, Ar-
H3,3′,5,5′), 3.72 (6H, s, OCH3); δC (75 MHz, DMSO-d6); 154.3 (4-C, 4′-C), 152.9 
(C=O), 132.9 (1-C, 1′-C), 119.8 (2-C, 2′-C, 6-C, 6′-C), 113.9 (3-C, 3′-C, 5-C, 5′-
C), 55.1 (OCH3); vmax/cm
-1 (neat); 3325, 3289, 2959, 2837, 1876, 1643, 1609, 
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1247, 825, 652, 527; m/z (ES) 295.1 (100%, MNa+); (Found MNa+, 295.1055. 
C15H16N2O3 requires MNa, 295.1053).   
 
1-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)urea (4.28) 
Prepared via general method B using p-
anisidine 4.3 (246 mg, 2.0 mmol) and 3,5-
dimethoxyphenylisocyanate 4.12 (394 mg, 2.2 
mmol). Recrystallization from dichloromethane 
gave the title compound 4.28 (568 mg, 1.9 
mmol, 94%) as colourless needles m.p. 174—175 °C. Rf 0.46 (40:10 petroleum 
ether—EtOAc); (Found: C, 63.2; H, 5.95; N, 9.0; C16H18N2O4 requires C, 63.5; 
H, 6.00; N, 9.2%). HPLC (Method A), R.t. 2.69 min, (100%); δH (300 MHz, 
DMSO-d6); 8.57 (1H, s, NH3′′′), 8.42 (1H, s, NH1′′′), 7.35 (2H, d, J = 9.0, Ar-H2′,6′), 
6.87 (2H, d, J = 9.0, Ar-H3′,5′), 6.67 (2H, d, J = 2.2, Ar-H2,6), 6.13 (1H, t, J = 2.2, 
Ar-H4), 3.73 (3H, s, OCH3 in 4′), 3.72 (6H, s, OCH3 in 3 and 5); δC (75 MHz, 
DMSO-d6); 160.6 (3-C, 5-C), 154.5 (4′-C), 152.6 (C=O), 141.6 (1-C), 132.5 (1′-
C), 120.1 (2′-C, 6′-C), 114.0 (3′-C, 5′-C), 96.3 (2-C, 6-C), 93.7 (4-C), 55.1 
(OCH3), 55.0 (OCH3); vmax/cm
-1 (neat); 3306, 3255, 1634, 1601, 1567, 1208, 
815; m/z (ES) 325.1 (100%, MNa+); (Found MNa+, 325.1169. C16H18N2O4 
requires MNa, 325.1159).   
 
1-(4-chlorophenyl)-3-(4-methoxyphenyl)urea (4.29)3 
Prepared via general method B using p-
anisidine 4.3 (123 mg, 1.0 mmol) and 4-
chlorophenylisocyanate 4.14 (194 mg, 1.1 
mmol). Recrystallization from dichloromethane 
gave the title compound 4.29 (180 mg, 0.65 mmol, 65%) as colourless needles 
m.p. 254—255 °C (Lit.3 250—255 °C). Rf 0.28 (40:10 petroleum ether—EtOAc); 
HPLC (Method A), R.t. 2.99 min, (100%); δH (300 MHz, DMSO-d6); 8.74 (1H, s, 
NH1′′′), 8.52 (1H, s, NH3′′′), 7.47 (2H, d, J = 8.9, Ar-H2,6), 7.34 (2H, d, J = 9.0, 
H2′,6′), 7.31 (2H, d, J = 8.9, Ar-H3,5), 6.87 (2H, d, J = 9.0, Ar-H3′,5′), 3.71 (3H, s, 
OCH3); δC (75 MHz, DMSO-d6); 154.5 (C=O), 152.6 (4′-C), 138.9 (1-C), 132.5 
(4-C), 128.5 (2-C, 6-C), 125.0 (1′-C), 120.1 (3-C, 5-C), 119.5 (3′-C, 5′-C), 113.9 
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(2′-C, 6′-C), 55.1 (OCH3); vmax/cm
-1 (neat); 3302, 1637, 1560, 1509, 1244, 828; 
m/z (ES) 277.1 (100%, MH+); (Found MH+, 277.0725. C14H13ClN2O2 requires 
MH, 277.0738).   
 
1-(3,5-dichlorophenyl)-3-phenylurea (4.30) 
Prepared via general method B using 3,5-
dichloroaniline 4.10 (162 mg, 1.0 mmol) and 
phenylisocyanate 4.13 (0.240 mL, 1.1 mmol). 
Recrystallization from dichloromethane gave the 
title compound 4.30 (143 mg, 0.51 mmol, 51%) as 
colourless needles m.p. 200—201 °C. Rf 0.56 (40:10 petroleum ether—EtOAc); 
(Found: C, 55.6; H, 3.50; N, 9.9; C13H10Cl2N2O requires C, 55.5; H, 3.59; N, 
10.0%). HPLC (Method A), R.t. 3.63 min, (100%); δH (300 MHz, DMSO-d6); 
9.04 (1H, s, NH1′′′), 8.87 (1H, s, NH3′′′), 7.54 (2H, d, J = 1.9, Ar-H2,6), 7.46 (2H, 
app. d, J = 8.0, Ar-H2′,6′), 7.31 (2H, app. t, J = 8.0, Ar-H3′,5′), 7.17 (1H, t, J = 1.9, 
Ar-H4), 7.02 (1H, app. t, J = 8.0, Ar-H4′); δC (75 MHz, DMSO-d6); 152.2 (C=O), 
142.3 (1-C), 139.1 (1′-C), 134.1 (3-C, 5-C), 128.8 (3′-C, 5′-C), 122.3 (4-C), 
120.8 (4′-C), 118.6 (2′-C, 6′-C), 116.3 (2-C, 6-C); vmax/cm
-1 (neat); 3325, 3183, 
1650, 1606, 1588, 1544, 1448, 1310, 1216; m/z (ES) 303.0 (100%, MNa+); 
(Found MNa+, 303.0048. C13H10Cl2N2O requires MNa, 303.0062).   
 
1-benzyl-3-phenylurea (4.31)4 
Prepared via general method B using benzylamine 
4.5 (0.22 mL, 2.0 mmol) and phenylisocyanate 
4.13 (0.24 mL, 2.2 mmol). Recrystallization from 
dichloromethane gave the title compound 4.31 
(385 mg, 1.7 mmol, 85%) as colourless needles 
m.p. 173—175 °C (Lit.4 173—175 °C). Rf 0.20 (40:10 petroleum ether—EtOAc); 
(Found: C, 73.8; H, 6.25; N, 12.6; C14H14N2O requires C, 74.3; H, 6.24; N, 
12.4%). HPLC (Method A), R.t. 2.52 min, (100%); δH (300 MHz, DMSO-d6); 
8.55 (1H, s, NH3′′′), 7.21-7.42 (9H, m, Ar-H), 6.89-6.92 (1H, m, Ar-H), 6.62 (1H, 
t, J = 5.9, NH1′′′), 4.32 (2H, d, J = 5.9, CH2); δC (75 MHz, DMSO-d6); 155.2 
(C=O), 140.4 (Ar-Cqt), 140.3 (Ar-Cqt), 128.6 (Ar-C), 128.3 (Ar-C), 127.1 (Ar-C), 
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126.7 (Ar-C), 121.0 (Ar-C), 117.6 (Ar-C), 42.7 (CH2); vmax/cm
-1 (neat); 3307, 
3030, 1952, 1686, 1599, 1556, 1309, 696; m/z (ES) 249.1 (100%, MNa+); 
(Found MNa+, 249.0990. C14H14N2O requires MNa, 249.0998).   
 
1-benzyl-3-(4-chlorophenyl)urea (4.32)5 
Prepared via general method B using 
benzylamine 4.5 (0.22 mL, 2.0 mmol) and 4-
chlorophenylisocyanate 4.14 (338 mg, 2.2 
mmol). Recrystallization from dichloromethane 
gave the title compound 4.32 (360 mg, 1.7 
mmol, 69%) as colourless needles m.p. 200—201 °C (Lit.5 201 °C) . Rf 0.31 
(40:10 petroleum ether—EtOAc); (Found: C, 64.2; H, 4.95; N, 10.8; 
C14H13ClN2O requires C, 64.5; H, 5.03; N, 10.7%). HPLC (Method A), R.t. 2.97 
min, (100%); δH (300 MHz, DMSO-d6); 8.71 (1H, s, NH3′′′), 7.44-7.47 (2H, m, Ar-
H), 7.24-7.36 (7H, m, Ar-H), 6.67 (1H, t, J = 5.9, NH1′′′), 4.31 (2H, d, J = 5.9, 
CH2); δC (75 MHz, DMSO-d6); 155.0 (C=O), 140.2 (Ar-Cqt), 139.4 (Ar-Cqt), 128.4 
(Ar-C), 128.3 (Ar-C), 127.1 (Ar-C), 126.7 (Ar-C), 124.5 (Ar-Cqt), 119.1 (Ar-C), 
42.7 (CH2); vmax/cm
-1 (neat); 3289, 1629, 1594, 1567, 1397, 1241, 810; m/z (ES) 
261.1 (100%, MH+); (Found MH+, 261.0790. C14H13ClN2O requires MH, 
261.0789).   
 
1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)thiourea (4.33) 
A solution of p-anisidine 4.3 (62 mg, 0.50 
mmol) in dichloromethane (4 mL) was added 
dropwise to a solution of 3,4,5-
trimethoxyphenylisothiocyanate 4.15b (124 
mg, 0.55 mmol) in dichloromethane (4 mL) at 
room temperature and stirred for 7 hours. The resulting yellow-white slurry was 
concentrated in vacuo and recrystallized from ether to give the title compound 
4.33 (119 mg, 0.34 mmol, 62%) as white-yellow platelets m.p. 100—102 °C. Rf 
0.40 (40:10 petroleum ether—EtOAc); HPLC (Method A), R.t. 2.41 min, (100%); 
δH (300 MHz, DMSO-d6); 9.53 (1H, s, NH1′′′), 9.51 (1H, s, NH3′′′), 7.29 (2H, d, J = 
8.9, Ar-H2′,6′), 6.90 (2H, d, J = 8.9, Ar-H3′,5′), 6.83 (2H, s, Ar-H2,6), 3.76 (3H, s, 
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OCH3 in 4), 3.75 (6H, s, OCH3 in 3 and 5), 3.65 (3H, s, OCH3 in 4′); δC (75 MHz, 
DMSO-d6); 179.6 (C=O), 156.6 (3-C, 5-C), 152.4 (4-C), 135.0 (1-C), 134.5 (1′-
C), 132.1 (4′-C), 126.2 (2′-C, 6′-C), 113.6 (3′-C, 5′-C), 101.7 (2-C, 6-C), 60.0 
(OCH3), 55.8 (OCH3), 55.2 (OCH3); vmax/cm
-1 (neat); 3276, 2995, 1598, 1505, 
1234; m/z (ES) 371.1 (100%, MNa+); (Found MNa+, 371.1051. C17H20N2O4S 
requires MNa, 371.1036).   
 
1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)urea (4.34) 
Prepared via general method B using p-
anisidine 4.3 (123 mg, 1.0 mmol) and 3,4,5-
trimethoxyphenylisocyanate 4.15a (230 mg, 
1.1 mmol). Recrystallization from 
dichloromethane gave the title compound 4.34 
(286 mg, 0.86 mmol, 86%) as colourless needles m.p. 196—197 °C. Rf 0.31 
(40:10 petroleum ether—EtOAc); (Found: C, 61.0; H, 5.95; N, 8.2; C17H20N2O5 
requires C, 61.4; H, 6.07; N, 8.4%). HPLC (Method A), R.t. 2.33 min, (100%); δH 
(300 MHz, DMSO-d6); 8.53 (1H, s, NH1′′′), 8.40 (1H, s, NH3′′′), 7.34 (2H, d, J = 
9.0, Ar-H2′,6′), 6.86 (2H, d, J = 9.0, Ar-H3′,5′), 6.78 (2H, s, Ar-H2,6), 3.74 (6H, s, 
OCH3 in 3 and 5), 3.71 (3H, s, OCH3 in 4), 3.60 (3H, s, OCH3 in 4′); δC (75 MHz, 
DMSO-d6); 154.4 (Ar-Cqt), 152.8 (Ar-Cqt), 152.7 (Ar-Cqt), 136.0 (Ar-Cqt), 132.6 
(Ar-Cqt), 132.2 (Ar-Cqt), 120.1 (2′-C, 6′-C), 113.9 (3′-C, 5′-C), 95.7 (2-C, 6-C), 
60.1 (OCH3 in 3 and 5), 55.6 (OCH3 in 4), 55.1 (OCH3 in 4′); vmax/cm
-1 (neat); 
3271, 2952, 1626, 1614, 1573, 1511, 1411, 1230, 1132; m/z (ES) 355.1 (100%, 
MNa+); (Found MNa+, 355.1256. C17H20N2O5 requires MNa, 355.1264).   
 
(E)-2-((2-carbamoylhydrazono)methyl)benzoic acid (5.15)6 
 
A solution of semicarbazide hydrochloride 5.31 (223 mg, 
2.0 mmol) and sodium acetate (164 mg, 2.0 mmol) in water 
(20 mL) was stirred at room temperature for 30 minutes. 2-
carboxybenzaldehyde 5.30 (300 mg, 2.0 mmol) was added 
to this solution and stirred for 12 hours. The resulting 
colourless slurry was filtered and the colourless solid 
washed with water (50 mL) and petroleum ether (50 mL) and recrystallized from 
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methanol / water to give the title compound 5.15 (381 mg, 1.8 mmol, 92%) as 
colourless plates m.p. 200 °C dec. (Lit.6 202 °C). Rf 0.13 (1:1 petroleum ether—
EtOAc); HPLC (Method B), R.t. 1.39 min, (100%); δH (500 MHz, DMSO-d6); 
13.24 (1H, br s, COOH), 10.43 (1H, s, N-H), 8.57 (1H, s, C-H1′), 8.18 (1H, app. 
d, J = 7.9, Ar-H5), 7.81 (1H, dd, J = 7.9, 1.0, Ar-H2), 7.54 (1H, app. td, J = 7.9, 
1.0, Ar-H4), 7.43 (1H, app. td, J = 7.9, 1.0, Ar-H3), 6.50 (2H, br s, NH2); δC (125 
MHz, DMSO-d6); 168.3 (COOH), 156.7 (C=O), 138.1 (1′-C), 134.7 (6-C), 131.5 
(4-C), 130.0 (1-C), 129.9 (2-C), 128.5 (3-C), 126.5 (5-C); vmax/cm
-1 (neat); 3477, 
2505, 1704, 1566, 1482, 1429, 1283; m/z (E-H-) 206.1 (100%, M-H-); (Found M-
H-, 206.0563. C9H9N3O3 requires M-H
-, 206.0571).   
 
3-butyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (5.16)7 
 
Sodium hydrogen sulphite (784 mg, 7.5 mmol) was 
added to a solution of 2-aminobenzenesulfonamide 
5.34 (861 mg, 5.0 mmol) and pentanal 5.35 (0.520 mL, 
5.0 mmol) in dimethylacetamide (10 mL). This mixture 
was heated with stirring at 170 °C for 2 hours and then poured into water (40 
mL). The light brown precipitate formed was filtered off and washed with water 
(100 mL) and recrystallized from petroleum ether / EtOAC to give the title 
compound 5.16 (836 mg, 3.5 mmol, 70%) as light brown needles, m.p. 148—
149 °C (Lit.7 150—151 °C); Rf  0.31 (1:1 petroleum ether—EtOAc); HPLC 
(Method A), R.t. 1.74 min, (100%); δH (500 MHz, DMSO-d6); 11.93 (1H, s, N-H), 
7.77 (1H, app. d, J = 8.0, Ar-H8), 7.65 (1H, app. t, J = 8.0, Ar-H7), 7.42 (1H, app. 
t, J = 8, Ar-H6), 7.31 (1H, app. d, J = 8.0, Ar-H5), 2.53 (2H, t, J = 7.5, H1′), 1.65 
(2H, quint, J = 7.5, H2’), 1.35 (2H, sext, J = 7.5, H3’), 0.90 (3H, t, J = 7.5, H4’); δC 
(75 MHz, DMSO-d6); 160.3 (3-C), 135.1 (4a-C), 133.0 (7-C), 126.2 (6-C), 123.4 
(8-C), 121.1 (8a-C), 117.3 (5-C), 34.9 (1′-C), 28.1 (2′-C), 21.4 (3′-C), 13.57 (4′-
C); vmax/cm
-1 (neat); 3185, 2958, 1941, 1824, 1616, 1479, 1274; m/z (ES) 239.1 








2-butyramidobenzoic acid (5.17)8 
 
Butanoyl chloride 5.33 (0.42 mL, 4.0 mmol) was added 
dropwise to a stirred solution of anthranilic acid 5.32 (274 mg, 
2.0 mmol) in pyridine (10 mL) at room temperature. This 
solution was stirred at room temperature for 12h. The reaction 
mixture was poured into EtOAc (10 mL) and the organic layer 
washed successively with 2M HCl (3 x 50 mL), water (50 mL) 
and brine (50 mL). The resulting solution was dried (MgSO4) and the solvent 
removed in vacuo and the colourless solid was recrystallised from MeOH / 
water to give the title compound 5.17 (373 mg, 1.8 mmol, 89%) as colourless 
plates m.p. 119—120 °C (Lit.8 117—118 °C); Rf 0.08 (1:1 petroleum ether—
EtOAc); (Found: C, 63.8; H, 6.25; N, 6.8; C11H13NO3 requires C, 63.8; H, 6.32; 
N, 6.8%). HPLC (Method A), R.t. 2.24 min, (100%); δH (300 MHz, DMSO-d6); 
13.62 (1H, br s, COOH), 11.13 (1H, s, N-H), 8.50 (1H, app. d, J = 9.0, Ar-H6), 
7.97 (1H, app. d, J = 9.0, Ar-H3), 7.58 (1H, app. t, J = 9.0, Ar-H4), 7.14 (1H, app. 
t, J = 9.0, Ar-H5), 2.36 (2H, t, J = 7.5, H2′), 1.64 (2H, sext, J = 7.5, H3′), 0.93 (3H, 
t, J = 7.5, H4′); δC (75 MHz, DMSO-d6); 174.1 (1′-C), 169.5 (COOH), 140.9 (2-C), 
134.0 (4-C), 131.0 (3-C), 122.5 (5-C), 119.8 (6-C), 116.2 (1-C), 39.4 (2′-C), 18.3 
(3′-C), 13.5 (4′-C); vmax/cm
-1 (neat); 3171, 2961, 1947, 1842, 1682, 1606, 1537, 
1414; m/z (EI) 207.1 (100%, M); (Found M, 207.0898. C11H13NO3 requires M, 




2-chlorobenzoyl chloride 5.36 (0.253 mL, 2.0 mmol) 
was added dropwise to a stirred solution of anthranilic 
acid 5.32 (274 mg, 2.0 mmol) in pyridine (10 mL) at 
room temperature. This solution was stirred at room 
temperature for 12h. The reaction mixture was poured 
into water (20 mL) and the colourless precipitate was filtered off. This colourless 
solid was washed with water (100 mL) and recrystallized from ethanol to give 
the title compound 5.18 (168 mg, 1.3 mmol, 65%) as colourless plates m.p. 
137—138 °C (Lit.9 138 °C). Rf 0.80 (1:1 petroleum Ether—EtOAc); (Found: C, 
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65.4; H, 3.10; N, 5.3; Cl, 13.6; C14H8ClNO2 requires C, 65.3; H, 3.13; Cl, 13.8; 
N, 5.4%). HPLC (Method A), R.t. 3.41 min, (100%); δH (500 MHz, CDCl3); 8.28 
(1H, dd, J = 7.8, 1.6, Ar-H5), 7.91 (1H, dd, J = 7.8, 1.6, Ar-H8), 7.86 (1H, app. t, 
J = 7.8, Ar-H6 or Ar-H7), 7.73 (1H, app. d, J = 8.1, Ar-H6′), 7.59 (1H, app. t, J = 
7.8, Ar-H6 or Ar-H7), 7.54 (1H, dd, J = 8.0, 1.3, Ar-H3′), 7.47 (1H, app. t, J = 8.0, 
Ar-H4′), 7.41 (1H, app. t, J = 8.0, Ar-H5′); δC (125 MHz, CDCl3); 158.7 (4-C), 
155.8 (2-C), 145.8 (Ar-C), 137.0 (Ar-C), 132.9 (Ar-C), 131.8 (2'-C), 131.7 (Ar-C), 
130.6 (Ar-C), 130.2 (8a-C), 129.4 (Ar-C), 128.0 (Ar-C), 127.5 (Ar-C), 127.1 (Ar-
C), 116.8 (4a-C); vmax/cm
-1 (neat); 1767, 1625, 1605, 1475, 1316; m/z (ES) 
280.0 (100%, MNa+); (Found MNa+, 280.0126. C14H8ClNO2 requires MNa, 




Sodium hydrogen sulphite (784 mg, 7.5 mmol) was 
added to a solution of anthranilamide 5.38 (681 mg, 
5.0 mmol) and pentanal 5.35 (0.520 mL, 5.0 mmol) in 
dimethylacetamide (10 mL). This mixture was heated 
with stirring  at 150 °C for 4 hours and then poured into water (40 mL). The light 
brown precipitate formed was filtered off and washed with water (100 mL) and 
recrystallized from petroleum ether / EtOAC to give the title compound 5.19 
(158 mg, 3.9 mmol, 78%) as light brown needles m.p. 159—160 °C (Lit.10 159—
160 °C). Rf 0.40 (1:1 petroleum ether—EtOAc); HPLC (Method A), R.t. 1.62 
min, (100%); δH (300 MHz, DMSO-d6); 12.19 (1H, br s, NH), 8.09 (1H, dd, J = 
7.8, 1.4, Ar-H5), 7.77 (1H, app. t, J = 7.8, Ar-H7), 7.59 (1H, app. d, J = 7.8, Ar-
H8), 7.45 (1H, app. t, J = 7.8, Ar-H6), 2.61 (2H, t, J = 7.7, H1’), 1.72 (2H, quint, J 
= 7.7, H2’), 1.36 (2H, sext, J = 7.7, H3′), 0.96 (3H, t, J = 7.7, H4′); δC (75 MHz, 
DMSO-d6); 161.8 (4-C), 157.5 (2-C), 148.9 (8a-C), 134.2 (7-C), 126.7 (5-C), 
125.9 (6-C), 125.6 (8-C), 120.7 (4a-C), 34.1 (1′-C), 28.9 (2′-C), 21.7 (3′-C), 13.7 
(4′-C); vmax/cm
-1 (neat); 2925, 1845, 1679, 1620, 1564, 1503, 1468; m/z (ES) 
225.1 (100%, MNa+); (Found MNa+, 225.0988. C12H14N2O requires MNa, 







Furan-2-carbonyl chloride 5.37 (0.197 mL, 2.0 mmol) 
was added dropwise to a stirred solution of anthranilic 
acid 5.32 (274 mg, 2.0 mmol) in pyridine (10 mL) at 
room temperature. This solution was stirred at room 
temperature for 12h. The reaction mixture was poured 
into water (20 mL) and the colourless precipitate was filtered off. This colourless 
solid was washed with water (100 mL) and recrystallized from ethanol to give 
the title compound 5.20 (192 mg, 0.9 mmol, 45%) as colourless plates m.p. 
101—102 °C (Lit.9 102 °C). Rf 0.78 (1:1 petroleum Ether—EtOAc); (Found: C, 
67.9; H, 3.40; N, 6.3; C12H7NO3 requires C, 67.6; H, 3.31; N, 6.6%). HPLC 
(Method A), R.t. 2.58 min, (100%); δH (500 MHz, CDCl3); 8.14 (1H, dd, J = 7.8, 
1.2, Ar-H5), 7.74 (1H, app. t, J = 7.8, Ar-H6 or Ar-H7), 7.62-7.64 (2H, m, Ar-H), 
7.50 (1H, app. t, J = 7.8, Ar-H6 or Ar-H7), 7.29 (1H, dd, J = 3.5, 0.7, Ar-H3' or Ar-
H4'), 6.55 (1H, dd, J = 3.5, 0.7, Ar-H3′ or Ar-H4′); δC (125 MHz, CDCl3); 158.2 (4-
C), 149.2 (2-C), 147.9 (Ar-C), 146.3 (2′-C), 144.1 (8a-C), 136.9 (Ar-C), 128.3 
(Ar-C), 128.2 (Ar-C), 126.6 (Ar-C), 117.0 (3′-C or 4′-C), 116.9 (4a-C), 112.9 (3′-
C or 4′-C); vmax/cm
-1 (neat); 1767, 1705, 1634, 1599, 1472, 1456, 1326, 1271; 
m/z (ES) 236.0 (100%, MNa+); (Found MNa+, 236.0311. C12H7NO3 requires 




To a solution of 2-mercaptoquinazolin-4(3H)-one 
5.39 (89 mg, 0.50 mmol) and triethylamine (5.0 mL, 
0.50 mmol) in acetone (5 mL) at room temperature 
was added 4-(bromomethyl)pyridine hydrobromide 
5.40 (126 mg, 0.50 mmol). The mixture was heated 
at 55 °C for 24 hours and then cooled to room temperature. The resulting brown 
slurry was dried under vacuo and the brown oily residue was recrystallized from 
water to give the title compound 5.21 (62 mg, 0.35 mmol, 70%) as colourless 
plates m.p. 204—205 °C . Rf 0.40 (1:1 petroleum ether—EtOAc); HPLC 
(Method B), R.t. 1.30 min, (100%); δH (300 MHz, DMSO-d6); 12.67 (1H, br s, N-
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H), 8.50 (2H, dd, J = 4.5, 1.5, Ar-H2′,6′), 8.02 (1H, dd, J = 7.9, 1.2, Ar-H5), 7.71-
7.83 (1H, m, Ar-H7), 7.59 (1H, app. d, J = 7.9, Ar-H8), 7.51 (1H, dd, J = 4.5, 1.5 
Hz, Ar-H3′,5′), 7.37-7.49 (1H, m, Ar-H6), 4.48 (2H, s, H1′′); δC (125 MHz, DMSO-
d6); 161.1 (4-C), 154.6 (2-C), 149.6 (2′-C, 6′-C), 148.2 (8a-C), 146.9 (4′-C), 
134.7 (7-C), 126.0 (5-C, 6-C), 125.8 (8-C), 124.2 (3′-C, 5′-C), 120.0 (4a-C), 32.4 
(1′′-C); vmax/cm
-1 (neat); 3061, 1682, 1579, 1562, 1455, 1241, 1117, 762; m/z 
(ES) 270.1 (100%, MH+); (Found MH+, 270.0689. C14H11N3OS requires MH, 




Prepared via general method D using 3,4,5-
tris(benzyloxy)benzohydrazide 6.32 (227 mg, 
0.5 mmol) and 3-pyridinecarboxyaldehyde 6.33 
(0.06 mL, 0.5 mmol). Recrystallization from 
ethanol gave the title compound 6.3 (215 mg, 
0.4 mmol, 79%) as colourless plates m.p. 
200—201 °C. Rf 0.36 (95:5 CH2Cl2—MeOH); 
(Found: C, 75.3; H, 5.10; N, 7.6; C34H29N3O4 
requires C, 75.1; H, 5.38; N, 7.7%). HPLC 
(Method B), R.t. 3.57 min, (100%); δH (300 MHz, DMSO-d6); 11.92 (1H, s, N-H), 
8.87 (1H, app. s, Ar-H2′), 8.63 (1H, app. d, J = 4.5, Ar-H6′), 8.54 (1H, s, C-H1′′), 
8.17 (1H, app. d, J = 7.9, Ar-H4′), 7.26-7.53 (18H, m, Ar-H), 5.22 (4H, s, OCH2 in 
3 and 5), 5.03 (2H, s, OCH2 in 4); δC (75 MHz, DMSO-d6); 162.5 (C=O), 152.1 
(3C, 5C), 150.7 (6′-C), 148.8 (2′-C), 145.0 (1′′-C), 140.1 (4-C), 137.4 (1b-C), 
136.7 (1a-C, 1c-C), 133.4 (4′-C), 130.2 (3′-C), 128.4 (Ar-C), 128.3 (1-C), 128.2 
(Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 124.0 (Ar-C), 
106.9 (Ar-C), 74.2 (OCH2 in 4), 70.4 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3231, 
3033, 1646, 1580, 1540, 1426, 1371, 1334; m/z (ES) 544.2 (100%, MH+); 






Methyl 3,4,5-tris(benzyloxy)benzoate (6.31)11 
 
Potassium carbonate (7.38 g, 54.3 mmol) and benzyl 
bromide (1.35 mL, 67.9 mmol) were added to a 
solution of 3,4,5-trihydroxybenzoate methyl ester 6.30 
(2.50 g, 13.6 mmol) in dry DMF (30 mL). This reaction 
mixture was stirred at 120 °C for seven hours, and 
then poured into water (90 mL). The mixture was 
extracted with EtOAc (4 x 60 mL). The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. The brown solid was purified using 
column chromatography on silica gel eluting with petroleum ether / ethylacetate 
(9:1) and recrystallized from hexane to give the title compound 6.3111 (1.85 g, 
4.08 mmol, 30%) as colourless needles m.p. 97—98 °C (Lit.11 99—100 °C). Rf  
0.95 (1:1 petroleum ether—EtOAc); HPLC (Method A), R.t. 4.48 min, (100%); 
δH (300 MHz, DMSO-d6); 7.45-7,47 (4H, m, Ar-H), 7.38-7.41 (4H, m, Ar-H), 
7.32-7.36 (6H, m, Ar-H), 7.24-7.28 (3H, m, Ar-H), 5.18 (4H, s, OCH2 in 3 and 5), 
5.04 (2H, s, OCH2 in 4), 3.82 (3H, s, OCH3); δC (75 MHz, DMSO-d6); 165.7 
(C=O), 152.1 (3C, 5C), 141.3 (4-C), 137.3 (Ar-Cqt), 136.7 (Ar-Cqt), 128.4 (Ar-C), 
128.2 (Ar-C), 128.1 (Ar-C), 127.89 (Ar-C), 127.88 (Ar-C), 127.6 (Ar-C), 124.8 (1-
C), 108.1 (2-C and 6-C), 74.2 (OCH2), 70.3 (OCH2), 52.2 (OCH3); vmax/cm
-1 
(neat); 3411, 3066, 3031, 2949, 2879, 1967, 1715, 1587, 1495, 1428; m/z (ES) 
477.2 (100%, MNa+); (Found MNa+, 477.1681. C29H26O5 requires MNa, 




Prepared via general method C using methyl 3,4,5-
tris(benzyloxy)benzoate 6.31 (2.0 g, 4.4 mmol) and 
hydrazine hydrate (2.3 ml, 44 mmol). 
Recrystallization from acetone / water to give the 
title compound 6.3212 (1.7 g, 3.7 mmol, 85%) as 
colourless fluffy solid m.p. 134—135 °C (Lit.12 
137—137.5 °C). Rf 0.72 (90:10 CH2Cl2—MeOH); HPLC (Method A), R.t. 0.40 
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min, (100%); δH (500 MHz, DMSO-d6); 9.73 (1H, s, N-H), 7.49-7.23 (17H, m, Ar-
H), 5.17 (4H, s, OCH2), 4.99 (2H, s, OCH2), 4.49 (2H, s, NH2); δC (125 MHz, 
DMSO-d6); 165.2 (C=O), 151.9 (3-C, 5-C), 139.4 (4-C), 137.5 (1′-C, 1′′′-C), 
136.9 (1-C), 128.5 (1′′-C), 128.4 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-
C), 127.8 (Ar-C), 127.6 (Ar-C), 106.1 (2-C, 6-C), 74.2 (OCH2), 70.2 (OCH2); 
vmax/cm
-1 (neat); 3278, 3065, 3032, 1951, 1630, 1583, 1499, 1345; m/z (ES) 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(241 mg, 0.53 mmol) and 4-
pyridinecarboxyaldehyde 6.118 (0.09 mL, 
0.53 mmol). Recrystallization from ethanol 
gave the title compound 6.34 (271 mg, 
0.50 mmol, 94%) as colourless needles 
m.p. 206—207 °C (Lit.13 not available). Rf 0.28 (95:5 CH2Cl2—MeOH); HPLC 
(Method A), R.t. 3.47 min, (100%); δH (500 MHz, DMSO-d6); 12.00 (1H, s, N-H), 
8.67 (2H, d, J = 4.5, Ar-H2′,6′), 8.48 (1H, s, C-H1′′), 7.68 (2H, d, J = 4.5, Ar-H3′,5′), 
7.48-7.51 (4H, m, Ar-H), 7.34-7.44 (10H, m, Ar-H), 7.26-7.32 (3H, m, Ar-H), 
5.21 (4H, s, OCH2 in 3 and 5), 5.03 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 
162.7 (C=O), 152.1 (3-C and 5-C), 150.3 (2′-C and 6′-C), 145.3 (1′′-C), 141.5 
(4′-C), 140.4 (4-C), 137.4 (1b-C), 136.7 (1a-C and 1c-C), 128.44 (Ar-C), 128.43 
(1-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 
121.0 (3′-C and 5′-C), 107.1 (2-C and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 
and 5); vmax/cm
-1 (neat); 3219, 3029, 1648, 1578, 1531, 1452, 1424, 1370, 
1324, 1112, 680; m/z (ES) 544.2 (100%, MH+); (Found MH+, 544.2235. 








Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(227 mg, 0.50 mmol) and benzaldehyde 
6.119 (0.05 mL, 0.50 mmol). 
Recrystallization from ethanol gave the 
title compound 6.35 (239 mg, 0.44 mmol, 
88%) as colourless needles m.p. 199—
200 °C. Rf 0.62 (95:5 CH2Cl2—MeOH); HPLC (Method C), R.t. 3.23 min, 
(100%); δH (300 MHz, DMSO-d6); 11.76 (1H, s, N-H), 8.49 (1H, s, C-H1′′), 7.74-
7.77 (2H, m, Ar-H), 7.09-7.57 (20H, m, Ar-H), 5.22 (4H, s, OCH2 in 3 and 5), 
5.03 (2H, s, OCH2 in 4); δC (75 MHz, DMSO-d6); 162.4 (C=O), 152.1 (3-C and 5-
C), 147.7 (1′′-C), 140.0 (4-C), 137.4 (1b-C), 136.7 (1a-C and 1c-C), 134.2 (1′-C), 
130.1 (Ar-C), 128.9 (Ar-C), 128.5 (1-C), 128.4 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-
C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 127.0 (Ar-C), 106.8 (2-C and 6-C), 
74.2 (OCH2 in 4), 70.4 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3209, 3033, 1640, 
1577, 1549, 1422, 1363, 1099, 752; m/z (ES) 565.2 (100%, MNa+); (Found 




Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (300 mg, 0.66 mmol) and 4-
hydroxybenzaldehyde 6.120 (80.6 
mg, 0.66 mmol). Recrystallization 
from ethanol gave the title compound 
6.36 (295 mg, 0.53 mmol, 80%) as 
colourless needles m.p. 204—205 
°C. Rf 0.24 (95:5 CH2Cl2—MeOH); (Found: C, 75.2; H, 5.40; N, 5.0; C35H30N2O5 
requires C, 75.2; H, 5.41; N, 5.0%). HPLC (Method B), R.t. 3.92 min, (100%); δH 
(500 MHz, DMSO-d6); 11.49 (1H, s, N-H), 9.91 (1H, s, O-H in 4′), 8.36 (1H, s, C-
H1′′), 7.56 (2H, d, J = 8.5, Ar-H2′,6′), 7.47-7.50 (4H, m, Ar-H), 7.32-7.45 (10H, m, 
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Ar-H), 7.32-7.22 (3H, m, Ar-H), 6.84 (2H, d, J = 8.5, Ar-H3′,5′), 5.20 (4H, s, OCH2 
in 3 and 5), 5.01 (2H, s, OCH2 in 4); δC (75 MHz, DMSO-d6); 162.1 (C=O), 159.4 
(4′-C), 152.0 (3-C and 5-C), 148.1 (1′′-C), 140.0 (4-C), 137.4 (1b-C), 136.8 (1a-
C and 1c-C), 128.82 (2′-C and 6′-C), 128.79 (1-C), 128.4 (Ar-C), 128.2 (Ar-C), 
128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 125.3 (1′-C), 115.7 (3′-C 
and 5′-C), 106.9 (2-C and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); 
vmax/cm
-1 (neat); 3486, 3419, 3030, 1648, 1596, 1510, 1424, 1233, 1073, 683; 
m/z (ES) 581.2 (100%, MNa+); (Found MNa+, 581.2034. C35H30N2O5 requires 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (119 mg, 0.26 mmol) and 4-
(dimethylamino)benzaldehyde 6.130 
(39 mg, 0.26 mmol). Recrystallization 
from ethanol gave the title compound 
6.37 (116 mg, 0.20 mmol, 76%) as 
light yellow plates m.p. 84—85 °C. Rf 0.84 (95:5 CH2Cl2—MeOH); (Found: C, 
75.7; H, 6.00; N, 7.2; C35H37N3O4 requires C, 75.9; H, 6.02; N, 7.2%). HPLC 
(Method B), R.t. 4.40 min, (100%); δH (300 MHz, DMSO-d6); 11.45 (1H, s, N-H), 
8.33 (1H, s, C-H1′′), 7.56 (2H, d, J = 8.8, Ar-H2′,6′), 7.46-7.50 (4H, m, Ar-H), 7.32-
7.45 (10H, m, Ar-H), 7.23-7.31 (3H, m, Ar-H), 6.77 (2H, d, J = 8.8, Ar-H3′,5′), 
5.21 (4H, s, OCH2 in 3 and 5), 5.02 (2H, s, OCH2 in 4), 2.98 (6H, s, CH3); δC 
(125 MHz, DMSO-d6); 161.9 (C=O), 152.0 (3-C and 5-C), 151.5 (4′-C), 148.7 
(1′′-C), 139.9 (4-C), 137.4 (1b-C), 136.8 (1a-C and 1c-C), 129.0 (2′-C and 6′-C), 
128.42 (Ar-C), 128.38 (1-C), 128.0 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-
C), 127.7 (Ar-C), 121.5 (1′-C), 111.8 (3′-C and 5′-C), 106.7 (2-C and 6-C), 74.2 
(OCH2 in 4), 70.4 (OCH2 in 3 and 5), 40.3 (NCH3); vmax/cm
-1 (neat); 3223, 3031, 
2899, 1644, 1588, 1521, 1315, 1092; m/z (ES) 586.3 (100%, MNa+); (Found 







Prepared via general method D using 3,4,5-
tris(benzyloxy)benzohydrazide 6.32 (156 
mg, 0.50 mmol) and indole-3-
carboxyaldehyde 6.132 (50 mg, 0.50 mmol). 
Recrystallization from ethanol / water gave 
the title compound 6.38 (238 mg, 0.41 mmol, 
82%) as colourless needles m.p. 231 °C 
(dec). Rf 0.48 (90:10 CH2Cl2—MeOH); HPLC 
(Method B), R.t. 4.09 min, (100%); δH (500 MHz, DMSO-d6); 11.61 (1H, s, N-H 
indole), 11.42 (1H, s, N-H hydrazide), 8.66 (1H, s, 1′′-C), 8.32 (1H, app. d, J = 
7.5, Ar-H4′), 7.85 (1H, d, J = 2.7, Ar-H2′), 7.26-7.57 (18H, m, Ar-H), 7.23 (1H, 
app. t, J = 7.5, Ar-H5′ or Ar-H6′),  7.18 (1H, app. t, J = 7.5, Ar-H5′ or Ar-H6′), 5.24 
(4H, s, OCH2 in 3 and 5), 5.05 (2H, s, OCH2 in 4); δC (75 MHz, DMSO-d6); 161.8 
(C=O), 152.0 (3-C and 5-C), 145.0 (1′′-C), 139.7 (4-C), 137.4 (1a-C and 1c-C), 
137.0 (Ar-Cqt), 136.8 (Ar-Cqt), 130.3 (2′-C), 129.2 (Ar-Cqt), 128.4 (1b-C), 128.2 
(Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 124.3 (Ar-Cqt), 
122.6 (4′-C), 122.0 (Ar-C), 120.4 (Ar-C), 111.9 (Ar-C), 111.6 (Ar-Cqt), 106.6 (Ar-
C), 74.2 (OCH2 in 4), 70.4 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3384, 3216, 
3029, 1636, 1577, 1555, 1525, 1321, 1095, 749; m/z (ES) 604.2 (100%, MNa+); 




Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (247 mg, 0.54 mmol) and 4-
nitrobenzaldehyde 6.131 (82.1 mg, 
0.54 mmol). Recrystallization from 
ethanol gave the title compound 6.39 
(289 mg, 0.49 mmol, 91%) as 
colourless plates m.p. 234—235 °C. Rf 0.34 (95:5 CH2Cl2—MeOH); (Found: C, 
71.5; H, 5.00; N, 7.2; C35H29N3O6 requires C, 71.5; H, 5.00; N, 7.2%). HPLC 
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(Method B), R.t. 4.38 min, (100%); δH (500 MHz, DMSO-d6); 12.00 (1H, s, N-H), 
8.57 (1H, s, C-H1′′), 8.31 (2H, d, J = 8.3, Ar-H3′,5′), 8.00 (2H, d, J = 8.3, Ar-H2′,6′), 
7.47-7.50 (4H, m, Ar-H), 7.32-7.44 (10H, m, Ar-H), 7.32-7.21 (3H, m, Ar-H), 
5.21 (4H, s, OCH2 in 3 and 5), 5.03 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 
162.7 (C=O), 152.1 (3-C, 5-C), 147.9 (4′-C), 145.3 (1′′-C), 140.6 (4-C or 1′-C), 
140.4 (4-C or 1′-C), 137.4 (1b-C), 136.7 (1a-C and 1c-C), 128.4 (Ar-C), 128.23 
(1-C), 128.17 (2′-C, 6′-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-
C), 127.7 (Ar-C), 124.1 (3′-C and 5′-C), 107.1 (2-C and 6-C), 74.3 (OCH2 in 4), 
70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3216, 3062, 3038, 1650, 1541, 1466, 
1425, 1267, 1127, 694; m/z (ES) 610.2 (100%, MNa+); (Found MNa+, 610.1921. 




Prepared via general method D using 3,5-
bis(benzyloxy)benzohydrazide 6.109 (174 
mg, 0.50 mmol) and 4-
pyridinecarboxyaldehyde 6.118 (0.047 mL, 
0.50 mmol). Recrystallization from ethanol 
gave the title compound 6.40 (192 mg, 0.44 
mmol, 88%) as colourless needles m.p. 
183—184 °C (Lit.13 not available). Rf 0.35 
(95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 4.12 min, (100%); δH (500 MHz, 
DMSO-d6); 12.01 (1H, s, N-H), 8.65 (2H, d, J = 4.5, Ar-H2′,6′), 8.44 (1H, s, C-
H1′′), 7.65 (2H, d, J = 4.5, Ar-H3′,5′), 7.30-7.49 (10H, m, Ar-H), 7.18 (2H, d, J = 
2.0, Ar-H2,6), 6.93 (1H, t, J = 2.0, Ar-H4), 5.16 (4H, s, OCH2 in 3 and 5); δC (125 
MHz, DMSO-d6); 162.8 (C=O), 159.5 (3-C and 5-C), 150.3 (2′-C and 6′-C), 
145.5 (1′′-C), 141.4 (4′-C), 136.7 (1aC), 135.0 (1-C), 128.5 (Ar-C), 127.9 (Ar-C), 
127.8 (Ar-C), 121.0 (3′-C and 5′-C), 106.8 (2-C and 6-C), 105.2 (4-C), 69.6 
(OCH2); vmax/cm
-1 (neat); 3227, 3032, 1657, 1596, 1537, 1364, 1133, 729; m/z 
(ES) 438.2 (100%, MH+); (Found MH+, 438.1824. C27H23N3O3 requires MH, 







Prepared via general method D using 4-
(benzyloxy)benzohydrazide 6.106 (121 
mg, 0.50 mmol) and benzaldehyde 
6.119 (0.05 mL, 0.50 mmol). Recrystal-
lization from ethanol gave the title 
compound 6.41 (140 mg, 0.42 mmol, 85%) as colourless plates m.p. 186—187 
°C (Lit.14 m.p. 185). Rf 0.50 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 3.74 
min, (100%); δH (500 MHz, DMSO-d6); 11.70 (1H, s, N-H), 8.44 (1H, s, C-H1′′′), 
7.90 (2H, d, J = 8.9, Ar-H2,6), 7.70-7.72 (2H, m, Ar-H), 7.30-7.50 (8H, m, Ar-H), 
7.13 (2H, d, J = 8.9, Ar-H3,5), 5.19 (2H, s, OCH2); δC (125 MHz, DMSO-d6); 
162.5 (C=O), 161.1 (4-C), 147.2 (1′′′-C), 136.6 (1′-C), 134.4 (1′′-C), 129.9 (2-C 
and 6-C), 129.5 (Ar-C), 128.8 (Ar-C), 128.5 (Ar-C), 128.0 (Ar-C), 127.8 (Ar-C), 
127.0 (Ar-C), 125.6 (1-C), 114.6 (3-C and 5-C), 69.4 (OCH2); vmax/cm
-1 (neat); 
3166, 2944, 1634, 1608, 1559, 1509, 1487, 1287, 1249, 1183, 691; m/z (ES) 
353.1 (100%, MNa+); (Found MNa+, 353.1274. C21H18N2O2 requires MNa, 




Prepared via general method D using benzoic 
hydrazide 6.112 (408 mg, 3.0 mmol) and 3-
pyridinecarboxyaldehyde 6.33 (0.366 mL, 3.0 mmol). 
Recrystallization from ethanol gave the title 
compound 6.42 (360 mg, 2.6 mmol, 88%) as colourless needles m.p. 185—186 
°C (Lit.15 m.p. 184—185 °C). Rf 0.34 (95:5 CH2Cl2—MeOH); HPLC (Method A), 
R.t. 1.46 min, (100%); δH (500 MHz, DMSO-d6); 12.01 (1H, s, N-H), 8.86 (1H, 
app. s, Ar-H2′), 8.61 (1H, app. d, J = 4.3, Ar-H6′), 8.52 (1H, s, C-H1′′), 8.14 (1H, 
app. d, J = 7.5, Ar-H4′), 7.92 (2H, app. d, J = 7.4, Ar-H2,6), 7.59 (1H, app. t, J = 
7.4, Ar-H4), 7.52 (2H, app. t, J = 7.4, Ar-H3,5), 7.48 (1H, dd, J = 7.5, 4.3, Ar-H5′); 
δC (75 MHz, DMSO-d6); 163.2 (C=O), 150.7 (6′-C), 148.7 (2′-C), 145.0 (1′′-C), 
133.4 (4′-C), 133.2 (1-C), 131.9 (4-C), 130.2 (3′-C), 128.5 (3-C, 5-C), 127.6 (2-
C, 6-C), 124.0 (5′-C); vmax/cm
-1 (neat); 3180, 3015, 1671, 1602, 1591, 1274, 
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1137, 685; m/z (ES) 226.1 (100%, MH+); (Found MH+, 226.0981. C13H11N3O 




Prepared via general method D using benzoic 
hydrazide 6.112 (400 mg, 2.94 mmol) and 2-
pyridinecarboxyaldehyde 6.117 (0.28 mL, 2.94 
mmol). Recrystallization from ethanol gave the title 
compound 6.43 (452 mg, 2.01 mmol, 76%) as colourless needles m.p. 107—
108 °C (Lit.16 m.p. 108—109 °C). Rf 0.52 (95:5 CH2Cl2—MeOH); HPLC (Method 
A), R.t. 1.64 min, (100%); δH (500 MHz, DMSO-d6); 12.04 (1H, s, N-H), 8.61 
(1H, app. d, J = 4.2, Ar-H6′), 8.48 (1H, s, C-H1′′), 7.84-8.00 (4H, m, Ar-H), 7.52-
7.62 (3H, m, Ar-H), 7.31-7.46 (1H, m, Ar-H pyridyl); δC (125 MHz, DMSO-d6); 
163.4 (C=O), 153.3 (2′-C), 149.5 (6′-C), 148.0 (1′′-C), 136.8 (Ar-C), 133.2 (1-C), 
131.9 (Ar-C), 128.5 (Ar-C), 127.7 (Ar-C), 124.4 (Ar-C), 119.9 (Ar-C); vmax/cm
-1 
(neat); 3646, 3182, 3004, 1656, 1558, 1468, 1280, 1182, 698; m/z (ES) 248.1 
(100%, MNa+); (Found MNa+, 248.0795. C13H11N3O requires MNa, 248.0794).   
 
(E)-N'-(pyridin-4-yl-methylene)benzohydrazide (6.44)15  
 
Prepared via general method D using benzoic 
hydrazide 6.112 (433 mg, 3.18 mmol) and 4-
pyridinecarboxyaldehyde 6.118 (0.30 mL, 3.18 
mmol). Recrystallization from ethanol gave the title 
compound 6.44 (572 mg, 2.54 mmol, 80%) as colourless needles m.p. 162—
163 °C (Lit.15 m.p. 162—163 °C). Rf 0.53 (95:5 CH2Cl2—MeOH); HPLC (Method 
A), R.t. 1.36 min, (100%); δH (500 MHz, DMSO-d6); 12.11 (1H, s, N-H), 8.65 
(2H, d, J = 4.5, Ar-H2′,6′), 8.45 (1H, s, C-H1′′), 7.92 (2H, app. d, J = 7.3, Ar-H2,6), 
7.69 (2H, d, J = 4.5, Ar-H3′,5′), 7.60 (1H, app. t, J = 7.3, Ar-H4), 7.53 (2H, app. t, 
J = 7.3, Ar-H3,5); δC (125 MHz, DMSO-d6); 163.4 (C=O), 150.3 (2′-C, 6′-C), 145.3 
(1′′-C), 141.5 (4′-C), 133.1 (1-C), 132.0 (4-C), 128.5 (3-C, 5-C), 127.7 (2-C, 6-
C), 121.0 (3′-C, 5′-C); vmax/cm
-1 (neat); 3257, 3038, 1646, 1546, 1489, 1306, 
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1277, 1140, 627; m/z (ES) 226.1 (100%, MH+); (Found MH+, 226.0979. 




Prepared via general method D using 3,4,5-
trimethoxybenzohydrazide 6.113 (452 mg, 2.0 
mmol) and 4-pyridinecarboxyaldehyde 6.118 
(0.10 mL, 2.0 mmol). Recrystallization from 
ethanol gave the title compound 6.45 (385 mg, 
1.7 mmol, 85%) as colourless plates m.p. 174—175 °C (Lit.17 not available). Rf 
0.20 (95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 1.61 min, (100%); δH (500 
MHz, DMSO-d6); 12.01 (1H, s, N-H), 8.67 (2H, d, J = 4.9, Ar-H2′,6′), 8.46 (1H, s, 
C-H1′′), 7.68 (2H, d, J = 4.9, Ar-H3′,5′), 7.25 (2H, s, Ar-H2,6), 3.87 (6H, s, OCH3 in 
3 and 5), 3.74 (3H, s, OCH3 in 4); δC (125 MHz, DMSO-d6); 162.8 (C=O), 152.7 
(3-C, 5-C), 150.3 (2′-C, 6′-C), 145.2 (1′′-C), 141.5 (4′-C), 140.7 (4-C), 128.1 (1-
C), 120.9 (3′-C, 5′-C), 105.4 (2-C, 6-C), 60.1 (OCH3 in 4), 56.1 (OCH3 in 3 and 
5); vmax/cm
-1 (neat); 3161, 3003, 1644, 1500, 1451, 1362, 1326, 1177, 1124; m/z 
(ES) 316.3 (100%, MH+); (Found MH+, 316.1302. C16H17N3O4 requires MH, 





Prepared via general method D using 3,4-
methylendioxybenzhydrazide 6.114 (180 mg, 1.0 
mmol) and 2-pyridinecarboxyaldehyde 6.117 
(0.095 mL, 1.0 mmol). Recrystallization from 
ethanol gave the title compound 6.46 (172 mg, 0.64 mmol, 64%) as colourless 
plates m.p. 181—182 °C (Lit.15 m.p. 182—183 °C). Rf 0.26 (95:5 CH2Cl2—
MeOH); HPLC (Method A), R.t. 1.71 min, (100%); δH (300 MHz, DMSO-d6); 
11.92 (1H, s, N-H), 8.62 (1H, app. d, J = 4.8, Ar-H6′), 8.45 (1H, s, C-H1′′), 7.97 
(1H, app. d, J = 7.8, Ar-H3′), 7.89 (1H, app. t, J = 7.8, Ar-H4′), 7.54 (1H, dd, J = 
8.1, 1.4, Ar-H6), 7.47 (1H, d, J = 1.4, Ar-H2), 7.36-7.45 (1H, m, Ar-H5′), 7.08 (1H, 
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d, J = 8.1, Ar-H5), 6.15 (2H, s, OCH2O); δC (125 MHz, DMSO-d6); 162.4 (C=O), 
153.3 (4-C), 150.3 (2′-C), 149.5 (6′-C), 147.6 (1′′-C), 147.4 (3-C), 136.8 (4′-C), 
126.9 (1-C), 124.3 (2-C), 123.0 (6-C), 119.8 (3′-C), 108.1 (5-C), 107.7 (5′-C), 
101.9 (OCH2O); vmax/cm
-1 (neat); 3224, 3079, 1644, 1498, 1434, 1365, 1257, 
1167, 1032; m/z (ES) 292.1 (100%, MNa+); (Found MNa+, 292.0693. 






Prepared via general method D using 3,4-
methylendioxybenzhydrazide 6.114 (180 mg, 1.0 
mmol) and 4-pyridinecarboxyaldehyde 6.118 
(0.094 mL, 1.0 mmol). Recrystallization from 
ethanol gave the title compound 6.47 (215 mg, 0.8 mmol, 81%) as colourless 
plates m.p. 259—260 °C (Lit.15 m.p. 257—258 °C). Rf 0.36 (95:5 CH2Cl2—
MeOH); HPLC (Method A), R.t. 1.52 min, (100%); δH (300 MHz, DMSO-d6); 
12.00 (1H, s, N-H), 8.65 (2H, d, J = 4.9, Ar-H2′,6′), 8.41 (1H, s, C-H1′′), 7.66 (2H, 
d, J = 4.9, Ar-H3′,5′), 7.54 (1H, app. d, J = 8.1, Ar-H6), 7.47 (1H, app. s, Ar-H2), 
7.08 (1H, d, J = 8.1, Ar-H5), 6.15 (2H, s, OCH2O); δC (75 MHz, DMSO-d6); 162.4 
(C=O), 150.4 (3-C or 4-C), 150.3 (2′-C, 6′-C), 147.4 (3-C or 4-C), 144.9 (1′′-C), 
141.5 (4′-C), 126.8 (1-C), 123.0 (6-C), 120.9 (3′-C, 5′-C), 108.1 (2-C), 107.7 (5-
C), 101.9 (OCH2O); vmax/cm
-1 (neat); 3236, 3028, 2904, 1645, 1538, 1497, 
1481, 1404, 1288, 1211, 1167; m/z (ES) 270.1 (100%, MH+); (Found MH+, 




Prepared via general method D using 2-
naphthohydrazide 6.105 (186 mg, 1.0 mmol) 
and 3-pyridinecarboxyaldehyde 6.33 (0.094 mL, 
1.0 mmol). Recrystallization from methanol / 
water gave the title compound 6.48 (201 mg, 0.73 mmol, 73%) as colourless 
needles m.p. 205—206 °C (Lit.18 not available). Rf 0.51 (95:5 CH2Cl2—MeOH); 
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HPLC (Method B), R.t. 2.93 min, (100%); δH (500 MHz, DMSO-d6); 12.18 (1H, 
s, N-H), 8.88 (1H, app. s, Ar-H2′), 8.62 (1H, app. s, J = 4.5, Ar-H6′), 8.56 (1H, s, 
C-H1′′), 8.55 (1H, app. s, Ar-H1), 8.17 (1H, app. d, J = 7.5, Ar-H4′), 7.91-8.10 (4H, 
m, Ar-H3,4,5,8), 7.57-7.68 (2H, m, Ar-H6,7), 7.50 (1H, dd, J = 7.3, 4.5, Ar-H5′); δC 
(125 MHz, DMSO-d6); 163.3 (C=O), 150.7 (6′-C), 148.8 (2′-C), 145.1 (1′′-C), 
134.4 (Ar-Cqt), 133.5 (4′-C), 132.0 (2-C), 130.5 (Ar-Cqt), 130.3 (Ar-Cqt), 128.9 (1-
C), 128.2 (Ar-C), 128.1 (6-C or 7-C), 128.0 (Ar-C), 127.7 (Ar-C), 126.9 (6-C or 
7-C), 124.3 (Ar-C), 124.0 (5′-C); vmax/cm
-1 (neat); 3200, 3054, 1645, 1604, 1589, 
1242, 1114, 740; m/z (ES) 276.1 (100%, MH+); (Found MH+, 276.1124. 




Prepared via general method D using 2-
naphthohydrazide 6.105 (186 mg, 1.0 mmol) 
and 2-pyridinecarboxyaldehyde 6.117 (0.094 
mL, 1.0 mmol). Recrystallization from methanol / 
water gave the title compound 6.49 (245 mg, 0.89 mmol, 89%) as colourless 
needles m.p. 186—187 °C (Lit.18 not available). Rf 0.45 (95:5 CH2Cl2—MeOH); 
HPLC (Method B), R.t. 2.58 min, (100%); δH (300 MHz, DMSO-d6); 12.27 (1H, 
s, N-H), 8.64 (1H, app. d, J = 4.5, Ar-H6′), 8.58 (1H, app. s, Ar-H1), 8.54 (1H, s, 
C-H1′′), 7.99-8.12 (5H, m, Ar-H4,5,8,3′), 7.91 (1H, app. t, J = 7.5, Ar-H4′), 7.52-7.74 
(2H, m, Ar-H6,7), 7.40-7.49 (1H, m, Ar-H5′); δC (75 MHz, DMSO-d6); 163.4 (C=O), 
153.2 (2′-C), 149.5 (6′-C), 148.0 (1′′-C), 136.9 (4′-C), 134.4 (Ar-Cqt), 132.0 (2-C), 
130.4 (Ar-Cqt), 128.9 (1-C), 128.20 (Ar-C), 128.17 (Ar-C), 128.0 (Ar-C), 127.7 
(6-C or 7-C), 127.0 (6-C or 7-C), 124.4 (5′-C), 124.3 (Ar-C), 119.9 (Ar-C); 
vmax/cm
-1 (neat); 3186, 3002, 1684, 1585, 1504, 1484, 1284, 1136; m/z (ES) 












Prepared via general method D using 2-
naphthohydrazide 6.105 (186 mg, 1.0 mmol) 
and 4-pyridinecarboxyaldehyde 6.118 (0.094 
mL, 1.0 mmol). Recrystallization from methanol / 
water gave the title compound 6.50 (217 mg, 0.79 mmol, 79%) as colourless 
needles m.p. 224—225 °C (Lit.18 not available). Rf 0.46 (95:5 CH2Cl2—MeOH); 
HPLC (Method B), R.t. 3.00 min, (100%); δH (300 MHz, DMSO-d6); 12.34 (1H, 
s, N-H), 8.68 (1H, d, J = 4.4, Ar-H2′,6′), 8.57 (1H, app. s, Ar-H1), 8.50 (1H, s, C-
H1′′), 7.96-8.14 (4H, m, Ar-H3,4,5,8), 7.71 (1H, d, J = 4.4, Ar-H3′,5′), 7.59-7.68 (2H, 
m, Ar-H6,7); δC (75 MHz, DMSO-d6); 163.4 (C=O), 150.3 (2′-C and 6′-C), 145.3 
(1′′-C), 141.5 (4′-C), 134.4 (Ar-Cqt), 132.0 (2-C), 130.3 (Ar-Cqt), 128.9 (1-C), 
128.23 (Ar-C), 128.21 (6-C or 7-C), 128.0 (Ar-C), 127.7 (Ar-C), 127.0 (6-C or 7-
C), 124.3 (Ar-C), 121.0 (3′-C and 5′-C); vmax/cm
-1 (neat); 3402, 3197, 3003, 
1644, 1541, 1376, 965, 750; m/z (ES) 298.1 (100%, MNa+); (Found MNa+, 
298.0946. C17H13N3O requires MNa, 298.0951).  
 
(E)-3,4,5-tris(benzyloxy)-N'-(pyridin-2-yl methylene)benzohydrazide (6.51) 
 
Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(241 mg, 0.53 mmol) and 2-
pyridinecarboxyaldehyde 6.117 (0.05 mL, 
0.53 mmol). Recrystallization from ethanol 
gave the title compound 6.51 (261 mg, 
0.48 mmol, 91%) as colourless plates m.p. 
166—167 °C. Rf 0.60 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 3.82 min, 
(100%); δH (300 MHz, DMSO-d6); 11.95 (1H, s, N-H), 8.64 (1H, app. d, J = 4.6, 
Ar-H6′), 8.52 (1H, s, C-H1′′), 8.00 (1H, app. d, J = 7.7, Ar-H3′), 7.90 (1H, app. t, J 
= 7.7, Ar-H4′), 7.21-7.56 (18H, m, Ar-H), 5.21 (4H, s, OCH2 in 3 and 5), 5.03 (2H, 
s, OCH2 in 4); δC (75 MHz, DMSO-d6); 162.6 (C=O), 153.2 (2′-C), 152.1 (3-C 
and 5-C), 149.6 (6′-C), 147.9 (1′′-C), 140.2 (4-C), 137.4 (1b-C), 136.9 (4′-C), 
136.7 (1a-C and 1c-C), 128.4 (Ar-C), 128.3 (1-C), 128.2 (Ar-C), 128.1 (Ar-C), 
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128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 124.4 (5′-C), 119.9 (3′-C), 107.0 (2-C 
and 6-C), 74.2 (OCH2 in 4), 70.4 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3209, 
3061, 1644, 1580, 1547, 1501, 1433, 1326, 1108, 655; m/z (ES) 566.2 (100%, 




Prepared via general method D using 3,5-
bis(benzyloxy)benzohydrazide 6.109 (174 
mg, 0.50 mmol) and 2-
pyridinecarboxyaldehyde 6.117 (0.047 mL, 
0.50 mmol). Recrystallization from ethanol 
gave the title compound 6.52 (197 mg, 0.45 
mmol, 90%) as light yellow needles m.p. 
73—74 °C. Rf 0.34 (95:5 CH2Cl2—MeOH); HPLC (Method C), R.t. 1.95 min, 
(96%); δH (500 MHz, DMSO-d6); 11.94 (1H, s, N-H), 8.61 (1H, app. d, J = 4.6, 
Ar-H6′), 8.48 (1H, s, C-H1′′), 7.97 (1H, app. d, J = 7.7, Ar-H3′), 7.88 (1H, app. t, J 
= 7.7, Ar-H4′), 7.30-7.50 (11H, m, Ar-H), 7.18 (2H, d, J = 2.0, Ar-H2,6), 6.93 (1H, 
t, J = 2.0, Ar-H4), 5.17 (4H, s, OCH2 in 3 and 5); δC (125 MHz, DMSO-d6); 162.7 
(C=O), 159.5 (3-C and 5-C), 153.2 (2′-C), 149.5 (6′-C), 148.2 (1′′-C), 136.9 (4′-
C), 136.7 (1aC), 135.1 (1-C), 128.5 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 124.4 
(Ar-C), 119.9 (Ar-C), 106.8 (2-C and 6-C), 105.1 (4-C), 69.7 (OCH2); vmax/cm
-1 
(neat); 3452, 3200, 3031, 1674, 1591, 1546, 1350, 1165, 735; m/z (ES) 460.2 




Prepared via general method D using 3,5-
bis(benzyloxy)benzohydrazide 6.109 (174 
mg, 0.50 mmol) and 3-
pyridinecarboxyaldehyde 6.33 (0.047 mL, 
0.50 mmol). Recrystallization from ethanol 
gave the title compound 6.53 (184 mg, 0.42 
mmol, 84%) as colourless needles m.p. 
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154—155 °C. Rf 0.38 (95:5 CH2Cl2—MeOH); HPLC (Method C), R.t. 1.86 min, 
(100%); δH (500 MHz, DMSO-d6); 11.91 (1H, s, N-H), 8.84 (1H, app. s, Ar-H2′), 
8.61 (1H, dd, J = 4.6, 1.3, Ar-H6′), 8.50 (1H, s, C-H1′′), 8.13 (1H, app. d, J = 7.9, 
Ar-H4′), 7.30-7.52 (11H, m, Ar-H), 7.17 (2H, d, J = 2.0, Ar-H2,6), 6.92 (1H, t, J = 
2.0, Ar-H4), 5.16 (4H, s, OCH2 in 3 and 5); δC (125 MHz, DMSO-d6); 162.6 
(C=O), 159.5 (3-C and 5-C), 150.7 (6′-C), 148.7 (2′-C), 145.2 (1′′-C), 136.7 
(1aC), 135.2 (1-C), 133.4 (4′-C), 130.2 (3′-C), 128.5 (Ar-C), 127.9 (Ar-C), 127.8 
(Ar-C), 124.0 (Ar-C), 106.8 (2-C and 6-C), 105.1 (4-C), 69.6 (OCH2); vmax/cm
-1 
(neat); 3191, 3029, 1651, 1590, 1547, 1416, 1299, 1158, 694; m/z (ES) 460.2 




Prepared via general method D using 3,5-
bis(benzyloxy)benzohydrazide 6.109 (174 
mg, 0.50 mmol) and benzaldehyde 6.119 
(0.05 mL, 0.50 mmol). Recrystallization from 
ethanol gave the title compound 6.54 (166 
mg, 0.38 mmol, 76%) as colourless needles 
m.p. 100—101 °C. Rf 0.52 (95:5 CH2Cl2—
MeOH); HPLC (Method C), R.t. 2.54 min, (100%); δH (500 MHz, DMSO-d6); 
11.74 (1H, s, N-H), 8.45 (1H, s, C-H1′′), 7.67-7.76 (2H, m, Ar-H), 7.30-7.50 (13H, 
m, Ar-H), 7.17 (2H, d, J = 2.1, Ar-H2,6), 6.91 (1H, t, J = 2.1, Ar-H4), 5.16 (4H, s, 
OCH2 in 3 and 5); δC (125 MHz, DMSO-d6); 162.5 (C=O), 159.5 (3-C and 5-C), 
148.0 (1′′-C), 136.7 (1a-C), 135.4 (1-C), 134.3 (1′-C), 130.1 (Ar-C), 128.8 (Ar-C), 
128.4 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 127.1 (Ar-C), 106.7 (2-C and 6-C), 
105.0 (4-C), 69.6 (OCH2); vmax/cm
-1 (neat); 3233, 3030, 1651, 1590, 1537, 1348, 
1164, 691; m/z (ES) 459.2 (100%, MNa+); (Found MNa+, 459.1697. C28H24N2O3 











Prepared via general method D using 4-
(benzyloxy)benzohydrazide 6.106 (121 
mg, 0.5 mmol) and 2-
pyridinecarboxyaldehyde 6.117 (0.047 
mL, 0.5 mmol). Recrystallization from 
methanol / water gave the title compound 6.55 (292 mg, 0.9 mmol, 88%) as 
colourless plates m.p. 161—162 °C. Rf 0.58 (95:5 CH2Cl2—MeOH); HPLC 
(Method B), R.t. 3.36 min, (98%); δH (500 MHz, DMSO-d6); 11.95 (1H, s, N-H), 
8.62 (1H, app. d, J = 4.8, Ar-H6′′), 7.81-8.00 (4H, m, Ar-H), 8.47 (1H, s, C-H1′′′), 
7.27-7.53 (6H, m, Ar-H), 7.16 (2H, d, J = 8.8, Ar-H3,5), 5.21 (2H, s, OCH2); δC 
(75 MHz, DMSO-d6); 162.6 (C=O), 161.2 (4-C), 153.3 (2′′-C), 149.5 (6′′-C), 
147.4 (1′′′-C), 136.8 (Ar-C), 136.6 (1′-C), 129.6 (Ar-C), 128.5 (Ar-C), 128.0 (Ar-
C), 127.8 (Ar-C), 125.3 (1-C), 124.3 (Ar-C), 119.8 (Ar-C), 114.6 (3-C, 5-C), 69.4 
(OCH2); vmax/cm
-1 (neat); 3454, 3180, 3064, 1653, 1602, 1471, 1281, 1247, 
1021, 738; m/z (ES) 354.1 (100%, MNa+); (Found MNa+, 354.1219. C20H17N3O2 




Prepared via general method D using 4-
(benzyloxy)benzohydrazide 6.106 (121 
mg, 0.5 mmol) and 3-
pyridinecarboxyaldehyde 6.33 (0.047 
mL, 0.5 mmol). Recrystallization from 
ethanol gave the title compound 6.56 (131 mg, 0.4 mmol, 79%) as colourless 
plates m.p. 210—211 °C. Rf 0.42 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 
3.34 min, (100%); δH (300 MHz, DMSO-d6); 11.93 (1H, s, N-H), 8.85 (1H, app. 
s, Ar-H2′′), 8.61 (1H, app. d, J = 4.2, Ar-H6′′), 8.49 (1H, s, C-H1′′′), 8.14 (1H, app. 
d, J = 7.5, Ar-H4′′), 7.92 (2H, d, J = 8.8, Ar-H2,6), 7.27-7.55 (6H, m, Ar-H), 7.16 
(2H, d, J = 8.8, Ar-H3,5), 5.21 (2H, s, OCH2); δC (75 MHz, DMSO-d6); 162.6 
(C=O), 161.1 (4-C), 150.6 (6′′-C), 148.6 (2′′-C), 144.3 (1′′′-C), 136.6 (1′-C), 133.3 
(4′′-C), 130.3 (3′′-C), 129.6 (2-C, 6-C), 128.5 (Ar-C), 128.0 (Ar-C), 127.8 (Ar-C), 
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125.4 (1-C), 124.0 (Ar-C), 114.6 (3-C, 5-C), 69.4 (OCH2); vmax/cm
-1 (neat); 3410, 
3190, 3010, 1660, 1605, 1508, 1216, 1177, 844; m/z (ES) 354.1 (100%, MNa+); 




Prepared via general method D using 4-
(benzyloxy)benzohydrazide 6.106 (121 
mg, 0.5 mmol) and 4-
pyridinecarboxyaldehyde 6.118 (0.047 
mL, 0.5 mmol). Recrystallization from 
methanol / water gave the title compound 6.57 (272 mg, 0.8 mmol, 82%) as 
colourless plates m.p. 203—204 °C. Rf 0.39 (95:5 CH2Cl2—MeOH); HPLC 
(Method B), R.t. 3.39 min, (100%); δH (300 MHz, DMSO-d6); 11.97 (1H, s, N-H), 
8.65 (2H, d, J = 4.5, Ar-H2′′,6′′), 8.43 (1H, s, C-H1′′′), 7.92 (2H, d, J = 8.9, Ar-H2,6), 
7.66 (2H, d, J = 4.5, Ar-H3′′,5′′), 7.31-7.53 (5H, m, Ar-H2′,3′,4′,5′,6′), 7.16 (2H, d, J = 
8.9, Ar-H3,5), 5.20 (2H, s, OCH2); δC (125 MHz, DMSO-d6); 162.8 (C=O), 161.3 
(4-C), 150.2 (2′′-C and 6′′-C), 144.6 (1′′-C), 141.6 (4′-C), 136.6 (1′-C), 129.7 (2-
C, 6-C), 128.5 (Ar-C), 128.0 (Ar-C), 127.8 (Ar-C), 125.3 (1-C), 120.9 (3′′-C and 
5′′-C), 114.6 (3-C, 5-C), 69.4 (OCH2); vmax/cm
-1 (neat); 3253, 3035, 1645, 1602, 
1487, 1247, 752; m/z (ES) 332.1 (100%, MH+); (Found MH+, 332.1386. 




Prepared via general method D using 3,4,5-
trimethoxybenzohydrazide 6.113 (679 mg, 3.0 
mmol) and 2-pyridinecarboxyaldehyde 6.117 
(0.360 mL, 3.0 mmol). Recrystallization from 
ethanol gave the title compound 6.58 (605 mg, 
1.9 mmol, 64%) as colourless plates m.p. 193—194 °C. Rf 0.68 (90:10 CH2Cl2—
MeOH); (Found: C, 60.7; H, 5.45; N, 13.5; C16H17N3O4 requires C, 60.9; H, 
5.43; N, 13.3%). HPLC (Method B), R.t. 1.77 min, (96%); δH (500 MHz, DMSO-
d6); 11.89 (1H, br s, N-H), 8.62 (1H, app. d, J = 4.7, Ar-H6′), 8.49 (1H, s, C-H1′′), 
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7.98 (1H, app. d, J = 7.8, Ar-H3′), 7.88 (1H, app. t, J = 7.8, Ar-H4′), 7.40-7.43 
(1H, m, Ar-H5′), 7.25 (2H, s, Ar-H2,6), 3.86 (6H, s, OCH3 in 3 and 5), 3.73 (3H, s, 
OCH3 in 4); δC (75 MHz, DMSO-d6); 162.6 (C=O), 153.3 (3-C, 5-C), 152.7 (2′-C), 
149.6 (1′′-C), 147.9 (6′-C), 140.6 (4-C), 136.9 (4′-C), 128.2 (1-C), 124.4 (5′-C), 
119.9 (3′-C), 105.4 (2-C, 6-C), 60.1 (OCH3 in 4), 56.1 (OCH3 in 3 and 5); 
vmax/cm
-1 (neat); 2940, 1860, 1680, 1582, 1548, 1499, 1323, 1215; m/z (ES) 
338.1 (100%, MNa+); (Found MNa+, 338.1104. C16H17N3O4 requires MNa, 




Prepared via general method D using 3,4,5-
trimethoxybenzohydrazide 6.113 (679 mg, 3.0 
mmol) and 3-pyridinecarboxyaldehyde 6.33 
(0.360 mL, 3.0 mmol). Recrystallization from 
ethanol gave the title compound 6.59 (681 mg, 
2.2 mmol, 72%) as colourless plates m.p. 195—196 °C. Rf 0.52 (90:10 CH2Cl2—
MeOH); HPLC (Method B), R.t. 1.50 min, (100%); δH (300 MHz, DMSO-d6); 
11.90 (1H, br s, N-H), 8.87 (1H, app. s, Ar-H2′), 8.63 (1H, dd, J = 4.7, 1.3, Ar-
H6′), 8.53 (1H, s, C-H1′′), 8.16 (1H, app. d, J = 7.9, Ar-H4′), 7.51 (1H, dd, J = 7.9, 
4.7, Ar-H5′), 7.25 (2H, s, Ar-H2,6), 3.87 (6H, s, OCH3 in 3,5), 3.73 (3H, s, OCH3 
in 4); δC (75 MHz, DMSO-d6); 162.6 (C=O), 152.7 (3-C, 5-C), 150.7 (6′-C), 148.7 
(2′-C), 144.9 (1′′-C), 140.5 (4-C), 133.4 (4′-C), 130.2 (3′-C), 128.3 (1-C), 124.0 
(5′-C), 105.2 (2-C, 6-C), 60.1 (OCH3 in 4), 56.1 (OCH3 in 3 and 5); vmax/cm
-1 
(neat); 3472, 3212, 2975, 1992, 1653, 1584, 1560, 1504, 1466, 1414; m/z (ES) 
316.1 (100%, MH+); (Found MH+, 316.1289. C16H17N3O4 requires MH, 




Prepared via general method D using 3,4-
methylendioxybenzhydrazide 6.114 (180 mg, 1.0 
mmol) and 3-pyridinecarboxyaldehyde 6.33 (0.120 
mL, 1.0 mmol). Recrystallization from ethanol 
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gave the title compound 6.60 (215 mg, 0.8 mmol, 80%) as colourless plates 
m.p. 196—197 °C. Rf 0.43 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 1.42 
min, (100%); δH (300 MHz, DMSO-d6); 11.84 (1H, s, N-H), 8.84 (1H, app. s, Ar-
H2′), 8.60 (1H, dd, J = 4.7, 1.4, Ar-H6′), 8.47 (1H, s, C-H1′′), 8.12 (1H, app. d, J = 
7.9, Ar-H4′), 7.53 (1H, dd, J = 8.1, 1.4, Ar-H6), 7.48 (1H, dd,  J = 7.9, 4.7, Ar-H5′), 
7.45 (1H, app. s, Ar-H2), 7.05 (1H, d, J = 8.1, Ar-H5), 6.12 (2H, s, OCH2O); δC 
(75 MHz, DMSO-d6); 162.2 (C=O), 150.6 (6′-C), 150.3 (3-C or 4-C), 148.6 (2′-
C), 147.4 (3-C or 4-C), 144.6 (1′′-C), 133.4 (4′-C), 130.3 (3′-C), 126.9 (1-C), 
124.0 (5′-C), 123.0 (6-C), 108.1 (5-C), 107.6 (2-C), 101.8 (OCH2O); vmax/cm
-1 
(neat); 3448, 3373, 3198, 3031, 1759, 1660, 1637, 1600, 1570, 1485, 1309, 
1262; m/z (ES) 270.1 (100%, MH+); (Found MH+, 270.0865. C14H11N3O3 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(150 mg, 0.33 mmol) and 5-nitrofuran-2-
carbaldehyde 6.134 (46.6 mg, 0.33 
mmol). Recrystallization from ethanol / 
water gave the title compound 6.61 (166 
mg, 0.29 mmol, 87%) as light yellow 
plates m.p. 229—230 °C. Rf 0.56 (95:5 CH2Cl2—MeOH); (Found: C, 68.9; H, 
4.75; N, 7.2; C33H27N3O7 requires C, 68.6; H, 4.71; N, 7.3%). HPLC (Method B), 
R.t. 4.13 min, (100%); δH (300 MHz, DMSO-d6); 12.13 (1H, s, N-H), 8.44 (1H, s, 
C-H1′′), 7.83 (1H, d, J = 3.9, Ar-H4′), 7.46-7.53 (4H, m, Ar-H), 7.33-7.45 (10H, m, 
Ar-H), 7.25-7.31 (4H, m, Ar-H), 5.22 (4H, s, OCH2 in 3 and 5), 5.04 (2H, s, 
OCH2 in 4); δC (125 MHz, DMSO-d6); 162.8 (C=O), 152.1 (3-C and 5-C), 151.9 
(5′-C or 2′-C), 151.7 (5′-C or 2′-C), 140.5 (4-C), 137.3 (1b-C), 136.7 (1a-C and 
1c-C), 135.5 (1′′-C), 128.44 (Ar-C), 128.40 (1-C), 128.2 (Ar-C), 128.1 (Ar-C), 
128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 115.4 (4′-C), 114.6 (3′-C), 107.2 (2-C 
and 6-C), 74.3 (OCH2 in 4), 70.6 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3140, 
3029, 1647, 1584, 1558, 1478, 1331, 1124, 732; m/z (ES) 600.2 (100%, MNa+); 





Prepared via general method D using 3,5-
bis(benzyloxy)benzohydrazide 6.109 (174 
mg, 0.50 mmol) and 4-
hydroxybenzaldehyde 6.120 (61 mg, 0.50 
mmol). Recrystallization from ethanol 
gave the title compound 6.62 (174 mg, 
0.38 mmol, 77%) as light yellow plates 
m.p. 171—172 °C. Rf 0.77 (100% EtOAc); 
HPLC (Method B), R.t. 3.51 min, (100%); δH (500 MHz, DMSO-d6); 11.54 (1H, 
s, N-H), 9.91 (1H, br s, O-H in 4′), 8.34 (1H, s, C-H1′′), 7.54 (2H, d, J = 8.6, Ar-
H2′,6′), 7.30-7.49 (10H, m, Ar-H), 7.15 (2H, d, J = 2.1, Ar-H2,6), 6.89 (1H, t, J = 
2.1, Ar-H4), 6.83 (2H, d, J = 8.6, Ar-H3′,5′), 5.15 (4H, s, OCH2 in 3 and 5); δC (125 
MHz, DMSO-d6); 172.0 (C=O), 162.2 (4′-C), 159.4 (3-C and 5-C), 148.3 (1′′-C), 
136.7 (1a-C), 135.6 (1-C), 128.8 (2′-C, 6′-C), 128.4 (Ar-C), 127.9 (Ar-C), 127.7 
(Ar-C), 125.2 (1′-C), 115.7 (3′-C, 5′-C), 106.6 (2-C and 6-C), 104.8 (4-C), 69.6 
(OCH2); vmax/cm
-1 (neat); 3649, 3231, 3063, 1649, 1589, 1495, 1438, 1275, 
1149, 694; m/z (ES) 475.2 (100%, MNa+); (Found MNa+, 475.1629. C28H24N2O4 




Prepared via general method D using 3,5-
bis(benzyloxy)benzohydrazide 6.109 (174 
mg, 0.50 mmol) and indole-3-
carboxyaldehyde 6.132 (72 mg, 0.50 mmol). 
Recrystallization from ethanol / water gave 
the title compound 6.63 (178 mg, 0.38 
mmol, 75%) as colourless plates m.p. 84 °C 
(dec). Rf 0.41 (95:5 CH2Cl2—MeOH); HPLC 
(Method B), R.t. 3.72 min, (100%); δH (500 
MHz, DMSO-d6); 11.57 (1H, s, N-H indole), 11.41 (1H, s, N-H hydrazide), 8.61 
(1H, s, C-H1′′), 8.28 (1H, app. d, J = 7.9, Ar-H4′), 7.80 (1H, d, J = 2.8, Ar-H2′), 
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7.27-7.50 (12H, m, Ar-H), 7.11-7.23 (3H, m, Ar-H), 6.88 (1H, t, J = 2.2, Ar-H4), 
5.16 (4H, s, OCH2 in 3 and 5); δC (125 MHz, DMSO-d6); 161.8 (C=O), 159.4 (3-
C and 5-C), 145.1 (1′′-C), 137.0 (7′a-C), 136.8 (1a-C), 136.1 (3′a-C), 130.3 (2′-
C), 128.5 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 124.3 (1-C), 122.6 (4′-C), 122.0 
(Ar-C), 120.4 (Ar-C), 111.8 (Ar-C), 111.7 (3′-C), 106.6 (Ar-C), 104.6 (4-C), 69.6 
(OCH2 in 3 and 5); vmax/cm
-1 (neat); 3408, 3224, 3033, 1643, 1589, 1300, 1154, 
741; m/z (ES) 498.2 (100%, MNa+); (Found MNa+, 498.1798. C30H25N3O3 
requires MNa, 498.1788).   
 
 (E)-4-(benzyloxy)-N'-(4-nitrobenzylidene)benzohydrazide (6.64)14 
 
Prepared via general method D using 
4-(benzyloxy)benzohydrazide 6.106 
(121 mg, 0.50 mmol) and 4-
nitrobenzaldehyde 6.131 (75.5 mg, 
0.50 mmol). Recrystallization from 
ethanol gave the title compound 6.64 (69.5 mg, 0.46 mmol, 92%) as yellow 
needles m.p. 232—233 °C (Lit.14 not available). Rf 0.28 (95:5 CH2Cl2—MeOH); 
HPLC (Method B), R.t. 3.30 min, (100%); δH (300 MHz, DMSO-d6); 12.06 (1H, 
s, N-H), 8.53 (1H, s, C-H1′′), 8.31 (2H, d, J = 8.3, Ar-H3′,5′), 7.99 (2H, d, J = 8.3, 
Ar-H2′,6′), 7.93 (2H, d, J = 8.8, Ar-H2,6), 7.30-7.52 (5H, m, Ar-H), 7.17 (2H, d, J = 
8.8, Ar-H3,5), 5.21 (2H, s, OCH2); δC (125 MHz, DMSO-d6); 162.7 (C=O), 161.2 
(4-C), 147.8 (4′-C), 145.3 (1′′-C), 140.8 (1′-C), 136.6 (1a-C), 129.7 (2-C, 6-C), 
128.7 (2′-C, 6′-C), 128.5 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 125.3 (1-C), 124.1 
(3′-C, 5′-C), 114.6 (3-C, 5-C), 69.4 (OCH2); vmax/cm
-1 (neat); 3255, 3065, 1650, 
1606, 1587, 1538, 1463, 1316, 1144, 741; m/z (ES) 398.1 (100%, MNa+); 




Prepared via general method D using 4-
(benzyloxy)benzohydrazide 6.106 (121 




(74.6 mg, 0.50 mmol). Recrystallization from ethanol gave the title compound 
6.65 (149 mg, 0.40 mmol, 80%) as light yellow needles m.p. 247—248 °C. Rf 
0.57 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 3.22 min, (100%); δH (300 
MHz, DMSO-d6); 11.45 (1H, s, N-H), 8.29 (1H, s, C-H1′′), 7.88 (2H, d, J = 8.8, 
Ar-H2,6), 7.27-7.61 (7H, m, Ar-H), 7.13 (2H, d, J = 8.8, Ar-H3,5), 6.76 (2H, d, J = 
8.8, Ar-H2′,6′), 5.20 (2H, s, OCH2), 2.97 (6H, s, CH3); δC (75 MHz, DMSO-d6); 
162.0 (C=O), 160.8 (4-C), 151.4 (1′-C), 148.0 (1′′-C), 136.6 (1a-C), 129.3 (2-C 
and 6-C), 128.4 (Ar-C), 128.3 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 126.0 (1-C), 
121.7 (4′-C), 114.4 (3-C, 5-C), 111.8 (2′-C and 6′-C), 69.3 (OCH2), 39.8 (NCH3); 
vmax/cm
-1 (neat); 3189, 3031, 1634, 1606, 1593, 1454, 1359, 1248, 1183, 658; 
m/z (ES) 396.2 (100%, MNa+); (Found MNa+, 396.1681. C23H23N3O2 requires 




Prepared via general method D using 4-
(benzyloxy)benzohydrazide 6.106 (121 mg, 
0.50 mmol) and indole-3-carboxyaldehyde 
6.132 (72 mg, 0.50 mmol). Recrystallization 
from ethanol gave the title compound 6.66 
(151 mg, 0.41 mmol, 82%) as colourless 
plates m.p. 216—217 °C. Rf 0.64 (92:8 
CH2Cl2—MeOH); HPLC (Method B), R.t. 3.07 min, (100%); δH (300 MHz, 
DMSO-d6); 11.59 (1H, s, N-H indole), 11.43 (1H, s, N-H hydrazide), 8.60 (1H, s, 
1′′-C), 8.30 (1H, app. d, J = 7.6, Ar-H4′), 7.91 (2H, d, J = 8.8, Ar-H2,6), 7.82 (1H, 
d, J = 2.6, Ar-H2′), 7.29-7.55 (6H, m, Ar-H), 7.11-7.23 (4H, m, Ar-H), 5.20 (2H, s, 
OCH2 in 4); δC (125 MHz, DMSO-d6); 162.0 (C=O), 160.7 (4-C), 144.4 (1′′-C), 
137.0 (7′a), 136.7 (1b-C), 130.0 (2′-C), 129.3 (2-C and 6-C), 128.5 (Ar-C), 127.9 
(Ar-C), 127.7 (4′-C), 126.3 (3′a), 124.4 (1-C), 122.6 (Ar-C), 122.0 (Ar-C), 120.3 
(Ar-C), 114.5 (Ar-C), 111.8 (3′-C), 111.7 (Ar-C), 69.4 (OCH2); vmax/cm
-1 (neat); 
3302, 3032, 1627, 1601, 1566, 1246, 1045, 744; m/z (ES) 392.1 (100%, MNa+); 







Prepared via general method D using 2-
naphthohydrazide 6.105 (100 mg, 0.54 
mmol) and 4-nitrobenzaldehyde 6.131 (82 
mg, 0.54 mmol). Recrystallization from 
ethanol gave the title compound 6.67 (140 mg, 0.44 mmol, 88%) as colourless 
plates m.p. 242—243 °C (Lit.19 m.p. 244—246 °C). Rf 0.38 (95:5 CH2Cl2—
MeOH); HPLC (Method B), R.t. 3.03 min, (100%); δH (500 MHz, DMSO-d6); 
12.24 (1H, s, N-H), 8.60 (1H, app. s, Ar-H1), 8.56 (1H, s, C-H1′′), 8.31 (2H, d, J = 
8.2, Ar-H3′,5′), 7.97-8.10 (6H, m, Ar-H3,4,5,8,2′,6′), 7.58-7.69 (2H, m, Ar-H6,7); δC 
(125 MHz, DMSO-d6); 163.5 (C=O), 147.9 (4′-C), 145.3 (1′′-C), 140.6 (1′-C), 
134.4 (Ar-Cqt), 132.0 (2-C), 130.3 (Ar-Cqt), 129.0 (Ar-C), 128.23 (Ar-C), 128.22 
(Ar-C), 128.0 (6-C or 7-C), 127.7 (Ar-C), 127.0 (6-C or 7-C), 124.27 (2′-C, 6′-C), 
124.26 (3′-C, 5′-C), 124.1 (Ar-C); vmax/cm
-1 (neat); 3491, 3423, 3047, 1645, 
1615, 1597, 1291, 1233, 696; m/z (ES) 342.1 (100%, MNa+); (Found MNa+, 




Prepared via general method D using 2-
naphthohydrazide 6.105 (93 mg, 0.50 mmol) 
and 4-(dimethylamino)benzaldehyde 6.130 
(75 mg, 0.50 mmol). Recrystallization from 
ethanol gave the title compound 6.68 (127 
mg, 0.40 mmol, 80%) as light yellow plates m.p. 212—213 °C. Rf 0.34 (5:95 
EtOAc—petroleum Ether); HPLC (Method B), R.t. 2.95 min, (100%); δH (500 
MHz, DMSO-d6); 11.70 (1H, s, N-H), 8.50 (1H, app. s, Ar-H1), 8.36 (1H, s, C-
H1′′), 7.92-8.09 (4H, m, Ar-H3,4,5,8), 7.58-7.66 (2H, m, Ar-H6,7), 7.56 (2H, d, J = 
8.8, Ar-H2′,6′),  6.77 (2H, d, J = 8.8, Ar-H3′,5′), 2.97 (6H, s, CH3); δC (125 MHz, 
DMSO-d6); 165.7 (C=O), 151.5 (4′-C), 148.7 (1′′-C), 134.2 (Ar-Cqt), 132.1 (2-C), 
131.1 (Ar-Cqt), 128.83 (Ar-C), 128.82 (Ar-C), 128.4 (2′-C, 6′-C), 128.0 (Ar-C), 
127.7 (Ar-C), 127.6 (Ar-C), 126.8 (Ar-C), 124.3 (Ar-C), 121.6 (1′-C), 111.8 (3′-C, 
5′-C), 40.3 (NCH3); vmax/cm
-1 (neat); 3340, 3213, 3046, 2962, 1640, 1627, 1590, 
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1550, 1323, 757; m/z (ES) 340.1 (100%, MNa+); (Found MNa+, 340.1423. 




Prepared via general method D using 2-
naphthohydrazide 6.105 (186 mg, 1.0 mmol) 
and indole-3-carboxyaldehyde 6.132 (145 
mg, 1.0 mmol). Recrystallization from 
ethanol gave the title compound 6.69 (241 mg, 0.77 mmol, 77%) as colourless 
needles m.p. 238—239 °C. Rf 0.47 (95:5 CH2Cl2—MeOH); HPLC (Method B), 
R.t. 2.76 min, (100%); δH (500 MHz, DMSO-d6); 11.67 (1H, s, N-H amide), 
11.58 (1H, s, N-H indole), 8.67 (1H, s, C-H1′′), 8.52 (1H, app. s, Ar-H1), 8.33 
(1H, app. d, J = 7.7, Ar-H4′), 7.97-8.10 (4H, m, Ar-H), 7.83 (1H, d, J = 2.7, Ar-
H2′), 7.57-7.68 (2H, m, Ar-H6,7), 7.45 (1H, d, J = 7.9, Ar-H), 7.13-7.25 (2H, m, 
Ar-H indole); δC (125 MHz, DMSO-d6); 162.5 (C=O), 145.0 (1′′-C), 137.0 (7′a-C), 
134.2 (2-C), 132.1 (Ar-Cqt), 131.9 (Ar-Cqt), 131.4 (3′a-C), 130.3 (2′-C), 128.8 (1-
C), 128.0 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 127.5 (Ar-C), 126.8 (Ar-C), 124.4 
(Ar-C), 122.6 (4′-C), 122.0 (Ar-C), 120.4 (Ar-C), 111.8 (Ar-C), 111.7 (3′-C); 
vmax/cm
-1 (neat); 3312, 3175, 2930, 1633, 1618, 1570, 1547, 1415, 1361, 1247, 
1146, 734; m/z (ES) 336.1 (100%, MNa+); (Found MNa+, 336.1119. C20H15N3O 
requires MNa, 336.1107).   
 
 (E)-3,4,5-tris(benzyloxy)-N'-(2-hydroxybenzylidene)benzohydrazide (6.70) 
 
Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(180 mg, 0.40 mmol) and 2-
hydroxybenzaldehyde 6.122 (0.03 mL, 
0.40 mmol). Recrystallization from ethanol 
gave the title compound 6.70 (165 mg, 
0.30 mmol, 74%) as creamy plates m.p. 
170—171 °C. Rf 0.39 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 1.16 min, 
(98%); δH (500 MHz, DMSO-d6); 11.94 (1H, s, N-H), 11.22 (1H, s, O-H), 8.66 
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(1H, s, C-H1′′), 7.56 (1H, dd, J = 7.7, 1.5, Ar-H6′), 7.47-7.50 (4H, m, Ar-H), 7.23-
7.44 (14H, m, Ar-H), 6.84-6.97 (2H, m, Ar-H hydroxybenzyl), 5.21 (4H, s, OCH2 
in 3 and 5), 5.03 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 162.1 (C=O), 
157.4 (2′-C), 152.1 (3-C and 5-C), 147.9 (1′′-C), 140.3 (4-C), 137.4 (1b-C), 
136.7 (1a-C and 1c-C), 131.4 (Ar-C), 129.2 (6′-C), 128.5 (1-C), 128.4 (Ar-C), 
128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 119.3 (Ar-
C hydroxybenzyl), 118.8 (1′-C), 116.4 (Ar-C hydroxybenzyl), 106.9 (2-C and 6-
C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3213, 3057, 
1638, 1621, 1606, 1577, 1533, 1422, 1370, 1077; m/z (ES) 581.2 (100%, 




Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (127 mg, 0.28 mmol) and 3-
hydroxybenzaldehyde 6.121 (34.1 
mg, 0.28 mmol). Recrystallization 
from ethanol gave the title compound 
6.71 (113 mg, 0.20 mmol, 72%) as 
colourless needles m.p. 167—168 °C. Rf 0.38 (95:5 CH2Cl2—MeOH); HPLC 
(Method B), R.t. 4.08 min, (100%); δH (500 MHz, DMSO-d6); 11.64 (1H, s, N-H), 
9.62 (1H, s, O-H), 8.38 (1H, s, C-H1′′), 7.46-7.50 (4H, m, Ar-H), 7.32-7.44 (10H, 
m, Ar-H), 7.22-7.30 (4H, m, Ar-H), 7.20 (1H, app. s, Ar-H2′), 7.10 (1H, app. d, J 
= 7.4, Ar-H6′), 6.83 (1H, app. dd, J = 7.4, 1.8, Ar-H4′), 5.20 (4H, s, OCH2 in 3 and 
5), 5.02 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 162.3 (C=O), 157.7 (3′-C), 
152.1 (3-C and 5-C), 147.8 (1′′-C), 140.1 (4-C), 137.4 (1b-C), 136.8 (1a-C and 
1c-C), 135.6 (1′-C), 129.9 (5′-C), 128.6 (1-C), 128.4 (Ar-C), 128.2 (Ar-C), 128.1 
(Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 118.8 (6′-C), 117.4 (4′-C), 
112.6 (2′-C), 106.9 (2-C and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); 
vmax/cm
-1 (neat); 3669, 3627, 3211, 3032, 1626, 1605, 1554, 1497, 1451, 1336, 
1221, 1118, 732; m/z (ES) 559.2 (100%, MH+); (Found MH+, 559.2237. 







Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (148 mg, 0.33 mmol) and 2,4-
dihydroxybenzaldehyde 6.123 (45.1 mg, 
0.33 mmol). A portion of the crude 
compound (60 mg out of 172mg) was 
purified via mass-directed preparative 
HPLC eluting with a gradient of methanol in water (50—95%) in presence of 
formic acid (0.1%) to give a solid which was recrystallized from water to give the 
title compound 6.72 (45 mg, 0.078 mmol, 75%) as colourless plates m.p. 135—
136 °C. Rf 0.37 (95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 4.03 min, 
(100%); δH (500 MHz, DMSO-d6); 11.74 (1H, s, N-H), 11.39 (1H, s, O-H in 4′), 
9.94 (1H, s, O-H in 2′), 8.51 (1H, s, C-H1′′), 7.47-7.50 (4H, m, Ar-H), 7.24-7.44 
(14H, m, Ar-H), 6.36 (1H, dd, J = 8.4, 2.3, Ar-H5′), 6.32 (1H, d, J = 2.3, Ar-H3′), 
5.20 (4H, s, OCH2 in 3 and 5), 5.02 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 
161.8 (C=O), 160.7 (4′-C), 159.4 (2′-C), 152.1 (3-C and 5-C), 148.9 (1′′-C), 
140.1 (4-C), 137.4 (1b-C), 136.8 (1a-C and 1c-C), 131.1 (Ar-C), 128.7 (1-C),  
128.4 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-
C), 110.6 (1′-C), 107.7 (5′-C), 106.9 (2-C and 6-C), 102.6 (3′-C), 74.3 (OCH2 in 
4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3578, 3422, 3210, 3231, 3031, 
1623, 1602, 1581, 1280, 1184, 1099; m/z (ES) 575.2 (100%, MH+); (Found 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(164 mg, 0.36 mmol) and 2-formylbenzoic 
acid 6.125 (54 mg, 0.36 mmol). 
Recrystallization from ethanol / water gave 
the title compound 6.73 (194 mg, 0.33 
mmol, 92%) as colourless plates m.p. 
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208—209 °C. Rf 0.29 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 4.00 min, 
(100%); δH (300 MHz, DMSO-d6); 13.39 (1H, br s, COOH), 11.97 (1H, s, N-H), 
9.21 (1H, s, C-H1′′), 8.08 (1H, app. d, J = 7.8, Ar-H6′), 7.92 (1H, app. d, J = 7.8, 
Ar-H3′), 7.67 (1H, app. t, J = 7.8, Ar-H4′ or Ar-H5′), 7.23-7.60 (18H, m, Ar-H), 5.22 
(4H, s, OCH2 in 3 and 5), 5.03 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 
168.1 (C=O carboxy), 162.6 (C=O hydrazono), 152.1 (3-C, 5-C), 146.4 (1′′-C), 
140.2 (4-C), 137.4 (1b-C), 136.8 (1a-C and 1c-C), 134.6 (2′-C), 132.0 (4′-C or 
5′-C), 130.6 (1′-C), 130.3 (3′-C), 129.6 (Ar-C), 128.44 (Ar-C), 128.43 (1-C), 
128.2 (Ar-C), 128.1 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 126.7 (6′-
C), 107.1 (2-C and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 
(neat); 3133, 3026, 1681, 1628, 1582, 1496, 1315, 1226, 1124, 693; m/z (ES) 
587.2 (100%, MH+); (Found MH+, 587.2169. C36H30N2O6 requires MH, 
587.2177).   
 
 (E)-3-((2(3,4,5-tris(benzyloxy)benzoyl)hydrazono)methyl)benzoic acid 
(6.74) 
 
Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (227 mg, 0.50 mmol) and 3-
formylbenzoic acid 6.124 (75 mg, 
0.50 mmol). Recrystallization from 
ethanol / water gave the title 
compound 6.74 (249 mg, 0.42 mmol, 
85%) as colourless fluffy solid m.p. 249—250 °C. Rf 0.52 (95:5 CH2Cl2—
MeOH); HPLC (Method B), R.t. 3.92 min, (100%); δH (300 MHz, DMSO-d6); 
13.23 (1H, br s, COOH), 11.87 (1H, s, N-H), 8.53 (1H, s, C-H1′′), 8.34 (1H, app. 
s, Ar-H2′), 8.00 (1H, app. d, J = 7.9, Ar-H4′ or Ar-H6′), 7.96 (1H, app. d, J = 7.9, 
Ar-H4′ or Ar-H6′), 7.61 (1H, app. t, J = 7.9, Ar-H5′), 7.20-7.54 (17H, m, Ar-H), 5.22 
(4H, s, OCH2 in 3 and 5), 5.03 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 
166.9 (C=O carboxy), 162.5 (C=O hydrazono), 152.1 (3-C, 5-C), 146.7 (1′′-C), 
140.2 (4-C), 137.4 (Ar-Cqt), 136.8 (Ar-Cqt), 134.8 (Ar-Cqt), 131.5 (Ar-C), 130.6 
(Ar-C), 129.2 (Ar-C), 128.7 (Ar-Cqt), 128.5 (Ar-Cqt), 128.4 (Ar-C), 128.2 (Ar-C), 
128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (2′-C), 127.2 (Ar-C), 107.0 (2-C 
and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3544, 
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3565, 3064, 1736, 1682, 1585, 1425, 1363, 1165; m/z (ES) 587.2 (100%, MH+); 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (198 mg, 0.44 mmol) and 4-
formylbenzoic acid 6.126 (65.5 mg, 
0.44 mmol). Recrystallization from 
ethanol / water gave the title 
compound 6.75 (235 mg, 0.40 mmol, 
91%) as colourless needles m.p. 
226—227 °C. Rf 0.38 (95:5 CH2Cl2—
MeOH); HPLC (Method B), R.t. 3.93 min, (100%); δH (500 MHz, DMSO-d6); 
13.06 (1H, br s, COOH), 11.86 (1H, s, N-H), 8.53 (1H, s, C-H1′′), 8.01 (2H, d, J = 
7.9, Ar-H2′,6′), 7.85 (2H, d, J = 7.9, Ar-H3′,5′), 7.46-7.50 (4H, m, Ar-H), 7.31-7.44 
(10H, m, Ar-H), 7.21-7.30 (3H, m, Ar-H), 5.21 (4H, s, OCH2 in 3 and 5), 5.03 
(2H, s, OCH2 in 4); δC (75 MHz, DMSO-d6); 166.9 (C=O carboxy), 162.6 (C=O 
amide), 152.1 (3-C and 5-C), 146.5 (1′′-C), 140.3 (4-C), 138.3 (1′-C), 137.4 (1b-
C), 136.8 (1a-C and 1c-C), 131.7 (4′-C), 129.8 (2′-C and 6′-C), 128.44 (Ar-C), 
128.37 (1-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-
C), 127.1 (3′-C and 5′-C), 107.0 (2-C and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 
3 and 5); vmax/cm
-1 (neat); 3512, 3031, 1694, 1581, 1552, 1499, 1423, 1331, 
1116, 639; m/z (ES) 587.2 (100%, MH+); (Found MH+, 587.2162. C36H30N2O6 
requires MH, 587.2177).   
 
(E)-2-((2-(2-naphthoyl)hydrazono)methyl)benzoic acid (6.76) 
 
Prepared via general method D using 2-
naphthohydrazide 6.105 (85 mg, 0.46 mmol) 
and 2-formylbenzoic acid 6.125 (69 mg, 0.46 
mmol). Recrystallization from methanol / water 
gave the title compound 6.76 (134 mg, 0.42 mmol, 92%) as colourless plates 
m.p. 213—214 °C. Rf 0.22 (95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 2.53 
min, (100%); δH (500 MHz, DMSO-d6); 13.38 (1H, br s, COOH), 12.23 (1H, s, N-
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H), 9.24 (1H, s, C-H1′′), 8.57 (1H, app. s, Ar-H1), 7.94-8.14 (5H, m, Ar-H), 7.91 
(1H, app. d, J = 7.5, Ar-H6′), 7.58-7.70 (3H, m, Ar-H), 7.53 (1H, app. t, J = 7.5, 
Ar-H5′); δC (125 MHz, DMSO-d6); 168.1 (C=O carboxy), 163.3 (C=O hydrazono), 
146.6 (1′′-C), 134.6 (Ar-Cqt), 134.4 (Ar-Cqt), 132.1 (Ar-Cqt), 132.0 (Ar-C), 130.7 
(Ar-Cqt), 130.6 (Ar-Cqt), 130.3 (6′-C), 129.6 (Ar-C), 128.9 (5′-C), 128.1 (1-C), 
128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 126.9 (Ar-C), 126.7 (Ar-C), 124.4 (Ar-
C); vmax/cm
-1 (neat); 3601, 3266, 3073, 1675, 1653, 1621, 1548, 1480, 1421, 
1362, 1241, 1145, 751; m/z (ES) 341.1 (100%, MNa+); (Found MNa+, 341.0899. 
C19H14N2O3 requires MNa, 341.0897).   
 
(E)-3-((2-(2-naphthoyl)hydrazono)methyl)benzoic acid (6.77) 
 
Prepared via general method D using 2-
naphthohydrazide 6.105 (186 mg, 1.0 mmol) 
and 3-formylbenzoic acid 6.124 (150 mg, 1.0 
mmol). Recrystallization from ethanol / water 
gave the title compound 6.77 (274 mg, 0.86 
mmol, 86%) as colourless plates m.p. 249—250 °C. Rf 0.16 (95:5 CH2Cl2—
MeOH); HPLC (Method B), R.t. 3.01 min, (100%); δH (300 MHz, DMSO-d6); 
13.24 (1H, br s, COOH), 12.19 (1H, s, N-H), 8.56 (1H, app. s, Ar-H2′), 8.55 (1H, 
s, C-H1′′), 8.36 (1H, app. s, Ar-H1), 7.97-8.11 (6H, m, Ar-H), 7.49-7.79 (3H, m, 
Ar-H); δC (125 MHz, DMSO-d6); 166.9 (C=O carboxy), 163.3 (C=O hydrazono), 
146.8 (1′′-C), 134.8 (Ar-Cqt), 134.4 (Ar-Cqt), 132.1 (Ar-Cqt), 131.5 (Ar-C), 131.4 
(Ar-Cqt), 130.60 (Ar-C), 130.57 (Ar-C), 129.2 (Ar-C), 128.9 (2′-C), 128.14 (1-C), 
128.08 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 127.4 (Ar-C), 126.9 (Ar-C), 124.3 (Ar-
C); vmax/cm
-1 (neat); 3208, 3054, 2837, 1801, 1685, 1643, 1548, 1269, 1064, 
689; m/z (ES) 341.1 (100%, MNa+); (Found MNa+, 341.0881. C19H14N2O3 









(E)-4-((2-(2-naphthoyl)hydrazono)methyl)benzoic acid (6.78)19 
 
Prepared via general method D using 2-
naphthohydrazide 6.105 (186 mg, 1.0 
mmol) and 4-formylbenzoic acid 6.126 
(150 mg, 1.0 mmol). Recrystallization from 
ethanol / water gave the title compound 
6.78 (290 mg, 0.91 mmol, 91%) as colourless plates m.p. >250 °C (Lit.19 m.p. 
150—151 °C). Rf 0.36 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 2.49 min, 
(100%); δH (300 MHz, DMSO-d6); 13.15 (1H, br s, COOH), 12.22 (1H, s, N-H), 
8.56 (2H, br s, Ar-H1, C-H1′′), 7.94-8.15 (6H, m, Ar-H), 7.87 (2H, d, J = 7.8, Ar-
H3′,5′), 7.57-7.73 (2H, m, Ar-H); δC (125 MHz, DMSO-d6); 166.9 (C=O carboxy), 
163.30 (C=O hydrazono), 146.6 (1′′-C), 138.4 (4′-C), 134.4 (Ar-Cqt), 132.0 (Ar-
Cqt), 131.7 (Ar-Cqt), 130.5 (Ar-Cqt), 129.8 (Ar-C), 128.9 (Ar-C), 128.2 (Ar-C), 
128.1 (Ar-C), 128.0 (Ar-C), 127.7 (Ar-C), 127.1 (3′-C, 5′-C), 126.9 (Ar-C), 124.3 
(Ar-C); vmax/cm
-1 (neat); 3206, 3042, 1828, 1677, 1504, 1385, 1239, 691; m/z 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(106 mg, 0.23 mmol) and 2-
formylbenzonitrile 6.128 (30.6 mg, 0.23 
mmol). Recrystallization from ethanol gave 
the title compound 6.79 (115 mg, 0.20 
mmol, 88%) as colourless needles m.p. 
177—178 °C. Rf 0.50 (95:5 CH2Cl2—
MeOH); HPLC (Method A), R.t. 4.38 min, (100%); δH (300 MHz, DMSO-d6); 
12.15 (1H, s, N-H), 8.85 (1H, s, C-H1′′), 8.16 (1H, app. d, J = 7.6, Ar-H6′), 7.94 
(1H, app. d, J = 7.6, Ar-H3′), 7.82 (1H, app. t, J = 7.6, Ar-H4′), 7.64 (1H, app. t, J 
= 7.6, Ar-H5′), 7.47-7.53 (4H, m, Ar-H), 7.33-7.45 (10H, m, Ar-H), 7.24-7.31 (3H, 
m, Ar-H), 5.23 (4H, s, OCH2 in 3 and 5), 5.04 (2H, s, OCH2 in 4); δC (125 MHz, 
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DMSO-d6); 162.5 (C=O), 152.1 (3-C and 5-C), 142.8 (1′′-C), 140.4 (4-C), 137.4 
(1b-C), 137.1 (1′-C), 136.8 (1a-C and 1c-C), 133.6 (5′-C), 133.4 (3′-C), 130.4 
(4′-C), 128.44 (Ar-C), 128.39 (1-C), 128.2 (Ar-C), 128.1 (6′-C), 128.0 (Ar-C), 
127.9 (Ar-C), 127.7 (Ar-C), 127.5 (Ar-C), 117.2 (CN), 110.8 (2′-C), 107.2 (2-C 
and 6-C), 74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3213, 
3058, 3025, 2223, 1645, 1582, 1539, 1453, 1336, 1134, 730; m/z (ES) 568.2 




Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (106 mg, 0.23 mmol) and 3-
formylbenzonitrile 6.127 (30.6 mg, 
0.23 mmol). Recrystallization from 
ethanol gave the title compound 6.80 
(119 mg, 0.21 mmol, 90%) as 
colourless needles m.p. 230—231 °C. Rf 0.43 (95:5 CH2Cl2—MeOH); HPLC 
(Method A), R.t. 4.22 min, (100%); δH (300 MHz, DMSO-d6); 11.97 (1H, s, N-H), 
8.51 (1H, s, C-H1′′), 8.15 (1H, app. s, Ar-H2′), 8.11 (1H, app. d, J = 7.9, Ar-H6′), 
7.92 (1H, app. d, J = 7.9, Ar-H4′), 7.69 (1H, app. t, J = 7.9, Ar-H5′), 7.46-7.50 
(4H, m, Ar-H), 7.32-7.46 (10H, m, Ar-H), 7.18-7.32 (3H, m, Ar-H), 5.22 (4H, s, 
OCH2 in 3 and 5), 5.03 (2H, s, OCH2 in 4); δC (125 MHz, DMSO-d6); 162.6 
(C=O), 152.1 (3-C and 5-C), 145.4 (1′′-C), 140.3 (4-C), 137.4 (1b-C), 136.8 (1a-
C and 1c-C), 135.7 (1′-C), 133.3 (4′-C), 131.0 (6′-C), 130.7 (2′-C), 130.1 (5′-C), 
128.4 (Ar-C), 128.3 (1-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-
C), 127.7 (Ar-C), 118.4 (CN), 112.0 (3′-C), 107.1 (2-C and 6-C), 74.3 (OCH2 in 
4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3171, 3062, 2230, 1684, 1644, 
1580, 1424, 1336, 1121, 736; m/z (ES) 568.2 (100%, MH+); (Found MH+, 









Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 
6.32 (167 mg, 0.37 mmol) and 4-
formylbenzonitrile 6.129 (48 mg, 0.37 
mmol). Recrystallization from ethanol 
gave the title compound 6.81 (183 
mg, 0.32 mmol, 87%) as colourless 
plates m.p. 223—224 °C. Rf 0.46 (95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 
4.22 min, (100%); δH (500 MHz, DMSO-d6); 11.94 (1H, s, N-H), 8.52 (1H, s, C-
H1′′), 7.92 (4H, app. br s, Ar-H2′,3′,5′.6′), 7.46-7.50 (4H, m, Ar-H), 7.32-7.44 (10H, 
m, Ar-H), 7.19-7.30 (3H, m, Ar-H), 5.20 (4H, s, OCH2 in 3 and 5), 5.03 (2H, s, 
OCH2 in 4); δC (125 MHz, DMSO-d6); 162.6 (C=O), 152.1 (3-C and 5-C), 145.7 
(1′′-C), 140.3 (4-C), 138.7 (4′-C), 137.3 (1b-C), 136.7 (1a-C and 1c-C), 132.8 
(2′-C and 6′-C), 128.5 (3′-C and 5′-C), 128.45 (Ar-C), 128.36 (1-C), 128.2 (Ar-C), 
128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 118.6 (CN), 111.9 (1′-C), 
107.0 (2-C and 6-C), 74.3 (OCH2 in 4), 70.4 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 
3655, 3203, 3027, 2223, 1645, 1582, 1539, 1453, 1336, 730; m/z (ES) 568.2 





Prepared via general method D using 
3,4,5-tris(benzyloxy)benzohydrazide 6.32 
(205 mg, 0.45 mmol) and 1H-pyrrole-2-
carbaldehyde 6.133 (42.9 mg, 0.5 mmol). 
Recrystallization from ethanol / water gave 
the title compound 6.82 (207 mg, 0.39 
mmol, 87%) as colourless plates m.p. 217 
°C (dec). Rf 0.32 (95:5 CH2Cl2—MeOH); (Found: C, 74.8; H, 5.55; N, 7.8; 
C33H29N3O4 requires C, 74.6; H, 5.50; N, 7.9%). HPLC (Method B), R.t. 4.12 
min, (100%); δH (500 MHz, DMSO-d6); 11.53 (1H, s, N-H pyrrole), 11.36 (1H, s, 
N-H amide), 8.29 (1H, s, C-H1′′), 7.46-7.50 (4H, m, Ar-H), 7.33-7.43 (10H, m, Ar-
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H), 7.24-7.30 (3H, m, Ar-H), 6.91 (1H, app. br s, Ar-H5′), 6.49 (1H, app. br s, Ar-
H3′), 6.14 (1H, dd, J = 5.2, 2.4, Ar-H4′), 5.20 (4H, s, OCH2 in 3 and 5), 5.01 (2H, 
s, OCH2 in 4); δC (125 MHz, DMSO-d6); 161.9 (C=O), 152.1 (3-C and 5-C), 
141.0 (1′′-C), 139.9 (4-C), 137.4 (1b-C), 136.8 (1a-C and 1c-C), 129.0 (1-C), 
128.4 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-
C), 126.9 (2′-C), 122.6 (5′-C), 113.4 (3′-C), 109.2 (4′-C), 106.8 (2-C and 6-C), 
74.3 (OCH2 in 4), 70.5 (OCH2 in 3 and 5); vmax/cm
-1 (neat); 3435, 3218, 1641, 
1606, 1579, 1553, 1454, 1305, 1115, 728; m/z (ES) 554.2 (100%, MNa+); 




Prepared via general method D using 2-
naphthohydrazide 6.105 (124 mg, 0.66 mmol) 
and 1H-pyrrole-2-carbaldehyde 6.133 (63.1 mg, 
0.66 mmol). Recrystallization from ethanol gave 
the title compound 6.83 (142 mg, 0.60 mmol, 91%) as light yellow plates m.p. 
243 °C (dec). Rf 0.33 (95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 2.59 min, 
(100%); δH (500 MHz, DMSO-d6); 11.66 (1H, s, N-H amide), 11.54 (1H, br s, N-
H pyrrole), 8.50 (1H, s, C-H1′′), 8.33 (1H, app. s, Ar-H1), 7.87-8.13 (4H, m, Ar-H 
naphthyl), 7.72-7.28 (2H, m, Ar-H4 naphthyl), 6.92 (1H, app. br s, Ar-H5′), 6.50 
(1H, app. br s, Ar-H3′), 6.15 (1H, dd, J = 5.2, 2.4, Ar-H4′); δC (75 MHz, DMSO-d6); 
162.6 (C=O), 140.8 (1-C), 134.2 (2-C), 132.1 (4a-C or 8a-C), 131.0 (4a-C or 8a-
C), 128.8 (Ar-C), 128.0 (Ar-C), 127.8 (Ar-C), 127.7 (1′′-C), 127.6 (Ar-C), 127.00 
(2′-C), 126.8 (Ar-C), 124.3 (Ar-C), 122.6 (5′-C), 113.4 (3′-C), 109.2 (4′-C); 
vmax/cm
-1 (neat); 3445, 3359, 3224, 3059, 1619, 1562, 1435, 1286, 724; m/z 
(ES) 264.1 (100%, MH+); (Found MH+, 264.1134. C16H13N3O requires MH, 












Prepared via general method D using 1-naphthohydrazide 
6.108 (127 mg, 0.68 mmol) and 3-pyridinecarboxyaldehyde 
6.33 (0.064 mL, 0.68 mmol). A portion of the crude 
compound (60 mg out of 182 mg) was purified via mass-
directed preparative HPLC eluting with a gradient of 
methanol in water (5—95%) in presence of formic acid 
(0.1%) to give a solid which was  recrystallized from ethanol 
to give the title compound 6.84 (52 mg, 0.19 mmol, 87%) as light yellow plates 
m.p. 221—222 °C. Rf 0.33 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 2.01 
min, (100%); δH (500 MHz, DMSO-d6); 12.16 (1H, s, N-H), 8.87 (1H, d, J = 1.6, 
Ar-H2′), 8.63 (1H, dd, J = 4.7 Hz, 1.6, Ar-H6′), 8.40 (1H, s, C-H1′′′), 8.19-8.24 (1H, 
m, Ar-H), 8.17 (1H, app. dt, J = 7.9, 1.6, Ar-H4′), 8.10 (1H, d, J = 8.3, Ar-H), 8.02 
(1H, dd, J = 6.5, 2.8, Ar-H), 7.76 (1H, d, J = 6.5, Ar-H), 7.56-7.64 (3H, m, Ar-H), 
7.50 (1H, dd, J = 7.9 Hz, 4.7, Ar-H5′); δC (75 MHz, DMSO-d6); 164.8 (C=O), 
150.8 (6′-C), 148.8 (2′-C), 145.0 (1′′′-C), 133.5 (4′-C), 133.2 (Ar-Cqt), 132.6 (Ar-
Cqt), 130.6 (Ar-C), 130.2 (3′-C), 130.0 (Ar-Cqt), 128.4 (Ar-C), 127.1 (Ar-C), 126.4 
(Ar-C), 126.0 (Ar-C), 125.1 (Ar-C), 125.0 (Ar-C), 124.0 (5′-C); vmax/cm
-1 (neat); 
3165, 3011, 1638, 1603, 1590, 1417, 1300, 698; m/z (ES) 276.1 (100%, MH+); 
(Found MH+, 276.1140. C17H13N3O requires MH, 276.1131).   
 
 (E)-N'-(pyridin-3-ylmethylene)quinoline-6-carbohydrazide (6.85) 
 
Prepared via general method D using quinoline-
6-carbohydrazide 6.107 (93.5 mg, 0.50 mmol) 
and 3-pyridinecarboxyaldehyde 6.33 (0.047 mL, 
0.50 mmol). Recrystallization from ethanol gave 
the title compound 6.85 (105 mg, 0.38 mmol, 76%) as colourless needles m.p. 
208—209 °C. Rf 0.40 (90:10 CH2Cl2—MeOH); HPLC (Method B), R.t. 1.29 min, 
(100%); δH (500 MHz, DMSO-d6); 12.24 (1H, s, N-H), 9.01 (1H, dd, J = 4.2, 1.7, 
Ar-H2), 8.89 (1H, app. s, Ar-H2′), 8.63 (1H, app. d, J = 4.3, Ar-H6′), 8.60 (1H, 
app. s, Ar-H5), 8.55 (1H, s, C-H1′′), 8.53 (1H, dd, J = 8.4, 1.7, Ar-H4), 8.08-8.29 
(3H, m, Ar-H4′, Ar-H7, Ar-H8), 7.64 (1H, dd, J = 8.2, 4.2, Ar-H3), 7.51 (1H, dd, J = 
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7.5, 4.3, Ar-H5′); δC (125 MHz, DMSO-d6); 162.8 (C=O), 152.4 (2-C), 150.8 (6′-
C), 148.8 (2′-C), 148.7 (8a-C), 145.4 (1′′-C), 137.1 (4-C), 133.5 (4′-C), 131.0 (Ar-
Cqt), 130.2 (5-C), 129.3 (3′-C), 128.6 (7-C or 8-C), 127.9 (7-C or 8-C), 127.1 (Ar-
Cqt), 124.0 (5′-C), 122.4 (3-C); vmax/cm
-1 (neat); 3451, 3165, 3011, 1675, 
1621,1591, 1568, 1327, 701; m/z (ES) 277.1 (100%, MH+); (Found MH+, 




Prepared via general method D using 
quinoxaline-6-carbohydrazide 6.115 (103 mg, 
0.55 mmol) and 3-pyridinecarboxyaldehyde 6.33 
(0.05 mL, 0.55 mmol). A portion of the crude 
compound (50 mg out of 89 mg) was purified via mass-directed preparative 
HPLC eluting with a gradient of methanol in water (5—95%) in presence of 
formic acid (0.1%) to give a solid which was recrystallized from ethanol to give 
the title compound 6.86 (40 mg, 0.18 mmol, 80%) as colourless plates m.p. 
106—107 °C. Rf 0.18 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 1.35 min, 
(100%); δH (500 MHz, DMSO-d6); 12.37 (1H, s, N-H), 9.02-9.10 (2H, m, Ar-
H2,3), 8.90 (1H, app. s, Ar-H2′), 8.72 (1H, d, J = 1.6, Ar-H5), 8.63 (1H, app. d, J = 
4.7, Ar-H6′), 8.58 (1H, s, C-H1′′′), 8.33 (1H, dd, J = 8.7, 1.6, Ar-H7), 8.24 (1H, d, J 
= 8.7, Ar-H8), 8.18 (1H, app. d, J = 7.8, Ar-H4′), 7.51 (1H, dd, J = 7.8, 4.7, Ar-
H5′); δC (125 MHz, DMSO-d6); 162.2 (C=O), 150.9 (6′-C), 148.9 (2′-C), 147.3 (2-
C or 3-C), 146.9 (2-C or 3-C), 145.8 (1′′′-C), 143.6 (4a-C), 141.5 (8a-C), 134.3 
(6-C), 133.6 (4′-C), 130.1 (3′-C), 129.6 (8-C), 128.8 (7-C), 128.7 (5-C), 124.0 
(5′-C); vmax/cm
-1 (neat); 3506, 3208, 3010, 1731, 1446, 1369, 1209; m/z (EI) 











 (E)-N'-(pyridin-3-yl-methylene)-1H-indole-3-carbohydrazide (6.87) 
 
Prepared via general method D using 1H-indole-3-
carbohydrazide 6.116 (175 mg, 1.0 mmol) and 3-
pyridinecarboxyaldehyde 6.33 (0.094 mL, 1.0 mmol). 
Recrystallization from ethanol gave the title compound 
6.87 (196 mg, 0.74 mmol, 74%) as colourless needles 
m.p. 248 °C (dec.). Rf 0.37 (95:5 CH2Cl2—MeOH); 
HPLC (Method B), R.t. 2.04 min, (100%); δH (500 MHz, 
DMSO-d6); 12.05 (1H, s, N-H amide), 11.82 (1H, s, N-H indole), 8.89 (1H, app. 
s, Ar-H2′), 8.61 (1H, dd, J = 4.8, 1.6, Ar-H6′), 8.51 (1H, s, 1′′-C), 8.16 (1H, app. d, 
J = 7.8, Ar-H4′), 7.68 (1H, app. d, J = 7.8, Ar-H5′), 7.42-7.54 (2H, m, Ar-H), 7.34 
(1H, s, Ar-H2), 7.22 (1H, m, Ar-H), 7.07 (1H, m, Ar-H); δC (125 MHz, DMSO-d6); 
157.8 (C=O), 150.6 (6′-C), 148.7 (2′-C), 144.3 (1′′-C), 136.9 (Ar-Cqt), 133.5 (4′-
C), 130.3 (3′-C), 129.8 (Ar-Cqt), 127.0 (3-C), 124.0 (Ar-C), 123.99 (Ar-C), 121.8 
(5′-C), 120.00 (Ar-C), 112.4 (Ar-C), 103.9 (2-C); vmax/cm
-1 (neat); 3279, 3048, 
1650, 1606, 1577, 1354, 1227, 745; m/z (ES) 265.1 (100%, MH+); (Found MH+, 
265.1074. C15H12N4O requires MH, 265.1084).  
  
 (E)-N'-(pyridin-3-ylmethylene)-1H-indole-5-carbohydrazide (6.88) 
                                                                  
Prepared via general method D using 1H-indole-
5-carbohydrazide 6.103 (175 mg, 1.0 mmol) and 
3-pyridinecarboxyaldehyde 6.33 (0.094 mL, 1.0 
mmol). Recrystallization from ethanol gave the 
title compound 6.88 (204 mg, 0.77 mmol, 77%) as light brown plates m.p. 151—
152 °C. Rf 0.32 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 1.55 min, 
(100%); δH (500 MHz, DMSO-d6); 11.90 (1H, s, N-H amide), 11.40 (1H, s, N-H 
indole), 8.84 (1H, d, J = 1.1, Ar-H2′), 8.59 (1H, dd, J = 4.7, 1.6, Ar-H6′), 8.51 (1H, 
s, 1′′-C), 8.22 (1H, app. s, Ar-H4), 8.13 (1H, app. d, J = 7.3, Ar-H4′), 7.70 (1H, 
dd, J = 8.5, 1.6, Ar-H6), 7.45-7.51 (3H, m, Ar-H2,7,5′), 6.57-6.59 (1H, m, Ar-H3); 
δC (125 MHz, DMSO-d6); 164.3 (C=O), 150.4 (6′-C), 148.6 (2′-C), 143.7 (1′′-C), 
137.7 (Ar-Cqt), 133.3 (4′-C), 130.5 (Ar-Cqt), 127.01 (Ar-Cqt), 126.97 (2-C or 7-C 
or 5′-C), 123.97 (2-C or 7-C or 5′-C), 123.95 (Ar-Cqt), 120.9 (6-C), 120.5 (4-C), 
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111.2 (2-C or 7-C or 5′-C), 102.2 (3-C); vmax/cm
-1 (neat); 3177, 3033, 1648, 
1592, 1553, 1414, 1293, 1188, 700; m/z (ES) 265.1 (100%, MH+); (Found MH+, 




Prepared via general method D using 1H-indole-
6-carbohydrazide 6.104 (88 mg, 0.50 mmol) and 
3-pyridinecarboxyaldehyde 6.33 (0.047 mL, 0.50 
mmol). Recrystallization from ethanol gave the 
title compound 6.89 (108 mg, 0.41 mmol, 82%) as light pink plates m.p. 118 °C 
(dec). Rf 0.17 (95:5 CH2Cl2—MeOH); HPLC (Method B), R.t. 1.55 min, (100%); 
δH (500 MHz, DMSO-d6); 11.94 (1H, s, N-H amide), 11.46 (1H, s, N-H indole), 
8.85 (1H, d, J = 1.4, Ar-H2′), 8.60 (1H, dd, J = 4.7, 1.4, Ar-H6′), 8.52 (1H, s, C-
H1′′′), 8.13 (1H, app. d, J = 8.3, Ar-H4′), 8.04 (1H, app. s, Ar-H7), 7.59-7.65 (2H, 
m, Ar-H4,5′), 7.55 (1H, app. t, J = 2.8, Ar-H2), 7.48 (1H, dd, J = 7.9, 4.8, Ar-H5), 
6.52 (1H, m, Ar-H3); δC (125 MHz, DMSO-d6); 164.5 (C=O), 150.5 (6′-C), 148.6 
(2′-C), 144.0 (1′′′-C), 135.1 (7a-C ), 133.3 (4′-C), 130.5 (6-C), 130.3 (3′-C), 
128.52 (2-C), 125.7 (3a-C), 124.0 (5′-C), 119.6 (4-C), 118.3 (5-C), 111.8 (7-C), 
101.4 (3-C); vmax/cm
-1 (neat); 3400, 3160, 3056, 1642, 1610, 1556, 1306, 1267, 
696; m/z (ES) 287.1 (100%, MNa+); (Found MNa+, 287.0904. C15H12N4O 




Prepared via general method D using 3-
morpholinobenzohydrazide 6.110 (75 mg, 
0.34 mmol) and 3-pyridinecarboxyaldehyde 
6.33 (0.32 mL, 0.34 mmol). Recrystallization 
from ether gave the title compound 6.90a (90 mg, 0.29 mmol, 85%) as light 
yellow plates m.p. 183—184 °C. Rf 0.13 (95:5 CH2Cl2—MeOH); HPLC (Method 
B), R.t. 1.61 min, (100%); δH (500 MHz, DMSO-d6); 11.88 (1H, s, N-H), 8.84 
(1H, app. s, Ar-H2a), 8.61 (1H, app. d, J = 4.8, Ar-H6a), 8.50 (1H, s, C-H1′′′), 8.13 
(1H, app. d, J = 7.6, Ar-H4a), 7.48 (1H, dd, J = 7.6, 4.8, Ar-H5a), 7.29-7.42 (3H, 
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m, Ar-H2,5,6), 7.17 (1H, app. d, J = 7.0, Ar-H4), 3.76 (4H, t, J = 5.0, CH2 in 2′ and 
3′), 3.18 (4H, t, J = 5.0, CH2 in 1′ and 4′); δC (125 MHz, DMSO-d6); 163.6 (C=O), 
151.0 (3-C), 150.7 (6a-C), 148.7 (2a-C), 144.9 (1′′′-C), 134.0 (1-C), 133.4 (4a-
C), 130.3 (3a-C), 129.14 (2-C or 5-C or 6-C), 124.0 (5a-C), 118.4 (4-C), 118.3 
(2-C or 5-C or 6-C), 113.9 (2-C or 5-C or 6-C), 66.0 (2′-C and 3′-C), 48.2 (1′-C 
and 4′-C); vmax/cm
-1 (neat); 3461, 3220, 3068, 1668, 1607, 1554, 1271, 1114, 
691; m/z (ES) 311.2 (100%, MH+); (Found MH+, 311.1507. C17H18N4O2 requires 




Prepared via general method D using 4-(1H-
imidazol-1-yl)benzohydrazide 6.111 (96 mg, 
0.47 mmol) and 3-pyridinecarboxyaldehyde 
6.33 (0.044 mL, 0.47 mmol). Recrystallization 
from ethanol gave the title compound 6.91a 
(116 mg, 0.40 mmol, 85%) as colourless needles m.p. 196—197 °C. Rf 0.30 
(95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 1.18 min, (100%); δH (500 MHz, 
DMSO-d6); 12.07 (1H, s, N-H), 8.87 (1H, app. s, Ar-H2a), 8.62 (1H, app. d, J = 
4.7, Ar-H6a), 8.53 (1H, s, C-H1′′′), 8.41 (1H, app. s, Ar-H5′), 8.15 (1H, app. d, J = 
7.6, Ar-H4a), 8.07 (2H, d, J = 8.3, Ar-H3,5), 7.88 (1H, t, J = 1.3, Ar-H2′), 7.86 (2H, 
d, J = 8.3, Ar-H2,6), 7.49 (1H, dd, J = 7.6, 4.7, Ar-H5a), 7.11-7.18 (1H, m, Ar-H4′); 
δC (125 MHz, DMSO-d6); 162.2 (C=O), 150.8 (6a-C), 148.8 (2a-C), 145.2 (1′′′-
C), 139.4 (4-C), 135.6 (5′-C), 133.5 (4a-C), 131.1 (1-C), 130.3 (4′-C), 130.2 (3a-
C), 129.5 (3-C and 5-C), 124.0 (5a-C), 119.7 (2-C and 6-C), 117.8 (2′-C); 
vmax/cm
-1 (neat); 3451, 3240, 3090, 1652, 1513, 1426, 1367, 1105, 967; m/z 
(ES) 292.1 (100%, MH+); (Found MH+, 292.1203. C16H13N5O requires MH, 









Methyl 3,5-bis(benzyloxy)benzoate (6.93)20  
 
Potassium carbonate (2073 mg, 15 mmol) and 
benzyl bromide (1.55 mL, 13 mmol) were added to 
a solution of 3,5-trihydroxybenzoate methyl ester 
6.92 (1684 mg, 10 mmol) in acetone (30 mL). This 
reaction mixture was stirred at reflux for twenty-
four hours and then poured into water (90 mL). The 
mixture was extracted with EtOAc (4 x 60 mL). The organic layer was dried over 
MgSO4 and concentrated under reduced pressure. The light brown solid was 
purified using column chromatography on silica gel eluting with petroleum ether 
/ ethylacetate (8:2) and recrystallized from hexane to give the title compound 
6.93 (3100 mg, 8.9 mmol, 89%) as colourless plates m.p. 58—60 °C (Lit.20 m.p. 
69.2 °C). Rf 0.56 (1:1 petroleum ether—EtOAc); HPLC (Method A), R.t. 1.28 
min, (100%); δH (300 MHz, DMSO-d6); 7.26-7.50 (10H, m, Ar-H), 7.17 (2H, d, J 
= 2.3, Ar-H2,6), 6.97 (1H, t, J = 2.3, Ar-H4), 5.15 (4H, s, OCH2 in 3 and 5), 3.84 
(2H, s, OCH3); δC (75 MHz, DMSO-d6); 165.8 (C=O), 159.5 (3-C and 5-C), 136.6 
(1′-C), 131.6 (1-C), 128.4 (Ar-C), 127.9 (Ar-C), 127.6 (Ar-C), 107.9 (2-C, 6-C), 
106.9 (4-C), 69.5 (OCH2), 52.3 (OCH3); vmax/cm
-1 (neat); 2947, 1711, 1498, 
1377, 1351, 1235, 1105, 1044, 729; m/z (ES) 371.1 (100%, MNa+); (Found 




Prepared via general method C using  methyl 1H-indole-
5-carboxylate 6.94 (521 mg, 3.0 mmol) and hydrazine 
hydrate (1.44 mL, 30 mmol). Recrystallization from 
ethanol / water gave the title compound 6.103 (468 mg, 
2.7 mmol, 89%) as colourless needles m.p. 173—175 °C (Lit.21 m.p. 173—177 
°C). Rf 0.52 (90:10 CH2Cl2—MeOH); HPLC (Method B), R.t. 0.80 min, (96%); δH 
(300 MHz, DMSO-d6); 11.33 (1H, s, N-H indole), 9.59 (1H, s, N-H amide), 8.09 
(1H, app. s, Ar-H4), 7.60 (1H, dd, J = 8.5, 1.6, Ar-H6), 7.38-7.42 (2H, m, Ar-H2,7), 
6.50-6.52 (1H, m, Ar-H3), 4.54 (2H, br s, NH2); δC (75 MHz, DMSO-d6); 167.3 
(C=O), 137.3 (5-C), 127.0 (7a-C), 126.6 (2-C or 7-C), 124.2 (3a-C), 120.2 (6-C), 
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119.6 (4-C), 110.9 (2-C or 7-C), 102.0 (3-C); vmax/cm
-1 (neat); 3296, 3213, 3028, 
1635, 1614, 1583, 1466, 1327, 755; m/z (ES) 198.1 (100%, MNa+); (Found 




Prepared via general method C using methyl 1H-indole-
6-carboxylate 6.95 (800 mg, 4.6 mmol) and hydrazine 
hydrate (4.50 mL, 91 mmol). Recrystallization from 
ethanol gave the title compound 6.104 (713 mg, 4.1 mmol, 89%) as light yellow 
needles m.p. 190—191 °C (Lit.21 Not available). Rf 0.46 (90:10 CH2Cl2—
MeOH); HPLC (Method A), R.t. 1.06 min, (100%); δH (300 MHz, DMSO-d6); 
11.40 (1H, s, N-H indole), 9.66 (1H, s, N-H amide), 7.92 (1H, app. s, Ar-H7), 
7.55 (1H, app. d, J = 8.3, Ar-H4), 7.47-7.51 (2H, m, Ar-H2,5), 6.49-6.55 (1H, m, 
Ar-H3), 4.45 (2H, s, NH2); δC (125 MHz, DMSO-d6); 167.1 (C=O), 135.2 (7a-C), 
129.7 (6-C), 127.8 (2-C), 126.1 (3a-C), 119.4 (4-C), 117.6 (5-C), 110.9 (7-C), 
101.2 (3-C); vmax/cm
-1 (neat); 3310, 3116, 3035, 1625, 1566, 1455, 1320, 1274, 
1106, 731; m/z (ES) 198.1 (100%, MNa+); (Found MNa+, 198.0633. C9H9N3O 






Prepared via general method C using methyl-2-
naphthoate 6.96 (1 g, 5.37 mmol) and hydrazine hydrate 
(6 mL, 123 mmol). Recrystallization from methanol gave 
the title compound 6.105 (0.9 g, 5.0 mmol, 93%) as 
colourless plates m.p. 146—148 °C (Lit.22 m.p. 147—152 °C). Rf 0.36 (95:5 
CH2Cl2—MeOH); HPLC (Method A), R.t. 1.68 min, (100%); δH (500 MHz, 
DMSO-d6); 9.95 (1H, s, N-H), 8.44 (1H, app. s, Ar-H1), 7.96-8.04 (3H, m, Ar-
H4,5,8), 7.92 (1H, dd, J = 8.6, 1.6, Ar-H3), 7.58-7.69 (2H, m, Ar-H6,7), 4.68 (2H, br 
s, NH2); δC (75 MHz, DMSO-d6); 165.8 (C=O), 134.0 (Ar-Cqt), 132.1 (2-C), 130.6 
(Ar-Cqt), 128.8 (4-C or 5-C or 8-C), 127.8 (6-C or 7-C), 127.6 (4-C or 5-C or 8-
C), 127.5 (1-C), 127.2 (6-C or 7-C), 126.7 (4-C or 5-C or 8-C), 123.8 (3-C); 
vmax/cm
-1 (neat); 3311, 3177, 3036, 1650, 1571, 1506, 1267, 724; m/z (ES) 
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209.1 (100%, MNa+); (Found MNa+, 209.0690. C11H10N2O requires MNa, 




Prepared via general method C using methyl-4-
benzyloxybenzoate 6.97 (2000 mg, 8.25 mmol) 
and hydrazine hydrate (10 mL, 206 mmol). 
Recrystallization from ethanol gave the title 
compound 6.106 (1879 mg, 7.76 mmol, 94%) as 
colourless needles m.p. 139—140 °C (Lit.23 m.p. 140). Rf 0.42 (95:5 CH2Cl2—
MeOH); HPLC (Method B), R.t. 2.87 min, (100%); δH (300 MHz, DMSO-d6); 
9.63 (1H, s, N-H), 7.80 (2H, d, J = 8.9, Ar-H2,6), 7.27-7.52 (5H, m, Ar-H2′,3′,4′,5′,6′), 
7.06 (2H, d, J = 8.9, Ar-H3,5), 5.16 (2H, s, OCH2), 4.44 (2H, br s, NH2); δC (75 
MHz, DMSO-d6); 165.5 (C=O), 160.4 (4-C), 136.7 (1′-C), 128.7 (2-C, 6-C), 
128.4 (Ar-C), 127.9 (Ar-C), 127.8 (Ar-C), 125.6 (1-C), 114.3 (3-C, 5-C), 69.2 
(OCH2); vmax/cm
-1 (neat); 3285, 3193, 1597, 1571, 1531, 1503, 1245, 1223, 834, 
652; m/z (ES) 265.1 (100%, MNa+); (Found MNa+, 265.0943. C14H14N2O2 




Prepared via general method C using methyl quinoline-
6-carboxylate 6.98 (700 mg, 3.74 mmol) and hydrazine 
hydrate (3.70 mL, 74.8 mmol). Recrystallization from 
ethanol gave the title compound 6.107 (595 mg, 3.18 
mmol, 85%) as colourless plates m.p. 192—194 °C (Lit.24 m.p. 193—194 °C). Rf 
0.40 (90:10 CH2Cl2—MeOH); HPLC (Method B), R.t. 0.72 min, (100%); δH (500 
MHz, DMSO-d6); 10.04 (1H, s, N-H), 8.98 (1H, dd, J = 4.2, 1.7, Ar-H2), 8.44-
8.50 (2H, m, Ar-H4 and Ar-H5), 8.15 (1H, dd, J = 8.8, 1.9, Ar-H7), 8.06 (1H, d, J 
= 8.8, Ar-H8), 7.61 (1H, dd, J = 8.3, 4.2, Ar-H3), 4.77 (2H, br s, NH2); δC (125 
MHz, DMSO-d6); 165.3 (C=O), 151.9 (2-C), 148.6 (8a-C), 137.0 (4-C or 5-C), 
131.1 (Ar-Cqt), 129.0 (8-C), 127.7 (4-C or 5-C), 127.4 (7-C), 127.1 (Ar-Cqt), 
122.1 (3-C); vmax/cm
-1 (neat); 3310, 3116, 3035, 1625, 1566, 1528, 1455, 1320, 
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1334, 731; m/z (ES) 188.1 (100%, MH+); (Found MH+, 188.0826. C10H9N3O 
requires MH, 188.0818).   
 
1-naphthohydrazide (6.108)25  
 
Prepared via general method C using ethyl 1-naphthoate 6.99 
(0.20 mL, 1.10 mmol) and hydrazine hydrate (1.1 mL, 22.0 
mmol). Recrystallization from ethanol gave the title compound 
6.108 (197 mg, 1.06 mmol, 96%) as colourless plates m.p. 159—
160 °C (Lit.25 m.p. 160—163 °C). Rf 0.78 (90:10 CH2Cl2—MeOH); HPLC 
(Method B), R.t. 1.44 min, (100%); δH (500 MHz, DMSO-d6); 9.71 (1H, s, N-H), 
8.19-8.24 (1H, m, Ar-H), 8.02 (1H, d, J = 7.4, Ar-H), 7.96-8.00 (1H, m, Ar-H), 
7.51-7.60 (4H, m, Ar-H), 4.61 (2H, br s, NH2); δC (125 MHz, DMSO-d6); 167.9 
(C=O), 133.3 (Ar-Cqt), 133.1 (Ar-Cqt), 130.0 (Ar-Cqt), 129.8 (Ar-C), 128.2 (Ar-C), 
126.6 (Ar-C), 126.2 (Ar-C), 125.4 (Ar-C), 125.3 (Ar-C), 125.0 (Ar-C); vmax/cm
-1 
(neat); 3274, 3046, 1644, 1608, 1588, 1515, 1208, 939, 734; m/z (ES) 209.1 
(100%, MNa+); (Found MNa+, 209.0691. C11H10N2O requires MNa, 209.0685).   
 
3,5-bis(benzyloxy)benzohydrazide (6.109)13  
 
Prepared via general method C using methyl 3,5-
bis(benzyloxy)benzoate 6.100 (3.0 g, 8.6 mmol) 
and hydrazine hydrate (8.0 mL, 172 mmol). 
Recrystallization from ethanol gave the title 
compound 6.109 (2.8 g, 8.0 mmol, 93%) as 
colourless plates m.p. 118—119 °C (Lit.13 not 
available). Rf 0.40 (95:5 CH2Cl2—MeOH); HPLC (Method A), R.t. 2.70 min, 
(100%); δH (300 MHz, DMSO-d6); 9.75 (1H, s, N-H), 7.28-7.51 (10H, m, Ar-H), 
7.09 (2H, d, J = 2.2, Ar-H2,6), 6.81 (1H, t, J = 2.2, Ar-H4), 5.13 (4H, s, OCH2 in 3 
and 5), 4.51 (2H, br s, NH2); δC (75 MHz, DMSO-d6); 165.2 (C=O), 159.3 (3-C 
and 5-C), 136.8 (1′-C), 135.3 (1-C), 128.4 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-C), 
105.9 (2-C and 6-C), 104.6 (4-C), 69.4 (OCH2); vmax/cm
-1 (neat); 3276, 3031, 
1625, 1453, 1353, 1162, 1058, 693; m/z (ES) 371.1 (100%, MNa+); (Found 





Prepared via general method C using methyl 3-
morpholinobenzoate 6.101 (256 mg, 1.16 mmol) and 
hydrazine hydrate (0.56 mL, 11.6 mmol). 
Recrystallization from ethanol gave the title 
compound 6.110 (239 mg, 1.08 mmol, 93%) as light yellow needles m.p. 109—
110 °C (Lit.26 not available). Rf 0.22 (90:10 CH2Cl2—MeOH); HPLC (Method B), 
R.t. 1.08 min, (95%); δH (300 MHz, DMSO-d6); 9.63 (1H, s, N-H), 7.13-7.32 (3H, 
m, Ar-H2,5,6), 6.96-7.03 (1H, m, Ar-H4), 4.42 (2H, br s, NH2), 3.66 (4H, t, J = 5.5, 
CH2 in 2′ and 3′), 3.05 (4H, t, J = 5.5, CH2 in 1′ and 4′); δC (75 MHz, DMSO-d6); 
166.1 (C=O), 150.9 (3-C), 134.0 (1-C), 128.9 (Ar-C), 117.7 (Ar-C), 117.6 (Ar-C), 
113.2 (Ar-C), 66.0 (2′-C and 3′-C), 48.2 (1′-C and 4′-C); vmax/cm
-1 (neat); 3305, 
3200, 2835, 1668, 1623 1597, 1574, 1516, 1487, 1240, 1121, 926; m/z (ES) 
222.1 (100%, MH+); (Found MH+, 222.1235. C11H15N3O2 requires MH, 




Prepared via general method C using methyl 4-(1H-
imidazol-1-yl)benzoate 6.102 (323 mg, 1.6 mmol) and 
hydrazine hydrate (0.82 mL, 16 mmol). 
Recrystallization from ethanol gave the title compound 
6.111 (303 mg, 1.5 mmol, 95%) as colourless needles m.p. 225—227 °C (Lit.27 
m.p. 223—225 °C). Rf 0.16 (90:10 CH2Cl2—MeOH); HPLC (Method A), R.t. 0.65 
min, (100%); δH (500 MHz, DMSO-d6); 9.85 (1H, s, N-H), 8.36 (1H, app. s, Ar-
H5′), 7.95 (2H, d, J = 8.7, Ar-H3,5), 7.83 (1H, t, J = 1.1, Ar-H2′), 7.75 (2H, d, J = 
8.7, Ar-H2,6), 7.12 (1H, app. s, Ar-H4′), 4.73 (2H, br s, NH2); δC (75 MHz, DMSO-
d6); 164.8 (C=O), 138.7 (4-C), 135.6 (5′-C), 131.2 (1-C), 130.2 (4′-C), 128.6 (3-
C and 5-C), 119.6 (2-C and 6-C), 117.8 (2′-C); vmax/cm
-1 (neat); 3318, 3276, 
3128, 3111, 1651, 1605, 1506, 1485, 1320, 1252, 1061, 651; m/z (ES) 203.1 
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Appendix I  
A) The SYBR green assay
1
 
The Kool NC-45 RNAP Activity and Inhibitor Screening Kit was used 
for biological evaluation of the synthesized compounds. This assay is based on 
the Rolling Circle Transcription (RCT) Technology which takes advantage of the 
observations that certain small, circular, single-stranded DNAs are efficiently 
transcribed by RNAP in vitro through a rolling circle in the absence of promoter 
sequences, primers and sigma factors allowing to study the activity of inhibitors 
of the core RNAP. The kit is constituted of E. coli RNA Polymerase (core 
enzyme) and SYBR Green I dye (Molecular Probes) for real-time detection of 
RNA polymerase activity. The dye binds to RNA increasing the intensity of 
fluorescent emission and this signal is proportional to the quantity of RNA 
produced. Therefore in the presence of RNAP inhibitors this signal is decreased 
(Figure 1). 
 
Figure 1 The SYBR green assay1 
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The assay was run in the presence of a negative control constituted by the 
absence of ribunucleoside tri-phosphate (rNTPs) and a positive control 
represented by rNTPs. A known bacterial RNAP inhibitor represented by the 
antibiotic rifampicin, is also used to check the turnover of the assay. The full 
assay protocol is described in the next paragraph. A detergent, Triton X-100A, 
was present in the assay at the concentration of 0.01% to exclude aspecific 
inhibition activity due to aggregating compounds.2  
The assay was  developed by Prof. Ian Chopra and his collaborators3 at 
the University of Leeds to screen compounds in a 384-well plate format for 
inhibition of bacterial RNAP. 
Compounds showing good inhibition activity at 100 μM (beyond 50% for 
this specified concentration), were shortlisted for a full dose-response curve 
determination in order to obtain the IC50 value, the dose required for a 50% in 
vitro inhibition.  
B) Experimental procedure for E. coli RNA Polymerase Assay
4,5
 
The ability of compounds to inhibit E. coli RNAP was determined in a 384-
well plate (Greiner 781096) in vitro assay. Compounds, in a final concentration 
of 10% DMSO, were pre-incubated with buffer comprising 40mM TrisHCl, pH 
7.5, 50mM KCl, 10mM MgCl2, 8mM DTT, 0.01% Triton X-100 with 20U/ml E.coli 
core RNA polymerase and 125ng/ml KoolTM NC-45TM Universal RNA 
polymerase template (Epicentre, Madison, WI, USA).  The reaction was initiated 
with the addition of 0.5mM rNTPs (Roche Diagnostics Ltd., UK) and incubated 
for 2 h at 37˚C and stopped with the addition of 20mM EDTA.  RNA products 
were detected using SYBR Green I dye (Invitrogen Ltd., UK) in a PerkinElmer 
2103 Multilabel reader with excitation and emission at 485nm and 531nm 
respectively. Assays were performed in duplicate and the % activity of 
compounds at 100μM was determined after deduction of background (no 
rNTPs) and comparison with no compound/DMSO control, designated having 
100% activity.  The IC50 value against E. coli RNAP was determined using an 8-
point 1:2 dilution series of compound and analysed using GraphPad Prism 6. 
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IC50 values reported in this thesis are the mean value ± standard deviation of 
three independent measurements. 
C) Selectivity and whole cell assays
4,5
 
Two structurally unrelated enzymes to bacterial RNAP, malate 
dehydrogenase and chymotrypsin, were used to assess selective inhibition of 
bacterial RNAP and to exclude promiscuous activity.6 A detergent, Triton X-
100A, was present in the assay at the concentration of 0.01% to exclude 
aspecific inhibition activity due to aggregating compounds.2  
Antibacterial activity was then evaluated against a panel of Gram Positive 
and Gram Negative organisms. Minimum inhibitory concentration (MIC) was 
defined as the lowest concentration of a substance that inhibit visible growth of 
an organism after 18 hours of incubations at 37˚C. Compounds were 
progressed only if they possessed a minimum suitable threshold, represented 
by MIC values against one or more test organisms comprised in a range 
between 32 and 64 μg/ml. The above cited minimum suitable threshold was 
established on the basis of possible improvement through analog refinement.7 
D) General experimental procedure for the selectivity assays
4,5
 
Stocks of compounds were typically prepared at 10mM in 10% DMSO in 
malate deyhdrogenase (MDH) and chymotrypsin assays and the results were 
controlled for the effect of DMSO. 
Assays were performed in a 50 mM potassium phosphate solution 
containing 10% DMSO at pH 7.0. 100% activity control was constituted by 
absence of inhibitor into the above specified solution containing the enzyme 
while negative control consisted in no enzyme or inhibitor in the presence of 
0.01% Triton-X100 at 25˚C. All reactions were monitored on a Molecular 
Devices SPECTRAmax PLUS384 spectrophotometer.  
For MDH assays,
6
 compound and 2nM enzyme were incubated in 50mM 
KPO4 buffer (pH 7.35) containing 0.01% Triton-X100 for 5 minutes and the 
reaction initiated with 200nM oxaloacetic acid and 200nM NADH and progress 
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monitored at 340 nm. Oxaloacetic acid and NADH were each prepared as 2mM 
stocks in 50mM KPO4 buffer (pH 7.35) containing 0.01% Triton-X100.  
For chymotrypsin assays,
8
 compound and 50nM enzyme were incubated 
for 5mins and the reaction initiated with 150nM succinyl-Ala-Ala-Pro-Phe-p-
nitroanilide and the reaction progress was monitored at 410nm. Succinyl-Ala-
Ala-Pro-Phe-p-nitroanilide was prepared as a 50mM stock in DMSO. 
With regard to the MDH assay, oxaloacetic acid, NADH and MDH from 
porcine heart were purchased from Sigma-Aldrich. 
For the Chymotrypsin assay, α-chymotrypsin Type II from bovine pancreas 





MIC determinations for compounds were performed by Liam Sharkey 
using the British Society for Antimicrobial Chemotherapy (BSAC) broth 
microdilution method9 on selected bacterial strains (Tab. 1). 
 
Table 1 Selected bacterial strains description 
Strain Description Reference/Source 
S. aureus SH1000 
rsbU+ derivative of 8325-4, 
common lab strain with 
genome sequenced 
Horsburgh et al, 10 
E. coli SM1411 
lacl3, lacZ118, proB, trp, 
nalA, rpsL, 
ΔacrAB::Tn903kanr  
1411 deficient in the AcrAB 
multidrug efflux pump 
component 
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